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Abstract
Molecular Simulation Studies of the Insulin Receptor Family
Harish Vashisth
Advisor: Cameron F. Abrams, Ph.D.
Molecular simulations of the ligands and receptors of the insulin family were con-
ducted. First, phenol dissociation mechanisms in the pharmaceutical storage form
of insulin, R6 insulin hexamer, are studied using random acceleration molecular dy-
namics (RAMD) simulations. Three major escape pathways for phenols are observed.
Several residues that directly participate in escape events serve to resolve ambigui-
ties from previous NMR experiments. Potentials of mean force (PMFs) along the
reaction coordinate for each pathway are further resolved using steered molecular dy-
namics (SMD) simulations. The results for binding free energy, ∆F, agree reasonably
well within the range of known experimental and previous simulation magnitudes of
this quantity. Structural analysis and energetic barriers for each pathway suggest a
plausible preferred mechanism of phenolic exchange that differs from previous mecha-
nisms, but is consistent with RAMD results. Several weakly-bound metastable states,
supported by experimental evidence, are also observed. These results give detailed
insights into the dissolution kinetics of insulin hexamers.
Next, the flexibility mechanisms of the ectodomains of the insulin receptor (IR)
and the type-1 insulin-like growth factor receptor (IGF1R) are studied. Both re-
ceptors are observed to display asymmetric mechanisms of flexibility due to interdo-
main and intersubunit conformational fluctuations that do not alter their quaternary
structures. Subtle variations in intersubunit buried surface areas of both receptors
are observed to coincide well with these conformational fluctuations, resulting in one
easily-accessible ligand binding pocket with the other blocked. Further, Monte Carlo
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(MC) docking simulations are used to construct all-atom structural models of the
ligand/receptor complexes which are consistent with a variety of known experimental
data, and provide detailed structural bases for ligand-recognition in the IR family.
Finally, a large-scale conformational change in the activation-loop (A-loop) of
the insulin receptor kinase domain (IRKD) is studied using temperature-accelerated
molecular dynamics (TAMD). The A-loop is observed to form a transient three-
turn helical conformation during TAMD, which facilitates the conserved DFG-motif
(D1150, F1151, and G1152) to switch from a “D-out/F-in” to “D-in/F-out” confor-
mation, thereby burying F1151 underneath αC-helix, and simultaneously presenting
D1150 for ATP binding. These transient helical conformations of the A-loop have
been observed in the crystal structures of related kinase families, and may be useful
for the design of novel inhibitors targeting IRKD.
1Chapter 1: Introduction
1.1 Historical accounts of research in diabetes
The current estimates of the World Health Organization indicate that more than
220 million people world-wide are diabetic. These estimates suggest that the world
is facing an unprecedented epidemic of diabetes mellitus, chiefly due to changes in
the lifestyle, nutritional and environmental factors [5]. The word ‘Diabetes’ comes
from the Greek word for ‘pipe-like’ because essential nutrients of the body start
to pass through the system instead of being utilized, while ‘Mellitus’ is the Latin
word for ‘honey’ or ‘sweet’ [6]. An early history of diabetes has been beautifully
summarized elsewhere [6]. Diabetes mellitus is a chronic disease, which occurs due
to inefficient production (type 1 diabetes) or improper utilization (type 2 diabetes)
of a protein hormone known as insulin. Insulin, described as a medical miracle [7]
and a “protein of the 20th century” [8], was discovered in 1922 by Frederick Banting
and his assistant Charles Best in the laboratory of John MacLeod, who was working
to isolate the pancreatic extracts responsible for glucose regulation [7, 9]. These
researchers extracted a concentrated secretion from the pancreases of dogs which
they initially named ‘isletin’, and subsequently administered to other dogs rendered
diabetic by removal of their pancreas [9, 10]. These early results showed that the
extract from pancreas lowered blood and urinary sugar levels, but for a short period
of time, and most animals could not survive due to toxic impurities in the extracts,
or due to infection after the surgery [7, 9, 10].
2It has been reported that the first injection of a pancreatic extract was adminis-
tered into a human patient (14-year-old Leonard Thompson) at Toronto General Hos-
pital in Canada on 23 January 1922 [7], whose blood sugar levels were immediately
reduced leading to significant improvements in his health. The citation classic [11]
records the enthusiasm of successful clinical tests that “These results taken together
have been such as to leave no doubt that in these extracts we have a therapeutic
measure of unquestionable value in the treatment of certain phases of the disease in
man”. Within 18 months of this discovery, Banting and MacLeod won 1923 Nobel
Prize in Physiology and Medicine in recognition of their work, which they unofficially
shared with Charles Best and James Collip (clarification on the prize debate written
by Nobel Laureate August Krogh is worth reading [12]).
These early successes led to large-scale production of insulin in 1923 at Nordisk
insulin laboratory in Copenhagen, Denmark [9, 13], and insulin was made available
to the vast majority of patients. While discovering ways to retard the absorption
of insulin following subcutaneous injection, Hagedorn et al. [14] found that addition
of protamine to insulin significantly reduced the solubility of insulin at normal pH,
therefore prolonging its action. Soon afterwards, it was reported that the addition of
zinc to insulin also prolonged its effect [15]. Subsequently, crystalline insulin, known
as Neutral Protamine Hagedorn (NPH), having fast action was produced [16]. By
1950s, patients had a choice among fast- and long-acting insulins, but many patients
developed antibodies to bovine or porcine insulin, and hence the development of pu-
rified human insulin was sought [7]. The discovery of the biosynthetic pathway of
insulin by Donald Steiner and colleagues in 1967 was a major advance [17]. Later,
discovery of radioimmunoassay which could measure minute circulating amounts of
insulin won Rosalyn Yalow a share of 1977 Nobel Prize in Physiology and Medicine.
Afterwards, Danish scientists in 1988 introduced the concept of insulin analogues, in-
3sulin with amino acid substitutions, with rapid action and decreased self-affinity [18].
A detailed list of commercially available insulin analogues is provided in the Table 1
of Ref. [7]. Physicochemical basis for the rapid time-action of a key insulin analogue
has been elucidated [19, 20]. Due to local degradation of insulin on subcutaneous
delivery, alternative routes of insulin administration, such as intranasal, pulmonary,
uterine, and oral have been proposed [7]. In this context, although not relevant to
this thesis, the advances in biomaterials for oral delivery of insulin by Peppas and
co-workers are worth reading [21–24].
Insulin has also remained a model protein in structural biology. Insulin was the
first protein to have its primary structure sequenced in 1955 by Frederick Sanger (1958
and 1980 Nobel Laureate in Chemistry) [25]. Although John Abel first crystallized
insulin as early as 1929, he could not reproduce his findings [8]. It was not until
1969 that Dorothy Crowfoot Hodgkin (1964 Nobel Laureate in Chemistry) and her
colleagues in Oxford, after years of struggle, solved the three-dimensional structure
of insulin by X-ray crystallography (a technique to determine protein structures by
bombarding their crystals with X-rays) [26]. This discovery later inspired much work
in the crystallography of different dimeric and hexameric forms of insulin [27–36].
While research on the hormone was progressing, Pedro Cuatrecasas [37], among
others, proposed that receptors of a protein nature for insulin exist on cell membranes,
which initiate the biological actions of insulin [38]. Soon afterwards, it was determined
that the insulin receptor is composed of two disulfide linked subunits, stimulates
phosphorylation, and in fact itself is a receptor tyrosine kinase (RTK) [39, 40]. It
was also realized that insulin shares several of its signalling pathways with other
growth factors, primarily the type-1 and type-2 insulin-like growth factors (IGF1 and
IGF2), which also exert their physiological effects via type-1 insulin-like growth factor
receptor (IGF1R), a receptor highly homologous to the insulin receptor (IR) [5, 41].
4In 1985 and 1986, Axel Ullrich and colleagues sequenced the primary structure of
IR and IGF1R, respectively [42, 43]. Rigorous work on elucidating the structural
basis of ligand-induced activation of receptors of the insulin family soon became a
priority. The first breakthrough came in 1998 from the laboratory of Colin Ward
(then at CSIRO in Melbourne, Australia), whose team solved the atomic structure of
the first three domains of IGF1R [41, 44]. In 1999, the same laboratory also reported
the first single-molecule images of human insulin receptor ectodomain (extracellular
parts) and its complexes with antibody fragments using electron microscopy [45]. In
1999, Luo et al. [46] reported the quaternary structure of the insulin-IR complex
using electron cryomicroscopy, which at the time was considered a major advance
in structural biology, but is now under debate due to inconsistency with the atomic
structure of the IR ectodomain [5, 8, 47, 48]. Another stunning breakthrough came
in 2006 from Colin Ward’s group (now at Walter and Eliza Hall institute of medical
research in Australia), which reported atomic resolution structures of the fragments
of the IR ectodomain [49], and the complete IR ectodomain [47]. In 2009, Whitten et
al. [4] have reported a homology model of the IGF1R ectodomain constructed based
upon previous crystal structure of the IGF1R fragment [44] and the IR ectodomain
crystal structures [47, 49]. The structural biology of IR and related receptors has been
extensively reviewed [48, 50–53]. We note that no experimental structure of ligand-
bound IR or IGF1R has yet been elucidated due likely to difficulties in crystallization
of these highly flexible proteins. Seeking atomic resolution structures of ligand-bound
receptors is a major motivation for the work reported in this thesis. In that context,
we have now successfully constructed all-atom structural models of insulin/IR and
IGFs/IGF1R complexes [54, 55] using computational techniques with the help of
published crystallographic data on ligands and receptors of the insulin family.
The purpose of this chapter is to provide motivations specific to work presented in
5this thesis. In the following, we first discuss the structural details of different forms
of peptide ligands, such as insulin and insulin-like growth factors, which have been
used in various simulation studies presented in subsequent chapters. We also describe
the key structural features of the insulin receptor (IR) and the type-1 insulin-like
growth factor receptor (IGF1R). Next, selected simulation studies on insulin from
the literature are discussed briefly. This chapter concludes with a discussion of the
specific aims of this thesis followed by an outline for the remainder of the thesis.
1.2 Background
In the following, we provide brief background on ligands and receptors of the
insulin family that have been used in various studies throughout this thesis.
1.2.1 Insulin and insulin-like growth factors
Insulin is a 5.8 kDa peptide hormone which is synthesized in the β cells of the islets
of Langerhans. The β cells have a few key features: they have rough endoplasmic
reticular (ER) surfaces, are full of storage vesicles, and in most animals they are rich
in zinc and calcium [56]. Insulin is synthesized according to normal mechanisms of
protein synthesis where its messenger RNA contains a signal sequence responsible for
stabilizing the ribosome on rough ER membrane. On translation, insulin is directed
into endoplasmic volume as a single chain molecule of∼110 residues (B-chain sequence
followed by 30-35 amino acids long connecting peptide, and A-chain sequence), which
is known as preproinsulin. Immediate removal of signal sequence forms proinsulin,
where proinsulin has the ability to correctly fold into a three-dimensional structure.
Proinsulin is transported with the help of vesicles to Golgi, which is an aqueous
environment having zinc ions. In this medium, proinsulin likely self-assembles to
form proinsulin hexamers, in which connecting peptide linking A and B chain is then
6cleaved by membrane-associated enzymes. This leads to formation of zinc assembled
hexameric species of insulin, which are capable of forming microcrystals. On release
into the serum, due to pH changes, hexamers have been suggested to fall apart into
monomers due to repulsion in certain charged residues at the core of the hexamer,
however, exact mechanisms of this process are yet unclear.
Therefore, the final mature insulin monomer is composed of two chains, an A
chain with 21 amino acids, and a B chain with 30 amino acids that are held together
by three disulfide bonds. Insulin monomers can exist in two different allosteric forms
called T and R insulin (Fig. 1.1 a and b). A key difference between both forms
is that the first eight residues of B-chain are extended in T-state, while the same
residues are helical in R-state (residues shown in green in Fig. 1.1 a and b). However,
insulin has high self-affinity, and at micromolar concentrations, it exists as a dimer,
which in turn can form hexamers in the presence of zinc ions or phenolic species.
Hexamers exist in three allosteric states termed T6, T3R3, and R6 [27–36], related
by a T6↔T3R3↔R6 dynamic equilibrium, which is shifted to R6 only by phenolic
derivatives [57, 58] (Fig. 1.1 e, f, and g). However, the T3R3 state can be achieved
either by concentrated anionic medium (Cl−, SCN−, etc.) or phenolic species or
both. Phenolic compounds act as antimicrobial agents and increase the shelf-life of
industrial formulations by stabilizing the R6 state [59]. Six hydrophobic cavities are
present for the phenolic ligands in the R6 state and none in the T6 state.
Insulin-like growth factors (IGF1 and IGF2), unlike insulin, are single-chain poly-
peptides which exist in blood at 20-80 nM concentrations [60]. Other than A and B
domains similar to insulin, each growth factor also contains additionally a C domain
(which connects A and B domains) and a D domain at their C termini (Fig. 1.1 c
and d). The amino acid sequences of six different species (human, porcine, ovine,
bovine, rat, and mouse) are now known; IGF1 in all contains 70 amino acids while
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Figure 1.1: Ligands of the insulin family. (a and b) T- and R-insulin are shown:
A-chain, red and B-chain, blue. The first eight residues of the B-chain, B1-B8, are in
green cartoon. (c and d) IGF1 and IGF2 are shown: A-domain, red; B-domain, blue;
C-domain, cyan; D-domain, yellow. Three disulfide bonds of insulin, IGF1, and IGF2
are also shown in upper panels. (e, f, and g) T6, T3R3, and R6 insulin hexamers are
shown in cartoon representations. Phenols in R6 hexamer are shown in yellow sticks.
Zinc ions are gray or black spheres. The HisB10 residues coordinating zinc ions are
shown in green sticks.
8IGF2 contains 67. Hence, both are slightly bigger than insulin. The main source of
circulating IGFs in the body is liver, however, they are also produced locally in many
other body tissues.
We have used R6 insulin hexamers in our studies presented in Chapters 3 and 4,
while T and R-insulin monomers were used in the construction of all-atom structural
models of insulin-bound IR presented in Chapter 5. Both types of growth factors
were useful in the construction of all-atom models of IGFs-bound IGF1R complexes
presented in Chapter 6.
1.2.2 Insulin receptor and type-1 insulin-like growth factor receptor
The ligands of the insulin family exert their physiological effects via their cell-
surface receptors: insulin binds to the insulin receptor (IR), while IGFs bind to
the type-1 insulin-like growth factor receptor (IGF1R). The entire sequence of IR
and IGF1R precursors contains 1370 and 1367 amino acids, respectively [42, 43].
Both receptors are 300-350 kDa proteins with two identical α subunits and two β
subunits. The mature α2−β2 receptors are formed after glycosylation, dimerization
and proteolytic processing of receptor precursors.
Both IR and IGF1R are highly homologous membrane-spanning glycoproteins of
the receptor tyrosine kinase (RTK) superfamily [43, 49]. Both are also unique among
RTKs due to their covalently-linked homo-dimeric architecture, which also means
that these receptors need domain rearrangements rather than receptor dimerization
for activation [41]. Each subunit in the IR family has an extracellular L1-CR-L2
motif common to hormone receptors, linked to three fibronectin type-III repeats,
F1, F2, and F3, which connect through the plasma membrane via a single helix to
the cytoplasmic kinase domain (Fig. 5.1). The (L1-CR) and (L2-F1-F2) domains of
IGF1R form two distinct binding epitopes for growth factors, designated traditionally
9as site 1, and site 2, respectively (Fig. 6.1). However, site 1 and site 2 of IR are limited
only to L1 and (F1-F2), respectively (Fig. 5.3) [5, 50].
The crystal structure of the IR ectodomain is now known [47, 49], while only
the L1-CR-L2 fragment of the IGF1R ectodomain has been crystallized to date [44].
However, a homology model of the IGF1R ectodomain has been constructed and val-
idated with small-angle X-ray scattering data [4]. We have used both IR ectodomain
structure and the IGF1R ectodomain homology model in our work presented in Chap-
ters 5 and 6. The specific details regarding these structures have been presented in
detail in those Chapters.
1.3 Brief review of selected previous computational studies
In the following, we review the findings of previous simulation studies on insulin.
By no means this review should be considered exhaustive, because only a few selected
studies are discussed. These studies include simulations on monomeric, dimeric, and
hexameric forms of insulin, and can be divided into two categories: vacuum sim-
ulations and explicit-solvent simulations. In 1984, Wodak et al. [61] reported first
energy minimization study of insulin monomers, dimers, and higher aggregates. The
purpose of this study was to test an atomistic force-field with explicit positions for
hydrogens, which they suggested to be as important as including solvent molecules.
However, they observed deformation of insulin molecules due to unrealistic vacuum
conditions. Next, Kru¨ger et al. [62] carried out first 120 ps long MD simulations of in-
sulin monomers in vacuum, although they pointed out that more realistic simulations
should be done to understand hormone’s solution behavior. Hence, MD simulations
of insulin monomer and dimer for 100 ps in the presence of explicit solvent were first
reported by Mark et al. [63] in 1991, which showed trends about insulin dynamics
opposite to previous studies. They report that the structures of two independently
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simulated insulin monomers diverge from each other as well as from their starting
structures during solvent MD simulations instead of converging, which was reported
earlier by Kru¨ger et al. [62]. Insulin dimer simulations suggested that the asymmetry
of the crystal dimer is not reduced in the absence of crystal contacts during MD sim-
ulation. Despite the results of these solvent MD simulations, Kru¨ger in 1994 further
studied a cross-linked insulin monomer (N-terminus of A-chain covalently bonded to
the C-terminus of B-chain) with vacuum MD simulations of upto 500 ps, and justified
vacuum MD simulations as acceptable for comparative studies. Falconi et al. [64] also
studied the insulin dimer with 600 ps long solvent MD simulations, demonstrating
that two insulin monomers in the dimer behave asymmetrically and are almost in-
dependent. These early simulation studies although limited either due to the short
length of simulated trajectories, or the absence of explicit solvent molecules were
nothing less than heroic in comparison to the first ∼9.2 ps simulation of a protein in
vacuum reported by McCammon et al. [65] in 1977. The T to R transition, both in
insulin monomer as well as hexamer, served as a test-case to study large-scale con-
formational changes in proteins via targeted molecular dynamics (TMD; a technique
that drives an initial structure (T-insulin) to a known final structure (R-insulin) using
final structure as a directing constraint in an MD simulation) [66, 67].
To explore the dynamics of insulin monomers and dimers, researchers have also
subjected these proteins to a variety of stresses via simulations: Budi et al. [68]
reduced the disulfide bonds of an insulin monomer or increased the simulation tem-
perature to 400 K, Kim et al. [69] studied the force-induced dissociation of an insulin
dimer via steered MD (SMD) simulations, while the insulin B-chain alone was inves-
tigated by MD simulations at 400 K [70] and also via bias exchange metadynamics
simulations [71]. An interesting simulation method called computational alanine scan-
ning (akin to alanine scanning mutagenesis) was also applied to an insulin monomer
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for the first time [72]. Although not relevant to this thesis, we note that a density
functional molecular orbital approach rooted in quantum mechanics was also applied
to an insulin hexamer by Inaba et al. [73], the largest system treated by electronic
structure calculations to date. A study by Zoete et al. [74] on the dynamics of insulin
is worth reading, because it reports 5-10 ns long explicit solvent MD simulations of
monomeric and dimeric insulins, their normal mode analysis results, and sheds new
light on the dynamic behavior of insulin in comparison to several previous studies.
A study on R6 insulin hexamer by Swegat et al. [75] is relevant to the work
presented in Chapters 3 and 4 of this thesis. This study reports one dissociation
mechanism for a phenolic ligand from R6 from insulin hexamer, while we hypothe-
sized that there may be multiple mechanisms through which a phenol molecule can
access/escape the binding cavities of the hexamer. Indeed, we found three dissocia-
tion routes for phenolic ligands as discussed in Chapter 3, and in Chapter 4 we report
the free energy profiles corresponding to these three escape pathways.
Prior to this thesis, to best of our knowledge, no molecular simulation studies on
the receptors of the insulin family have been reported in the literature.
1.4 Specific Aims
The central goal of this thesis is to develop an understanding of the structure-
function relationships in the insulin receptor family . Here, we have taken a com-
putational strategy to gain a better understanding of the mechanisms underlying
hormone-recognition by IR and IGF1R. To that end, we have extensively studied the
dynamics of ligands and receptors of the insulin family using molecular simulations.
The following lists an outline of the specific aims of this thesis.
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1.4.1 Specific Aim 1: Ligand (un)binding studies in the R6 insulin hex-
amer
Hypothesis: Multiple dissociation mechanisms may exist for phenolic ligands in
R6 insulin hexamer instead of a single route suggested by an earlier computational
study [75].
We tested this hypothesis by applying a novel simulation technique named random
acceleration molecular dynamics (RAMD) to explore binding/unbinding mechanisms
of phenolic ligands in R6 insulin hexamer. We identify and characterize a variety of
phenol dissociation pathways using a judicious combination of molecular simulation
techniques and find that a previously suggested gatekeeper pathway is likely not
the preferred pathway for ligand dissociation. We have also carried out free-energy
calculations to demonstrate that a “gate-leaping” mechanism is the preferred pathway
for phenolic exchange.
1.4.2 Specific Aim 2: Flexibility mechanisms of IR and IGF1R
Hypothesis: IR and IGF1R possess asymmetric mechanisms of flexibility.
Using the crystal structure of the IR ectodomain (IR∆β), and a homology model
of the IGF1R ectodomain with the help of molecular dynamics simulations, we have
extensively studied the flexibility mechanisms of these proteins that can allow bind-
ing of their cognate ligands. We observe that the apo ectodomains of both receptors
display asymmetric flexibility mechanisms that are consistent with previously pro-
posed notion of a “see-saw” mechanism of receptor activation. The conformational
changes that were observed in our MD simulations of these proteins can be exploited
for studying ligand binding to their ectodomains, as discussed in Specific Aim 3.
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1.4.3 Specific Aim 3: All-atom structural models of insulin/IR and IGF-
s/IGF1R complexes
Hypothesis: The flexibility observed in the binding pockets of IR and IGF1R in our
MD simulations (see Specific Aim 2) may allow binding of insulin and IGFs to their
cognate receptors.
The inter- and intra-domain flexibility observed in our MD simulations of the
ectodomains of IR and IGF1R results in accessible binding pockets for their cognate
ligands. We used a custom MD-assisted MC-docking protocol to construct all-atom
structural models of ligand-bound receptor complexes. We observe that ligands re-
main stably bound in post-docking MD equilibration simulations. Moreover, our
models for insulin/IR and IGFs/IGF1R are consistent with a variety of published
experimental data, and provide detailed structural bases for differences in affinities
of insulin, IGF1, and IGF2 for their non-cognate receptors.
1.4.4 Specific Aim 4: Large-scale conformational changes in the insulin
receptor kinase domain
Hypothesis: The conformational changes in the activation-loop (A-loop) of the in-
sulin receptor kinase domain (IRKD) likely facilitate the flip of highly conserved
DFG-motif (D1150, F1151, and G1152).
We have tested this hypothesis via a new accelerated conformational sampling
method for proteins called temperature-accelerated MD (TAMD). We applied TAMD
to the A-loop of the inactive structure of IRKD, which generates a target A-loop
conformation very close to the known active A-loop conformation. A further 20-
ns MD-equilibration of this structure in the presence of ATP and phosphotyrosines
stabilizes the A-loop conformation to an RMSD of ∼4 A˚ with respect to its active
state. Significantly, we also capture the DFG-backflip during TAMD, and observe
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that this back-flip is facilitated by a transient three-turn helical conformation of the
A-loop, the folding of which draws the placement of the side-chains of D1150 and F1151.
Such transient helical conformations of the A-loop can potentially be exploited for
the design of novel inhibitors that target a specific DFG conformation, and have been
observed in crystal structures of related kinase families.
1.5 Thesis Outline
After this introductory chapter, the thesis continues with a discussion of compu-
tational techniques in Chapter 2, which covers the statistical mechanics of molecular
simulation methods, basics of molecular dynamics (MD) and Monte Carlo (MC) sim-
ulations. Chapter 3 and 4 report on the studies of R6 insulin hexamer. Chapter
3 is devoted to the study of ligand (un)binding mechanisms in R6 insulin hexamer
using random acceleration MD (RAMD) simulations, while Chapter 4 deals with the
thermodynamics of ligand access/escape pathways and provides in particular the free
energy profiles of phenol dissociation mechanisms with the help of steered MD (SMD)
simulations. Chapter 5 and 6 are devoted to the studies of structure-function rela-
tionships in the insulin receptor (IR) family. Both Chapters 5 and 6 first describe
the detailed flexibility mechanisms of the IR ectodomain and the type-1 insulin-
like growth factor receptor (IGF1R) ectodomain, and then report on the all-atom
structural models of complexes of these receptors with their cognate ligands. Par-
ticularly, Chapter 5 describes all-atom structural models of T- and R-insulin-bound
IR ectodomain, and Chapter 6 describes all-atom structural models for complexes
of insulin-like growth factors (IGF1 and IGF2) with the IGF1R ectodomain. These
structural models provide detailed insights into the ligand binding mechanisms in the
IR family, and confirm many earlier hypotheses in the field. Chapter 7 is the study of
a large-scale conformational transition in the activation loop (A-loop) of the intracel-
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lular catalytic kinase domains of IR via temperature-accelerated molecular dynamics
(TAMD), a conformational sampling technique for proteins. Finally, in Chapter 8 we
summarize in brief the findings of this thesis and suggest some new possible research
directions for future. For dissemination purposes, appendices at the end of this thesis
provide the computer codes for RAMD and MC docking calculations.
The detailed literature relevant to the work presented in this thesis is not de-
scribed in this introductory chapter, but is instead covered at appropriate places in
the individual chapters.
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Chapter 2: Computational Techniques
2.1 Abstract
The purpose of this chapter is to familiarize the reader with how molecular simula-
tion techniques are applied in the study of complex multi-atom biological systems. In
particular, we describe the basics of two fundamental molecular simulation techniques:
(a) Molecular Dynamics (MD) simulations; and (b) Monte Carlo (MC) simulations.
The discussion of these methods in this thesis is limited, but the interested reader may
refer to several advanced texts [76–78] and excellent review articles for details [79–81].
2.2 Introduction
Computer simulation is an approach to understand the macroscopic properties of
a molecular system in terms of interactions among its constituting atoms with the
help of model building and computation. Computer simulation has now become an
ubiquitous tool to study molecular systems both in academic and industrial research,
and is applied to diverse areas ranging from materials science and chemistry to phar-
macy and molecular biology [82]. Given that the interactions between the atoms of
a molecular system are known with sufficient accuracy, a computer simulation not
only can provide us with quantitative measures of various macroscopic properties,
but also their microscopic origins. However, we cannot measure all properties di-
rectly in a computer simulation, and most of the quantities directly measured in
a simulation such as the instantaneous positions and velocities of all molecules, al-
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though extremely powerful, are inaccessible to laboratory experiments. Experiments
typically measure a property averaged over a large number of particles, and some-
times, also averaged over the measurement time [76]. If we want to use the computer
simulation as an additional tool to interpret experimental information and provide
mechanistic explanations of observed phenomena, we need a robust tool to formulate
macroscopic properties in terms of instantaneous positions and velocities of particles.
This mathematical tool for computer simulations is known as Statistical Mechanics.
Statistical Mechanics, originally proposed as Statistical Thermodynamics by Aus-
trian physicist Ludwig Boltzmann in the 19th century, is a powerful mathematical
formulation to derive macroscopic or bulk properties of matter from the atomic struc-
ture and microscopic dynamics. Specifically in molecular simulations, these properties
can be experimentally measurable thermodynamic quantities such as temperature,
pressure, heat, and work, which are typically characteristic of many-particle systems,
and do not exist for microscopic systems. With the help of probabilistic theories
and known physical laws, the tools of statistical mechanics elegantly bridge macro-
scopic observables to microscopic details, making it feasible to carry out computer
simulations that provide experimentally measurable properties.
The computer simulations relevant to this thesis concern complex biological macro-
molecules such as proteins, nucleic acids, and DNA, etc. These simulations work on
the assumption that classical mechanics can be used to describe the motions of atoms
and molecules [76]; it is not yet feasible to treat these systems quantum-mechanically
due to the large number of atoms and hence electrons. Due to advances in experi-
mental techniques, we can now visualize biomolecules in atomic detail: X-ray crys-
tallography can provide us the static picture of the spatial organization of atoms in a
biomolecule (sometimes the extent of disorder also indicates atomic dynamics), and
nuclear magnetic resonance (NMR) spectroscopy can provide information on solution
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dynamics of relatively smaller proteins [83]. However, none of these experimental
techniques can provide information on the complete conformational dynamics of any
biomolecule in solution, which is encoded in its structure and is an essential element
of its function [81]. The energetic information at the atomic level is also not accessi-
ble to any experimental technique [83]. Nonetheless, such detailed information on the
dynamics and energetics of biomolecules can be obtained by molecular simulations.
Molecular simulation techniques can be both stochastic as well as deterministic
in nature, and are applied based upon the problem at hand. The stochastic phe-
nomenon such as Brownian motion is studied via an approach termed Monte Carlo
(MC) simulation, while the problem of studying the dynamics of complex biological
systems is well-suited to the deterministic approach termed molecular dynamics (MD)
simulation [78]. The interatomic interactions in these simulation techniques are repre-
sented via an empirical potential energy function also known as the “force field,” the
parameters of which are derived through a combination of experiments and quantum-
mechanical calculations. The force field is further tested for fidelity in reproducing
the structural, dynamic, thermodynamic, and also bulk properties of experimentally
well-characterized molecules [84]. These empirical potential energy functions neglect
electronic degrees of freedom, yet their frequent need of computation during the sim-
ulation can be a computationally demanding task. MC simulations randomly explore
the conformational space of the system via its potential energy surface by the method
of importance sampling , which was first introduced by Metropolis and co-workers in
1953 [85]. Hence, MC simulations provide information about those conformational
states of a system which are significantly different in terms of their overall potential
energy, and hence can be useful in calculation of various thermodynamic properties.
MD simulations, on the other hand, compute the natural time evolution of individual
atoms interacting under the influence of underlying force field by numerically inte-
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grating their Newtonian equations of motion, and averaging the quantity of interest
over a sufficiently long time [76]. In the following, we briefly describe the working
principles of MC and MD simulations.
2.3 Statistical mechanics
In this section, we describe a few concepts from statistical mechanics which may
help the reader better understand the underlying physics of molecular simulations.
Again, the description of these concepts has been intentionally kept brief in compar-
ison to several texts on the subject [76–78, 86].
First, we envision a system of particles with coordinates ri and momenta pi,
where the system can be fully specified by stating its volume V, number of particles
N, and total energy E. Each particular snapshot of the system corresponding to a
fixed set of internal coordinates (ri, pi) is known as a microstate. Because of the
large number of particles N, there can be an enormously large number of microstates
which collectively form what is known as a state or macrostate of the system. Hence,
the set of all microscopic states that give rise to the same macroscopic state is called
an ensemble. When we measure system properties, we measure statistical averages
over multiple microstates of the system, which are also called ensemble averages. In
statistical mechanics, different kinds of ensembles exist which are characterized by
fixed values of thermodynamic variables such as total number of particles N, volume
V, temperature T, total energy E, or chemical potential µ. Constant NVE defines the
microcanonical ensemble, and constant NVT defines the canonical ensemble, while the
isothermal-isobaric ensemble is defined by constant NPT. Even the grand canonical
ensemble can be formulated by constant µVT. The two ensembles used in this thesis
for most of the MD simulations are NVT and NPT ensemble. There are practical
reasons to avoid the use of NVE ensemble, because maintaining constant total energy
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E of the system over long simulation period is extremely difficult and computationally
demanding due to the accuracy of numerical integration schemes used (vide infra).
According to statistical mechanics, the value of an observable property A that we
measure in experiments strictly depends upon the positions ri and momenta pi of
N particles, and the instantaneous value of A at a particular time t can be written
as A(r(t), p(t)) [77]. This instantaneous value of A fluctuates due to inter-particle
interactions, and the value that we really measure in experiments is a time average
over the time of measurement. As the time of measurement increases to infinity, the
value of the following integral approaches the “true” average of the property:
A¯ = lim
τ→∞
1
τ
∫ τ
0
A(r(t),p(t)) dt, (2.1)
It is therefore obvious that in order to calculate the average value of an observable
property, we need to simulate the dynamic behavior of the system. In principle, it
is relatively straightforward to generate a trajectory in time by numerically solving
Newtonian equations of motion of all interacting particles in the system, from which
we can compute the average value of the desired property. However, for macroscopic
systems containing molecules of the order of 1023, it is not even feasible to propose
an initial configuration of the system, let alone do numerical integration to generate
a trajectory. This problem in statistical mechanics was solved by recognizing that a
single system evolving in time can be replaced by a large number of the replications
of the system that are considered simultaneously. Hence, the time average of A given
in equation 2.1 can be replaced by ensemble average:
〈A〉ensemble =
∫ ∫
dpdrA(p, r)P (p, r), (2.2)
where the angle brackets 〈〉 indicate an ensemble average, the average value of prop-
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erty A over the ensemble of configurations generated by the simulation. This leads
us to one of the fundamental axioms of statistical mechanics, the ergodic hypothesis,
which states that the ensemble average is equal to the time average. P(p, r) is the
probability density of the ensemble, which is the probability of finding a particular
configuration with positions ri and momenta pi. In the canonical (constant NVT)
ensemble, P(p, r) is given by:
P (p, r) =
1
Z
exp (−H(p, r)/kBT ), (2.3)
where kB is the Boltzmann’s constant, T is the temperature, and H is the Hamiltonian
of the system, which is equivalent to the total energy, and is defined as the sum of
kinetic energy K and potential energy U of the system: H = K + U. Z is known as
the partition function, which is given by:
Z =
∫ ∫
dpdr exp (−H(p, r)/kBT ), (2.4)
If we know the partition function, all other thermodynamic properties can be
derived from it. For example, we can express internal energy U, entropy S, and
Helmholtz free energy F in terms of partition function Z as follows:
U = kBT
2
(
∂ lnZ
∂T
)
V,N
, (2.5)
S = kB lnZ +
U
T
, (2.6)
F = −kBT lnZ. (2.7)
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2.4 Foundations of molecular dynamics simulations
2.4.1 Langevin equation
The fundamental equation of MD simulations is the Langevin equation, which is
given by:
mir¨i = −
(
∂U
∂ri
)
− γmir˙i + ηi(t; β), (2.8)
where mi is the mass of each particle, β=1/kBT , kB is Boltzmann’s constant, and
T is the temperature. U(ri) is the interatomic potential, which is a function only of
atomic positions (see Sec. 2.4.4), γ is the Langevin friction coefficient, η is the white
noise satisfying fluctuation-dissipation theorem at physical temperature β−1:
〈ηi(t; β)ηj(t
′; β)〉 = β−1γmiδijδ(t− t
′). (2.9)
2.4.2 Numerical integration
The equation of motion (Eq. 2.8) for each atom in the system is numerically
integrated to propagate the system in time. Due to the chaotic nature of biological
systems, the trajectories starting from slightly different initial configurations diverge
exponentially fast and are uncorrelated after a few picoseconds. However, the goal
of biomolecular simulations is to do proper sampling of phase space (ri, pi) rather
than generate highly accurate trajectories. Therefore, the key feature of a numerical
integration scheme is not only how accurate it is locally, but also how efficient it
is, and how well it does preserve the fundamental properties of the system, such as
energy, momentum, and time-reversibility [84]. One such efficient scheme which has
been used in this thesis is velocity-Verlet algorithm [76, 87]. This method obtains the
position and velocity at the next time step (rn+1,vn+1) from the current one (rn,vn),
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assuming Fn = F(rn) is already computed, in the following way:
vn+1/2 = vn +M
−1Fn∆t/2, (2.10)
rn+1 = rn + vn+1/2∆t, (2.11)
Compute, Fn+1 = F (rn+1),
vn+1 = vn+1/2 +M
−1Fn+1∆t/2. (2.12)
where ∆t is the time-step, and M is the mass matrix. The distinctive feature is that
this algorithm requires only one force evaluation for each time-step. For a fixed time
period, the method exhibits a global error proportional to ∆t2. No method has been
found yet that is both more accurate than the Verlet method, and as practical for
biomolecular simulations.
2.4.3 Choice of integration time-step
The choice of most appropriate time-step ∆t in an MD simulation is a crucial
one: too small time-step will only allow a limited exploration of phase space; too
large time-step will lead to numerical instabilities in the integration schemes (see
Sec. 2.4.2). These instabilities would certainly violate conservation of energy and
momentum. Hence, a major goal in choosing ∆t is the requirement that the inte-
gration time-step be small enough to resolve fastest moving atoms in the simulation
(such as hydrogen atoms) and yet be numerically stable during integration [88]. A
suitable ∆t which ensures these things in protein simulations is 1 fs, and if the bonds
to hydrogen atoms are frozen at their equilibrium values, we can also use 2 fs time-
step. In practice, however, such a small time-step of numerical integration on current
computers can only generate nanosecond long trajectories. Hence, better schemes
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such as multiple-time-stepping method have been proposed to improve integration ef-
ficiency [84]. In these schemes, slower-varying forces such as long-range electrostatics
are computed less frequently than the faster varying forces such as the Lennard-Jones
and short-range electrostatics. Using multiple time-stepping can increase computa-
tional efficiency by a factor of 2 [84]. The multiple-time-stepping scheme used for
MD simulations presented in this thesis computes bonded interactions every ∆t, non-
bonded interactions including short-range electrostatics every 2∆t, and long-range
electrostatics every 4∆t. We note that this scheme is not accurate enough to carry
out simulations in the NVE ensemble, because it violates energy conservation prin-
ciple. That is not a problem, as only the NPT or NVT ensembles have been used
for simulations presented in this thesis. However, it is important to point out that
the NVE ensemble should be used with much caution, because the interparticle in-
teractions need to be computed more frequently than the other possible ensembles to
guarantee energy conservation.
2.4.4 Interatomic potential
For all-atomMD simulations of proteins, it is assumed that every atom experiences
a force specified by an empirical model potential which accounts for the interactions of
that particular atom with the rest of the system [84]. The empirical model potential
used in this thesis for all MD simulations is called CHARMM [89, 90], which is an
acronym for Chemistry at HARvard Macromolecular Mechanics. The CHARMM
potential energy function has following contributions:
Utotal = Ubond+Uangle+Udihedral+Uimpropers+UUrey−Bradley+UvdW+UCoulomb, (2.13)
where the first four terms describe the stretching, bending, and torsional bonded
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interactions, the fifth term accounts for angle bending using 1,3 nonbonded interac-
tions, and the final two terms describe interactions between nonbonded atom pairs
as follows:
Ubond =
∑
bonds
Kb(b− b0)
2, (2.14)
Uangle =
∑
angle
Kθ(θ − θ0)
2, (2.15)
Udihedral =
∑
dihedral
Kχ(1 + cos(nχ− δ)), (2.16)
Uimpropers =
∑
impropers
Kϕ(ϕ− ϕ0)
2, (2.17)
UUrey−Bradley =
∑
Urey−Bradley
KU(u− u0)
2, (2.18)
UvdW =
∑
i
∑
j>i
4ǫij
[(
σij
rij
)12
−
(
σij
rij
)6]
, (2.19)
UCoulomb =
∑
i
∑
j>i
qiqj
4πǫ0rij
, (2.20)
where b and b0 are the instantaneous and equilibrium bond lengths for each cova-
lent bond in the system, θ and θ0 are instantaneous and equilibrium valence bond
angle, χ is a dihedral angle which describes atom pairs separated by exactly three
covalent bonds with the central bond subject to the torsion χ, ϕ is an improper di-
hedral angle governing the geometry of four planar covalently bonded atoms, n is
multiplicity, and δ is phase shift. Parameters are force constants Kb, Kθ, KU , Kχ,
andKϕ corresponding to bond, angle, Urey-Bradley (cross-terms accounting for angle
bending using 1,3 nonbonded interactions), and dihedral terms. ǫij , σij , and rij are
the Lennard-Jones well depth, the distance at which inter-particle potential is zero,
and the inter-particle separation, respectively. ǫ0 is the dielectric constant and qi is
the partial charge on each atom. There are no special terms to represent hydrogen
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bonding, as they are treated as a sum of van der Waals and electrostatic interactions.
The parameters for interactions are laid out in the force field parameters files, the
location of which should be included in the initial start up file for any MD simulation.
We note that determination of these parameters is a significant undertaking, and is
generally accomplished through rigorous quantum-mechanical calculations that are
validated further with experimental data [84].
2.4.5 Initial conditions, minimization, temperature control, and pressure
control
Before beginning an MD simulation, it is necessary to specify an initial configura-
tion of the system. The choice of initial configuration can often determine the success
or failure of a simulation, and should be closest to the desired state of the system.
The initial configuations of different proteins used in this thesis were obtained from
the Protein Data Bank (PDB) (http://www.pdb.org/pdb/home/home.do), which is
a repository containing several tens of thousands of structures of biological molecules
determined by various experimental techniques such as X-ray crystallography and
NMR. Unfortunately, in the absence of such structures, it is not yet possible to pro-
pose initial configurations for proteins or other complex biological entities, which can
be used in an MD simulation. However, not all configurations obtained from PDB
are directly usable to launch an MD simulation, because many of these structures
may contain high-energy interactions due to atomic overlaps which cause numerical
instabilities during an MD simulation. Hence, the structures obtained from PDB are
first energy minimized to remove steric overlaps using standard enery minimization
methods such as steepest descents or conjugate gradient schemes [77]. The latter has
been used in all MD simulations presented in this thesis.
Because protein molecules are always in the biological milieu, we need to sol-
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vate them realistically, and this is accomplished by adding a layer of water molecules
around the protein with counterions added to neutralize the overall charge of the sys-
tem. The water molecules resolved by experimental techniques can also be retained,
but the lighter nuclei such as that of the hydrogen atoms are often missing. There-
fore, the net initial configuration contains the protein molecules, water molecules,
and counterions, where the solvent molecules alone may be 5-10 times higher than
the protein itself.
As much as it is necessary to establish an initial configuration of the system,
it is also necessary to assign initial velocities to the atoms. The velocities in MD
simulations are randomly assigned from a Maxwell-Boltzmann Gaussian distribution
at the temperature of interest:
P (v) =
(
mi
2πkBT
)1/2
exp
[
−
1
2
miv
2
kBT
]
. (2.21)
The Maxwell-Boltzmann equation provides the probability that an atom i of mass mi
has a velocity v at a temperature T. The instantaneous value of the temperature is
related to the kinetic energy via the particles’ momenta pi as follows:
H =
N∑
i=1
|pi|
2
2mi
=
kBT
2
(3N −Nc). (2.22)
where H is the Hamiltonian of the system, and 3N-Nc is the total number of degrees of
freedom. In constant temperature or pressure ensembles (NVT and NPT), there are
various ways to maintain the system at constant T and P. The temperature control
for MD simulations was achieved via Langevin thermostat (Eq 2.8). Other possi-
ble techniques for temperature control are Andersen thermostat [91], and Berendsen
thermostat [92], but are not discussed here for brevity. The pressure control in all
MD simulations presented in this thesis was achieved by the Nose´-Hoover barostat,
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which was first proposed independently by S. Nose´ [93] and W. G. Hoover [94, 95].
2.4.6 Boundary conditions
Careful thought must also be given to treat the spatial boundary of the simulation
system. The simplest possible choice is the vacuum boundary condition (BC), similar
to a gas-phase environment. But using such BC will distort the dynamics of atoms
near or at the surface of the system, and global properties computed will not be
representative of the condensed phase [83]. We can solvate the protein in a sphere
of water molecules, but this only shifts the distortive boundary effects from solute-
solvent to solvent-vacuum interface. To overcome these distortive effects, periodic
boundary conditions (PBC) were devised, in which the particles are enclosed in a unit
cell that is replicated to infinity by periodic translations [84]. In two dimensions,
each unit cell has eight nearest neighbors, while in three dimensions each unit cell
would have 26 nearest neighbors. An atom can interact with the nearest ‘image’ of
its neighbor, which is a statement of the ‘minimum image convention’. Should the
particle leave its unit cell during the simulation, it is replaced by an image of the
particle which enters from the opposite side of the unit cell. PBC were used in all
MD simulations presented in this thesis.
2.4.7 Software packages for biomolecular simulations
We have primarily used NAMD (NAnoscale Molecular Dynamics) (versions 2.5-
2.7) as a major tool to carry out MD simulations. NAMD is a parallel molecular
dynamics code designed for high-performance simulations of large biomolecular sys-
tems [84]. NAMD scales to hundreds of processors on high-end parallel platforms, as
well as tens of processors on commodity clusters and also runs on individual desk-
tops and laptops. NAMD has been used to simulate massive systems containing
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upto 2.64 million atoms with 85% parallel scaling efficiency, for example [96]. The
NAMD source code implements various techniques for efficient numerical integration
of Newtonian equations of motion, uses accurate statistical mechanics methods to
control temperature and pressure, evaluates electrostatic interactions through par-
ticle mesh Ewald (PME) summations, and also does steered molecular dynamics
(SMD) simulations (see Sec. 4.3.1). It is freely available to academic users from
http://www.ks.uiuc.edu/, and is an open source code package where users have
the flexibility to modify it for some new implementations of their interest. The users
can readily extend NAMD through scripting languages such as Tcl/Tk and Perl.
We used the software tool VMD (Visual Molecular Dynamics) (versions 1.8.6-
1.8.7) [97] to visualize and analyze the trajectories generated by NAMD and also to
calculate various properties related to our systems of interest.
2.5 Foundations of Monte Carlo simulations
AMonte Carlo (MC) simulation in simplest terms is a method of random sampling,
that is, it generates configurations of a system by making random changes to the
positions of constituting particles. MC simulations typically make use of a method
known as importance sampling for random exploration of phase space, which was
originally proposed by Metropolis et al. [85]. The critical feature of the Metropolis
approach is that it biases the generation of configurations towards those that make
the most significant contribution to the desired property. The Metropolis algorithm
generates what is known as a Markov chain of states, where a Markov chain satisfies
the following two criteria:
1. The outcome of each random trial depends upon the preceding trial and not
upon any previous trials.
2. Each trial belongs to a finite set of possible outcomes.
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A traditional MC simulation of a system of N particles would require the following
steps [77]:
1. Assign initial positions ri (i = 1 to N) to all particles in the system.
2. Obtain a new configuration of the system by randomly displacing the 3N Carte-
sian coordinates corresponding to N particles by a small amount (This small
random displacement is known as a trial move. The simplest trial moves are
random translational and orientational displacements of particles comprising
any system. We have used these trial moves to dock different ligands into the
pockets of their receptors as described in Chapters 5 and 6).
3. Calculate the potential energy of the system as a function of new atomic posi-
tions, Unew(ri).
4. Compute the ratio between the Boltzmann’s factor of current (new) and pre-
ceding (old) trial move, exp(-∆U(ri)/kBT ), where ∆U = Unew-Uold.
5. Compare the ratio to a random number in the interval [0, 1] (for a description of
good and bad random number generators, refer to [76, 78]). If the ratio between
Boltzmann factors is greater than the random number, then accept the new
state, otherwise reject it. It means that if the energy of the new state is very
close to that of the old state, then the Boltzmann factor of energy difference
will be very close to 1, and the trial move will be most likely accepted. On the
contrary, if the energy difference is very large, the Boltzmann factor of energy
difference will be close to zero and the move will be most likely rejected.
2.5.1 Condition of detailed balance
While accepting and rejecting the trial moves to guarantee correct sampling in an
MC simulation, it is sufficient but not necessary to impose the condition of microscopic
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reversibility or detailed balance: at equilibrium the transitions between two states of
a system occur at the same rate. This guarantees the equilibrium state probabilities
are invariant. The rate of transition from state m to a state n equals the product
of the population (ρm) and the appropriate element of the transition matrix (πmn).
Therefore, at equilibrium:
πmnρm = πnmρn. (2.23)
where πmn/πnm is the ratio of the Boltzmann factors of the two states.
2.6 Differences between MD and MC simulations
Molecular dynamics and Monte Carlo simulations can differ in several ways. First,
MD simulation based methods provide the information about the time dependence of
system properties, while such temporal relationship does not exist in successive MC
configurations. Second, in MC simulations the outcome of each trial move depends
upon its predecessor, while in MD simulations we can predict the configuration of
the system at any time in future or in the past. The total energy in MD simulations
has a contribution from the kinetic energy of the system, while in MC simulations
only potential energy is considered. Also, a traditional MD simulation is carried out
in the NVE ensemble, but a traditional MC simulation is typically done in the NVT
ensemble. However, we note that both MD and MC techniques can be modified to
sample from other ensembles described in Sec. 2.3.
2.7 Validation and limitations of molecular simulations
How the results obtained from molecular simulations can be validated, and in
what sense they can be limited, is important to consider. Five issues pointed out by
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Van Gunsteren and Mark [82] on which validation of molecular simulations depends
are worth reiterating:
1. The quality of theory or model. The choice of degrees of freedom chosen or
neglected, the type of boundary conditions used, and the approximation of
numerical integration schemes will determine the accuracy of simulated results.
2. The accuracy of interatomic potential or force field. The choice of functional
form, the parameters, and the theoretical or experimental data used to generate
those parameters will determine the force field accuracy. The accuracy of force
field also depends upon the type of molecules, the phase (gas or condensed),
and the kind of property under consideration.
3. The degree of phase space sampling. It is important that the simulation period
should be much longer than the relaxation time of property being computed.
4. The quality of simulation software. The software used for molecular simulations
has to be rigorously maintained and updated with newer developments. For the
proper use of the software package, it is also necessary to provide detailed user-
guides, tutorials, and benchmark studies for the benefit of scientific community.
5. How competently the simulation software is used. Most of the softwares come
with a multitude of input parameters, a combination of parameters that induces
erroneous results can be easily selected by the user. An example is a poor
choice of multiple-time-stepping scheme for the NVE ensemble simulations (see
Sec. 2.4.3), which can lead to violation of conservation principles.
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Chapter 3: Ligand (Un)binding Mechanisms in R6 Insulin Hexamer
3.1 Abstract
In this chapter, we describe the dissociation mechanisms of phenolic ligands from
R6 insulin hexamers, the cooperative binding of which is known to stabilize phar-
maceutical preparations of the hormone. Phenol dissociation is rapid on hexamer
dissolution timescales, and phenol unbinding upon dilution is likely the first step in
the conversion of (pharmaceutical) hexameric insulin to the active monomeric form
upon injection. However, a clear understanding of the determinants of the rates of
phenol unbinding remains obscure, chiefly because residues implicated in phenol ex-
change as determined by NMR are not all associated with likely unbinding routes
suggested by the best-resolved hexamer structures. We apply random acceleration
molecular dynamics (RAMD) simulation method of Lu¨demann et al. [98] to iden-
tify potential escape routes of phenol from hydrophobic cavities in the hexameric
insulin-phenol complex. We find three major pathways which provide new insights
into (un)binding mechanisms for phenol [99]. We identify several residues directly
participating in escape events that serve to resolve ambiguities from recent NMR
experiments.
3.2 Introduction
The insulin-phenol complex is a pharmacologically important protein-ligand sys-
tem. Insulin is a dual chain hormone (A-chain with 21 residues, and B-chain with
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30 residues) responsible for carbohydrate metabolism and is used in the treatment of
insulin-dependent (type 1) diabetes mellitus. Insulin monomers (51 residues and 5800
Da each) self-associate at physiological concentration (1 ng/ml) to form torus-shaped
hexamers in the presence of zinc ions [100]. Hexamers exist in three allosteric states
termed T6, T3R3, and R6 [27–36], related by a T6↔T3R3↔R6 dynamic equilibrium,
which is shifted to R6 only by phenolic derivatives [57, 58]. However, the T3R3 state
can be achieved either by concentrated anionic medium (Cl−, SCN−, etc.) or pheno-
lic species or both. Phenolic compounds act as antimicrobial agents and increase the
shelf-life of industrial formulations by stabilizing the R6 state [59]. Six hydrophobic
cavities are present for the phenolic ligands in the R6 state and none in the T6 state.
The conformation of the N-terminal B-chain residues (B1-B8) are extended in the
T state and helical in the R state. Spectroscopic evidence [101] for pre-existing T
and R state hexamers suggests that binding pockets come into existence only after
the T→R transition [102], which also means phenol binding/unbinding happens in
R-state hexamers.
Phenolic exchange does not require hexamers to dissociate because the lifetime of
R-state hexamers (days) is several orders of magnitude larger than the characteristic
time of phenolic dissociation (2-5 ms) [103]. Also, fast to intermediate (relative to
the NMR timescale) exchange of phenols is surprising given that the ligand is almost
completely buried in R-state hexamers [30]. Although NMR spectroscopy predicts
the existence of gatekeeper residues whose flexibility provides portals for entry/exit of
phenol, the A-chain Ile10 being one example [67], many other such important residues
remain unidentified. Additionally, unambiguous identification of residues displaying
several aromatic ring flips correlated to phenol exchange remains elusive [67]. The
N-terminal A-chain α-helix (residue A2 to A8) is speculated to facilitate entry/exit
of phenol [67], but exact identities of residues whose movement in particular aids this
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event are also unclear. Crystallographic thermal factors (β-factors) are an indirect
measure of residue mobility in proteins, but large scale displacements observed in
different residues during phenol escape are not obvious from β-factor data. Moreover,
analysis of X-ray crystal structures provides limited information on whether several
other entry/exit routes exist.
Given the need to understand the dissociation mechanisms of phenol from the
insulin-phenol complex, molecular simulations can play an important role by provid-
ing valuable insights into dynamics of phenol release on the molecular level. There
are two parts to this study: (1) this chapter is devoted to identifying and charac-
terizing a variety of phenol binding/unbinding pathways using random acceleration
molecular dynamics (RAMD) [98, 104], which is essentially an unbiased search for
escape pathways, and (2) the next chapter deals with the thermodynamics of these
exit pathways using steered molecular dynamics (SMD) simulations (see Sec. 4.3.1).
3.3 Simulation description
3.3.1 System preparation and equilibration details
We generated all trajectories using NAMDv2.5 [105] and the CHARMM force
field [89]. We used VMDv1.8.6 for visualization purposes and protein rendering [97].
Classical MD simulation is detailed in Sec. 2.4, and the functional form of the
CHARMM potential is described in Sec. 2.4.4. Initial coordinates are taken from
the X-ray crystal structure (2.0 A˚ resolution) of the human R6-state insulin hexamer
(PDB code 1ZNJ). The A- and B-type chain pairs for six monomers in the PDB file
are labelled and grouped as follows: (A,B), (C,D), (E,F), (G,H), (I,J), and (K,L) re-
spectively (Fig. 3.1 b). Three dimers in the hexamer are made up of chains (A,B,C,D),
(E,F,G,H), and (I,J,K,L) respectively. The original structure has two Zn2+ ions, two
Cl− ions in tetrahedral coordination sites on the Zn2+, seven phenols, and 331 water
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Figure 3.1: Schematic representation of the simulation system, (a) Simulation domain
(82.46A˚×82.65A˚×80.90A˚) as viewed along the z-axis: all the A- and B-type chains
are colored blue and green respectively. Six phenols are depicted with space-filling
spheres. Both zincs are rendered as gray spheres. Water molecules are in wireframe
representation, along with neutralizing media, sodium ions (yellow spheres) and chlo-
ride ions (cyan spheres). The system contains 50717 atoms in all. (b)(i) Top view
of R6 insulin hexamer (PDB code 1ZNJ) is shown along 3-fold axis of symmetry.
Hexamer and dimer interfaces are marked with arrows. Three top monomers are in
cartoon representation and the remaining three, below them, are in ribbon repre-
sentation. Top three phenols are darkened and lower three phenols are transparent.
(b)(ii) Top view of three upper monomers. The A- and B-type chains for each are
named individually as per PDB designations. Three phenols, one for each monomer,
are marked as 1, 2, and 3, respectively. (b)(iii) Top view of three lower monomers.
The A- and B-type chains are named accordingly. Three lower phenols are marked as
4, 5, and 6, respectively. (c) (i,ii,iii) Side views of panel b show the hexamer assembly
from one of the dimer interface β-sheet side (green antiparallel arrow).
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molecules in addition to the protein atoms. The missing threonines from C-terminus
position 30 of the chains D, F, and H are modeled. The seventh phenol molecule
situated next to one of the tetrahedrally coordinated Cl− ions is deleted. Missing
hydrogen atoms are added. The hexamer is then solvated using water molecules in a
rectangular box of volume 82.46×82.65×80.90 A˚3 such that its dimensions exceeded
those of protein by ∼12 A˚ in all directions. Charge neutrality is ensured with ran-
dom placement of 34 Na+ and 24 Cl− ions at 0.2 M concentration with a minimum
distance of 5 A˚ between ions. The solvated and ionized system has 50,717 atoms.
The CHARMM parameters for phenols are adapted directly from those of tyrosine.
A schematic representation of simulation system is given in Fig. 3.1 a.
This system is energy-minimized via 1000 cycles of conjugate-gradient optimiza-
tion. In order to relax the solvent a 20 ps NPT molecular dynamics simulation is
run. The temperature is held at 300K using the Langevin thermostat with damping
coefficient of 5 ps−1, and pressure using the Nose´-Hoover barostat. This equilibra-
tion phase is continued in the NVT ensemble for ∼1 ns. In all simulations, no rigid
bonds are used, periodic boundary conditions (PBC) are applied, full electrostatics
are computed every time step using the particle mesh ewald (PME) method, and van
der Waals interactions are cut off beyond 12 A˚ with the switching function taking
effect at 10 A˚. Configurations are saved every 5 ps and energy-like quantities every
half picosecond. The initial conditions for all RAMD trajectories in this chapter and
the SMD trajectories in the Chapter 4 are randomly sampled from the ensemble of
configurations in the final ∼100 ps of this equilibration simulation.
3.3.2 Random acceleration molecular dynamics (RAMD)
The RAMD method of Lu¨demann et al. [98] was originally applied to cytochrome
P450cam to discover exit routes of camphor. The two main advantages of RAMD are
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(i) it speeds up dissociation kinetics, thereby making it feasible to study at nanosecond
time scales; and (ii) it allows unbiased pathway search through various escape routes.
In RAMD, one applies randomly directed external forces to the ligand molecules
following a specific protocol. First, a force direction is chosen based on a randomly
oriented unit vector, rˆ, so that the external force applied to the ligand is given by
~fext = f0rˆ (3.1)
where f0 is the constant magnitude of the randomly chosen force. The force is main-
tained for a pre-determined number of steps, m. The ligand is expected to maintain a
certain threshold velocity vmin = rmin/m∆t over m steps, where ∆t is the time step (1
fs), and rmin is the specified minimum distance before a direction change. The average
velocity of the ligand over the previous m steps is computed. If the ligand’s velocity
falls below vmin a new random force vector is computed. RAMD is discontinued when
the ligand has escaped. It is generally non-trivial to find suitable RAMD parameters
to guarantee successful expulsions. The success probability varied between 19-42%
depending on f0 and m. For example, we tested m values between 10 to 100 steps
and f0 values from 5 to 20 kcal/mol·A˚ (Table 3.1). We used tclforces to implement
RAMD in NAMD (see tclforces script provided in Appendix A).
3.3.3 Reaction coordinates
Each successful RAMD trajectory is approximated to a smooth curvilinear path.
All such paths that lie within a cylindrical tube of radius 2.5 A˚ from each other are
clustered into three distinct pathway classes. For each pathway class, an average
path based upon all the successful trajectories of that class is constructed. A straight
line having minimal standard deviation from its averaged path is determined that
served as reaction coordinate (RC) for the free energy calculations described in the
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Table 3.1: Characterization of ligand exit pathways. RAMD simulation results for four different combination of f0
(kcal/mol·A˚), m, and rmin (A˚). Ns and % are successful trajectories and occurrence frequency respectively. Nsi denotes
successful expulsions for ith pathway (i = 1, 2, and 3 for PW1, PW2, and PW3 respectively). Minimum (min.), average
(avg.), and maximum (max.) expulsion times (texpulsion) are provided. A total of 200 trajectories are carried out for each
combination of f0, m, and rmin.
f0 m rmin Ns PW1 PW2 PW3
texpulsion (ps) texpulsion (ps) texpulsion (ps)
Ns1 % min. avg. max. Ns2 % min. avg. max. Ns3 % min. avg. max.
20 10 0.006 84 33 39 4.80 6.00 9.30 40 48 5.70 9.20 13.1 11 13 9.30 10.9 14.0
15 10 0.005 53 18 33 11.3 13.1 14.6 30 57 9.20 12.3 15.0 5 10 9.60 12.1 14.7
10 30 0.004 45 13 29 14.4 20.3 28.4 29 64 17.6 23.3 25.0 3 7 10.8 22.2 28.5
5 100 0.030 38 6 16 60.0 113 131 32 84 54.0 89.2 147 0 0 0.00 0.00 0.00
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Chapter 4. Successful trajectories observed only with the smallest perturbing forces
in RAMD simulations are used in the determination of RCs.
3.4 Results
3.4.1 Phenol escape pathways
We observed three types of escape pathways using RAMD simulations. They
are denoted Pathway 1 (PW1), Pathway 2 (PW2) and Pathway 3 (PW3). PW1
and PW2 involve residues in the proximity of the hexamer interfaces as shown in
Fig. 3.1 b. Three such interfaces are present in the R6 insulin hexamer, one between
each pair of dimers. PW3 mainly involves residues around the dimer interfaces visible
as green antiparallel β-sheets in Fig. 3.1 c. Three dimer interfaces are also present,
one between each pair of monomers forming each dimer. The locations of all pathways
is shown in Fig. 3.2 a. Parameters and trajectory statistics for RAMD simulations
are given in Table 3.1. The RCs along each unbinding pathway are straight lines.
Three such straight lines are drawn from the phenol binding cavity to exit points
on protein surface in Fig. 3.2 b. The dynamics of phenol release along the RCs
for various pathways can be explicitly understood through displacements of residues
lining each escape route. These RMS displacements from the crystal structure (PDB
code 1ZNJ) for all the residues lining each pathway are plotted in Fig. 3.3. The RCs
for each pathway are partitioned into sections S0, S1, etc., as given in Table 4.1. The
particular phenol molecule we interrogated is marked as “1” and is situated in the
binding pocket formed by the chains A, B, F, and H (Fig. 3.1 b).
3.4.2 Pathway 1: Gate-opening mechanism
PW1 is situated in the hexamer interfaces of the insulin-phenol complex as shown
in Fig. 3.2 a. The phenol molecule in the binding pocket is surrounded by CysA6,
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Figure 3.2: (a) Locations of three pathway classes determined using RAMD simula-
tions are shown: PW1 (green curve), PW2 (brown curve), and PW3 (yellow curve).
The A-chain is shown in blue cartoon representation, while the B-chain and F-chain
are in green cartoon representations. The H-chain is in green ribbons. The terminal
ends of each chain are marked by letters N and C. Phenol is rendered as space-filling.
Zincs are gray spheres. The gatekeeper residues, HisF5 and IleA10, are shown along
with ValF2, LeuH17, LeuA13, IleA2, GlnA5, CysA6, CysA11, GluA17, and TyrA19 (all
in licorice representation). The B-chain residues are colored: LeuB11 (pink), LeuB15
(red), PheB25 (brown), and TyrB26 (magenta). (b) The SMD pulling directions along
three pathways are rendered in same color as pathways. The length of three different
reaction coordinates along three straight lines are 14.5 A˚ (green), 15.0 A˚ (brown),
and 16.0 A˚ (yellow), respectively. The residue naming is same as in panel a.
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Figure 3.3: RMS displacements for all important residues (see text) for each pathway
in each individual section Si (i = 0 to 5 for PW1, PW2, and 0 to 6 for PW3)
of the reaction coordinate (Table 4.1). Each residue is shown in a different color.
Equilibrium fluctuations of all the residues are marked with “Eq.” on the abscissa.
The reference X-ray structure for RMSD calculation is R6 insulin hexamer (PDB code
1ZNJ).
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Figure 3.4: Top view snapshots of the gate-opening mechanism (see Pathway 1 in
text) at RC = 0.0, 4.8, 7.8, and 10.8 A˚. The gatekeeper residues, HisF5 and IleA10,
are in licorice representation. Phenol is rendered in space-filling representation. The
gate opens to the left.
CysA7, ThrA8, SerA9, IleA10, and CysA11 of the A-chain from one dimer and ValF2, and
HisF5 from the adjacent dimer. While in the binding pocket, phenol forms hydrogen
bonds by donating a proton to the carbonyl O atom of CysA6 and accepting another
from the amide N atom of CysA11. The “gate” of the pocket is guarded on one side
by the imidazole ring of HisF5, and on the other side by the side-chain of IleA10.
A front view and a top view nearly parallel to the histidine ring of the gate are
shown in Fig. 3.2 and Fig. 3.4 a respectively. During breakage of the hydrogen bonds
to cysteines in the previous 4 A˚ of the reaction coordinate (sections S0 and S1 of
PW1 in Table 4.1), the ligand significantly displaces CysA6 in comparison to CysA11
(Fig. 3.3). These hydrogen bonds are immediately substituted for by several water
molecules (resolved crystallographically) present in the cavity, along with phenol. At
this point, the aromatic ring of the ligand is in close van der Waals contact with the
imidazole ring of HisF5 and the side-chain of IleA10 forming the gate, where increasing
deviations of these residues from their equilibrium positions are visible in Fig. 3.3.
The imidazole ring of HisF5 can freely rotate about Cγ of the ring, and it flips towards
the solvent when it encounters an outgoing phenol, early in section S2 (Table 4.1).
This ring flipping on the onset of opening the gate is captured in a snapshot, at a
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distance of 4.8 A˚ along the reaction coordinate in Fig. 3.4 b. Noticeably, the aromatic
rings of phenol and HisF5 interact parallel to each other throughout section S2 (4.5
A˚ to 8.5 A˚) as shown in Fig. 3.4 b,c. Phenol advances into the gate, pushing it
wide-open by displacing the side-chains of HisF5 and IleA10 significantly (Fig. 3.4 c).
The pronounced RMS displacements of these two side-chains, concomitant with the
“gate-opening” mechanism, are depicted in section S2 of PW1 in Fig. 3.3.
Phenol is completely out of the gate at a distance of 10.8 A˚ (Fig. 3.4 d). Simulta-
neously, concerted fluctuations in several neighboring residues of the binding pocket,
located on both sides of the gate, are seen during the ligand’s escape (Fig. 3.3). To-
wards the end (sections S4 and S5), no residue explicitly hinders the outgoing ligand
though it weakly interacts hydrophobically with the protein. The side-chain of IleA10
relaxes back toward the cavity but the imidazole ring of HisF5 remains flipped into
the solvent as depicted through nearly equal RMS shifts of this residue in the last 6 A˚
(sections S3, S4, and S5 in Fig. 3.3). The change in the structure of the hydrophobic
pocket can also be inferred from different relaxation state of all the residues with-
out the ligand relative to its bound state. The ligand is completely free from any
interactions with the protein after 14.5 A˚.
At least ∼12 water molecules (7 solvent and 5 crystallographic) in comparison to
∼2-3 molecules in the initial state, are observed within a sphere of 5 A˚ radius around
original COM position of the phenol in the binding pocket. The binding pockets in
several T3R3 hexamers crystallized in the presence of concentrated anionic medium
lack phenol, but possess several water molecules in its place [106, 107]. Similar inflow
of ∼8 water molecules in the binding pocket was observed in the simulation study of
phenol dissociation from the hexamer by Swegat et al. [75]. 1H-NMR spectroscopy
experiments hint at the existence of “gatekeeper” residues and aromatic ring flipping
events correlated with phenolic exchange [67]. Swegat et al.’s constrained molecular
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dynamics study of phenol dissociation suggested IleA10 as one such gatekeeper residue.
In PW1, we find involvement both of IleA10 and HisF5 as gatekeeper residues for the
ligand’s escape. The unrestricted ring flipping of HisF5 suggested in PW1 was not ob-
served in Swegat’s study and is a new finding to be verified experimentally. However,
two ring rotamers of HisF5 in an R-state trimer were observed in a comparative crys-
tal structure analysis of T3R3 insulin hexamers that bind p-hydroxybenzamide (PDB
code 1BEN) or methylparaben (PDB code 3MTH) and are thought to have occurred
during binding of these phenolic species to the R-state pockets [108]. We argue HisB5
ring flipping is generally important for accessing the binding pocket for any of the six
ligands.
3.4.3 Pathway 2: Gate-leaping mechanism
PW2 is also located in the hexamer interfaces as shown in Fig. 3.2 a. In this
case, phenol encounters two new residues, LeuH17 and LeuA13, in addition to all the
residues mentioned in PW1. These leucines are involved in a close van der Waals
contact in the hexamer interfaces (Fig. 3.2 a), which helps bind adjacent dimers in
the insulin-phenol complex. A narrow open channel exists in the space between the
gatekeeper residues (vide supra) and both the leucines in the hexamer interface. Front
and side views of this channel are shown in Fig. 3.2 a and Fig. 3.5 a (RC = 0.0 A˚)
respectively.
The hydroxyl group of phenol is accompanied to the entrance of this channel by
∼3-4 water molecules (also resolved in the crystal), where solvent molecules replace
crystallographic water for hydrogen bonding, in the first 4 A˚ of the escape (sections
S0 and S1 for PW2 in Table 4.1). Contrary to PW1, where gate-opening is due to
the aromatic ring of phenol, in PW2 the ligand enters the narrow channel with its
hydroxyl group first after considerable reorientation, as represented in the snapshot
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Figure 3.5: Side view snapshots of the gate-leaping mechanism (see Pathway 2 in
text) at RC = 0.0, 3.8, 6.8, and 9.8 A˚. Narrow channel between gatekeeper residues
and both leucines, LeuA13 and LeuH17, is visible. Crystallographic and solvent water
molecules within 5 A˚ of phenol are rendered in yellow and red licorice representations,
respectively. All residues and phenol are also in licorice representation as indicated
in panel a. The arrow in panel b shows still frames of reorienting ligand at every 15
ps.
in Fig. 3.5 b (RC = 3.8 A˚). Phenol continues to steer through the channel making a
smooth leap over the gate in the next 3 A˚ (section S2 for PW2 in Table 4.1).
In this “gate-leaping mechanism”, the RMS fluctuations of HisF5 and IleA10 (the
gatekeeper residues) are relatively smaller (RC = 4.0 to 7.0 A˚) in comparison to the
gate-opening mechanism (notice sections S2 of PW1 and PW2 in Fig. 3.3). While
making the leap, the phenolic ring interacts with the imidazole ring of HisF5, and the
fluctuations of HisF5 can be mainly attributed to the semi-flipped state of this ring
(Fig. 3.5 c,d) in this region. At RC = 9.8 A˚, phenol has nearly exited this narrow
opening, where it is surrounded by a cluster of solvent water molecules, shown in
Fig. 3.5 d. It is not until RC = 15.0 A˚, that the ligand ceases to interact with
the protein. The RMS displacements for all other residues common with PW1 are
depicted in Fig. 3.3. Only ∼6 water molecules are observed in the cavity (within a
sphere of 5 A˚ radius) after the ligand has dissociated. To a greater extent, decreased
inflow of water is a result of closed-gate conformation of the gatekeeper residues,
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because of which the binding pocket has not significantly expanded in comparison to
PW1. One such channel, similar to PW2, that extends from the binding site to the
surface of R-state trimer was suggested in a comparative crystal structure analysis
of T3R3 insulin hexamers [108]. Moreover, this pathway is observed in the highest
frequency among all the exit routes discovered using RAMD simulations (Table 3.1).
3.4.4 Pathway 3: Dimer-interface mechanism
PW3 is completely unrelated to the previous pathway classes because the ligand
exits through the dimer interface (Fig. 3.1 c). The exact location of PW3 can be
appreciated from the RAMD expulsion trajectory and the SMD pulling direction
indicated in Fig. 3.2. The escape route passes through a sterically dense region in
the core of the insulin monomer made up of the chains A and B, and is primarily
lined by residues IleA2, GlnA5, CysA6, CysA11, LeuA16, TyrA19, LeuB11, LeuB15, PheB25,
TyrB26, and ProB28. The first four of these residues belong to the lower N-terminal
α-helix of the A-chain, the next two to the upper C-terminal α-helix of same chain,
the following two to the N-terminal α-helix of the B-chain, and the last three to the
dimer interface β-sheet region of the B-chain. Mostly, the A-chain residues hinder
the ligand’s passage in the beginning, while the B-chain residues play a role in the
latter stages of escape because these residues actually participate in formation of the
dimer interfaces.
At early stages of escape in section S0 and S1 of the reaction coordinate (Ta-
ble 4.1), the hydroxyl group of phenol repeatedly switches hydrogen-bonds between
crystallographic water molecules and neighboring cysteine residues. The side-chain
of LeuB11 hinders motion of the ligand in these regions of the reaction coordinate
experiencing a significant RMS displacement (Fig. 3.3). Comparison of crystal struc-
tures has shown previously that this side-chain restricts the size and shape of phenol
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binding cavity in R6 species to be significantly smaller, and less open than T3R3, and
is proposed to be naturally displaced when larger allosteric ligands such as 2,6-and
2,7-dihydroxynaphthalene occupy the cavity [109].
The aromatic ring of the ligand chiefly interacts through hydrophobic and van
der Waals interactions with the side-chains of LeuA16 and LeuB15, and phenol moves
through section S2 with its aromatic ring oriented towards the monomer interior,
possibly maintaining a weak hydrogen bond with amide proton of CysA11 through its
hydroxyl group. The location of these leucines (vide supra) does not permit them
to block phenol escape directly, though small RMS shifts in these side-chains are
observed (Fig. 3.3). The phenol encounters mainly IleA2 and TyrA19 (Fig. 3.2 a)
during its passage from sections S3 and S4. The tyrosine residue is exposed to the
solvent but the aromatic ring is oriented towards the subunit interior, and it rotates
about Cγ to flip back to the solvent region on its first collision with the escaping
ligand. In the course of inducing ring flip, phenol also displaces significantly the
side-chain of IleA2 (Fig. 3.3). GlnA5, situated in the vicinity of IleA2, simultaneously
displays a smaller displacement. Throughout section S5, phenol weakly interacts with
IleA2, TyrA19, and TyrB26, chiefly through its aromatic ring, and finally leaves with
the hydroxyl group into the solvent.
At this stage, the ligand eventually finds itself in the unblocked open space between
the N-terminus of the A-chain and the antiparallel β-sheet of the dimer interface. It
mainly displaces the side-chain of ProB28 in section S6 whereas the aromatic parts
of phenol and PheB25 keep interacting weakly until the end of this section. Phenol
is completely dissociated beyond the reaction coordinate distances of 16 A˚ with the
exit point located in proximity of the β-sheet region.
That aromatic ring rotation of TyrA19 is related to phenol exchange suggested by
NMR studies and speculation exists for structural fluctuations in the N-terminal A-
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chain α-helix (residue A2 to A8) facilitating entry/exit of phenol [67]. This pathway
indeed involves mainly two residues, IleA2 and GlnA5, that are part of this domain.
More importantly, the mutation of GluA17 to GlnA17, which eliminates salt-bridging
interactions between ArgB22 and GluA17, has been shown to have negligible effects on
the dissociation constants for the ligand binding to phenolic pockets [110]. We indeed
observe that GluA17 does not interact with phenol directly or indirectly in any of our
pathways, which is consistent with the mutagenesis studies [110].
3.5 Discussion
An important aspect of this study is the observation of different escape pathways
for phenolic ligands from the insulin-phenol complex using RAMD. The knowledge of
multiple exit routes provides new insights into the dissociation mechanisms of phenol
and certainly complements experimental findings. As an example, the structural anal-
ysis of pathways found several aromatic ring flips involved in the ligand’s release along
multiple pathways, some of which are suggested by experimental studies [67, 103], and
thought to be related to phenol exchange. We identify such ring flips in HisF5 (PW1)
and TyrA19 (PW3) during the ligand’s escape. The kinetics of phenol (un)binding
is not experimentally accessible yet [75], and rates of dissociation computed by us-
ing various kinetic models can depend upon the way ligand dissociates along any of
multiple pathways. Due to the lack of such knowledge, a preference for a particular
pathway is not given in a hierarchical modeling study of phenol binding [111], but we
consider it to be important for improving and generalizing any kinetic model.
3.6 Conclusions
Phenolic preservatives are used in pharmaceutical preparations of insulin, where
the hexamer stability is ensured by non-covalent association of these ligands to six
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hydrophobic cavities buried inside the protein. We used random acceleration molec-
ular dynamics (RAMD) [98] to identify escape routes of phenol from the hexameric
insulin-phenol complex. Three different escape pathways, two through the hexamer
interface, and one through the dimer interface, were observed. Several events relating
to opening of entry/exit portals for phenol exchange were suggested by experiments,
such as flipping of aromatic rings in various residues. We are the first to observe such
flipping motions exclusively in two residues, HisF5 (PW1) and TyrA19 (PW3). We
also observed the direct involvement of several other residues (Fig. 3.3) lining each
pathway. Structural examination identified a gatekeeper residue IleA10 in PW1 sug-
gested previously by Swegat et al. [75], along with HisF5 as a new gatekeeper residue.
The α-helix of the A-chain (residue A2 to A8) is thought to play a role in phenolic
exchange [67], and we are the first to quantify important fluctuations in two residues,
IleA2 and GlnA5, situated in this domain, that correlate with phenol unbinding. We
hope future experimental studies will corroborate these observations. Previous simu-
lations of this complex identified only one phenol escape route [75]. We argue instead
for the existence of several competing dissociation mechanisms corresponding to dif-
ferent escape routes.
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Chapter 4: Thermodynamics of Phenol Entry/Exit Pathways
4.1 Abstract
Reaction coordinates (RCs) for dissociation of phenol are developed based on three
exit pathways described in the Chapter 3. Potentials of mean force (PMFs) along
the RC for each pathway are resolved using multiple independent steered molecular
dynamics (SMD) simulations with second order cumulant expansion of Jarzynski’s
equality [112]. Our results for ∆F agree reasonably well within the range of known
experimental and previous simulation magnitudes of this quantity. Based on struc-
tural analysis and energetic barriers for each pathway, we suggest a plausible preferred
mechanism of phenolic exchange [99] that differs from previous mechanisms. Several
weakly-bound metastable states are also observed for the first time in the phenol
dissociation reaction which are supported by recent experimental evidence [113].
4.2 Introduction
Free energy, the energy available for useful work, is a central concept in ther-
modynamics since the time of Helmholtz and Gibbs. The free energy at constant
temperature (T ) and volume (V ) is known as the Helmholtz free energy (denoted
by F(T,V)), while at constant T and pressure (P) is known as the Gibbs free energy
(denoted by G(T,P)). The calculation of free energy is of great importance for un-
derstanding the kinetics and molecular determinants of biomolecular processes such
as folding and unfolding of proteins, ligand binding to receptors and enzymes, and
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transport of small molecules through channels [114]. The fundamental free energy cal-
culations demand a thorough sampling of configurational phase space of the system,
which makes such calculations extremely challenging for computer simulations [76].
Also, active perturbation of the system in experiments and computer simulations
leads to hysteresis and non-equilibrium effects [115]. We need numerous details of
the system to completely specify such irreversible and non-equilibrium processes. Re-
versible processes on the contrary are powerful tools of thermodynamics, because they
make it possible to relate heat and work to a fewer thermodynamic variables such as
T and P . It follows from the second law of thermodynamics that the increase in the
Gibbs free energy ∆G and the mean work 〈W 〉 to bring this increase are related by:
∆G ≤ 〈W 〉 (4.1)
The equality holds only when the process is carried out infinitely slowly and
hence reversibly. At finite rates, the average work will always exceed the free en-
ergy difference. However, many processes in nature relax very slowly to equilibrium,
precluding reversible measurements of thermodynamic variables. Therefore, the prob-
lem of recovering thermodynamic quantities from irreversible experiments remains an
unfinished task [116]. An important question in this context is: How to extract equi-
librium thermodynamic properties from non-equilibrium finite-time measurements?
Jarzynski’s equality [112], also known as the non-equilibrium work theorem, is a new
fundamental result in the statistical mechanics of systems driven far away from equi-
librium. Specifically, this theorem extends the second law of thermodynamics to non-
equilibrium systems, because it relates the equilibrium free energy difference (∆F ) to
the mean work extracted from finite-time non-equilibrium measurements:
e−β∆F = 〈e−βW 〉 (4.2)
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where β=1/kBT , kB is Boltzmann’s constant, and T is the temperature. The equa-
tion 4.2 is independent of the path taken by the system to go from an initial to
a final state, and also the rate at which this process is carried out. The theoreti-
cal foundations for the application of Jarzynski’s equality to both experiments and
simulations have been detailed by Hummer and Szabo [115]. The first experimental
demonstration of the application of this equality to extracting free energy differences
via single-molecule pulling experiments is worth reading [116]. The free energy cal-
culations via both equilibrium and non-equilibrium simulations in biological systems
have also been the subject of various doctoral theses: Shirts has extensively com-
pared the methods to calculate accurate free energies in biological systems [117], and
Park has studied the application of Jarzynski’s equality via non-equilibrium SMD
simulations [118]. The concept of the free energy as a function of the reaction co-
ordinate, also known as the potential of mean force (PMF), was first introduced by
Kirkwood [119]. PMF can be computed by equilibrium as well as non-equilibrium
simulation methods, and twelve such different techniques to compute PMF were com-
pared for their accuracy by Trzesniak et al. [120]. We have used the non-equilibrium
methods, originally developed by Park and coworkers, to compute PMF using SMD
simulations [114, 121].
In this chapter, we perform steered molecular dynamics (SMD) simulations in
combination with cumulant expansion of Jarzynski’s equality (JE) [112] to construct
(Helmholtz) free energy profiles of ligand dissociation reactions along RCs for three
pathways (see Chapter 3). Based on PMF profiles, we determine that the gate-leaping
mechanism is the most likely phenol dissociation pathway, and a previously studied
gate-keeper pathway is likely not the preferred pathway for unbinding. We also note
several weakly bound (∼3-4 kcal/mol) metastable states on the surface of the insulin
hexamer.
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4.3 Simulation description
4.3.1 Steered molecular dynamics (SMD)
We have used two different types of SMD simulations in this study: constant-
velocity SMD (cv-SMD) and constant-force SMD (cf-SMD). In the cv-SMD scheme,
the center of mass (COM) of phenol is attached to a dummy atom via a virtual spring
with spring constant k. The dummy atom is then pulled with constant velocity in a
fixed direction along the RC. The distance along the pulling coordinate, λ, increases
at constant velocity such that λt = λ0 + vt, where λ0 = 0 initially. One efficient
way to sample the reaction coordinate ξ is to use high k, i.e., sufficiently stiff spring.
Hence, work performed for one such trajectory is given by
W0→t = −kv
∫ t
0
[ξ − (λ0 + vt)]dt (4.3)
The cf-SMD simulations help in identifying short-lived intermediate states when
the magnitude of external force is comparable to or smaller than system forces. At
each such short-lived intermediate state, we then break reaction coordinates in to
sections S0, S1, etc., as given in Table 4.1. cv-SMD simulations are performed multiple
times in each such independent section to sample efficiently that part of the RC. The
RCs along each unbinding pathway are straight lines. Three such straight lines are
drawn from the phenol binding cavity to exit points on protein surface in Fig. 3.2 b.
The starting coordinates for three straight lines are (12.105, -12.547, -4.271), and the
unit vectors corresponding to straight lines for PW1, PW2, and PW3, are (0.645,
-0.173, -0.744), (-0.338, -0.174, -0.924), and (-0.539, -0.443, 0.715), respectively. The
length of RCs for PW1, PW2, and PW3, are 14.5, 15.0, and 16.0 A˚, respectively.
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Table 4.1: cv-SMD trajectory times in each section of the reaction coordinate for each
pathway. A total of three cv-SMD trajectories are carried out in each section with
a velocity of 1×10−5 A˚/fs. Stars indicate sections in which much slower trajectories
(refer text) are carried out with a velocity of 5×10−6 A˚/fs.
Pathway Section RC (A˚) Total simulated time
(Si) in each section (ps)
PW1
S0 0.0-2.5 1050
S1 2.5-4.5 900
S⋆2 4.5-8.5 2000
S3 8.5-10.5 900
S4 10.5-11.5 600
S5 11.5-14.5 1500
PW2
S0 0.0-2.0 900
S1 2.0-4.0 900
S⋆2 4.0-7.0 1800
S3 7.0-9.0 900
S4 9.0-13.0 1500
S5 13.0-15.0 900
PW3
S0 0.0-2.0 900
S1 2.0-3.5 750
S2 3.5-5.0 750
S3 5.0-7.0 900
S4 7.0-9.0 900
S5 9.0-13.0 1500
S6 13.0-16.0 1200
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4.3.2 Potential of mean force (PMF) construction
Following the protocol of Jensen et al. [122], we used second order cumulant
expansion of the Jarzynski’s equality [112] to compute the potential of mean force
(PMF) along each reaction coordinate from work distributions obtained using cv-SMD
simulations. Briefly, the second order cumulant expansion is
∆F = 〈W¯ 〉 −
1
2
β(〈W¯ 2〉 − 〈W¯ 〉2) (4.4)
whereW is the work performed, β = 1/kBT , kB is Boltzmann’s constant, T is the bulk
temperature, and ∆F is the free energy difference. Bars denote averages over time
windows of 20 ps, and angle brackets denote ensemble averages over independent
cv-SMD trajectories. The second order cumulant expansion is valid for Gaussian
work distributions generated using cv-SMD simulations with the use of sufficiently
stiff springs [114, 121]. Overall potentials of mean force are assembled using sectional
PMFs such that they match at boundaries. Performing independent pullings in each
section significantly decreases non-equilibrium effects, and improves the quality of the
PMFs [122].
4.4 Results
4.4.1 Steered molecular dynamics simulations
We performed both cf-SMD and cv-SMD simulations to quantify the free energy
change of the ligand dissociation reaction. In the cf-SMD scheme, a constant force is
applied to the COM of phenol to pull it along the respective RC for each pathway.
Forces of magnitude 280 pN, 105 pN, and 350 pN were used for PW1, PW2, and
PW3, respectively. The length of trajectory for each pathway was 700 ps, 1000
ps, and 400 ps, respectively. The dwelling positions for COM of phenol along the
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reaction coordinate for each pathway are identified from cf-SMD simulations. Each
such dwelling position serves to mark sections (e.g., S0, S1, etc., in Table 4.1) for
subsequent cv-SMD simulations along the RC for each pathway.
In the subsequent cv-SMD simulations, the COM of phenol was constrained with
a harmonic spring of stiffness 8 kcal/mol·A˚2 in the beginning of each section, while
the system underwent 200 steps of energy minimization, and 100 ps equilibration.
cv-SMD simulations were conducted in 5 independent sections of the RC for PW1,
and PW2, and 6 independent sections for PW3 (Table 4.1). Three such trajectories
in each independent section of the RC, for each pathway, were performed (Table 4.1).
We chose a velocity of 1×10−5 A˚/fs, and spring constant k of 5 kcal/mol·A˚2 to ensure
the stiff spring approximation was valid. The velocities used in this study are much
slower in comparison to several other similar studies with cv-SMD [122, 123]. In some
sections (S2 of PW1 and PW2), even slower velocities (5×10
−6 A˚/fs) were used to
decrease non-equilibrium effects (see Discussion). The external work, W, of gradually
decoupling the ligand from protein pocket was computed from several independent
cv-SMD simulations in each section of the reaction coordinate (Table 4.1), and these
microscopic work values were used to estimate ∆F using second order cumulant ex-
pansion of Jarzynski’s equality (eq. 4.4). The COM position of the ligand in each
pulling window, unbinding forces, and combined potential of mean force (henceforth
denoted by PMF) for PW1, PW2, and PW3, are plotted in Fig. 4.1, Fig. 4.2, and
Fig. 4.3, respectively. Overall trajectory statistics for the cv-SMD simulations are
given in Table 4.1.
The intermediate events during the course of phenol release along three pathways
can be qualitatively appreciated from their respective unbinding cv-SMD force pro-
files (panel b in Fig. 4.1 - 4.3). In the beginning of unbinding along each pathway,
phenol is in the bound state with no external force acting on it. Early in the pull,
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Figure 4.1: SMD simulation results for PW1 in each independent section of the
reaction coordinate (green line in Fig. 3.2 b and Table 4.1). (a) The COM trajectory
of phenol. (b) Unbinding forces. (c) Combined potential of mean forces such that they
match at boundaries. Three colors (red, blue and green) in panels a, and b, represent
data from three independent SMD simulations in each section (Table 4.1). Error
bars for each independent section are also plotted. Vertical dotted lines represent
boundaries of each independent section in which unidirectional pulling was performed.
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Figure 4.2: SMD simulation results for PW2 in each independent section of the
reaction coordinate (brown line in Fig. 3.2 b and Table 4.1). See caption of Fig. 4.1
for details.
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Figure 4.3: SMD simulation results for PW3 in each independent section of the
reaction coordinate (yellow line in Fig. 3.2 b and Table 4.1). See caption of Fig. 4.1
for details.
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negative cv-SMD forces indicate the larger magnitude of thermal fluctuations over
the external force. Phenol escape is triggered soon after this initial drop, visible as
an increasing external force dominance over system forces that try to reinstate the
initial state. The steep increase in force for each pathway following this reflects the
breakage of hydrogen bonds between phenol and disulfide cysteines. The continued
increase in force until reaching a maximum reflects displacements of side-chains of
residues lining each pathway (Fig. 3.3) that hinder unbinding of phenol, and the
magnitude of this maximal force measures in some way the difficulty in unbinding
for a particular pathway. It should be mentioned here that the total work done in
dissociating phenol along a particular pathway mostly arises from the external force
after it reaches its maximum, because in the earlier regime, the ligand has moved a
considerably smaller distance along the reaction coordinate for each pathway. The
unbinding forces decrease further as the ligand moves away from the binding pocket.
The forces fluctuate about a mean drag force when the ligand is out of the protein
in the dissociated state. The dissociated state for each pathway is achieved at 14.5,
15.0, and 16.0 A˚, respectively (Fig. 4.1 - 4.3).
4.4.2 Free energy profiles for exit pathways
RAMD simulations discussed in Chapter 3 provide limited information on the like-
lihood of occurrence of each pathway, but the PMF (panel c in Fig. 4.1 - 4.3) along
the chosen RC can help us gain more quantitative insights into the relative likeli-
hoods of the several (un)binding mechanisms for phenol. It is crucial to minimize the
fluctuations of the RC among different trajectories before constructing the PMF, and
in this case, the COM of phenol closely follows the constraint center (λ) in all path-
ways, ensuring that the stiff-spring approximation is valid (panel a in Fig. 4.1 - 4.3).
Minimizing fluctuations in the reaction coordinate allows us to sample efficiently the
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contributions to the PMF arising from the region around λ. In the respective S0
sections, the PMFs for PW1 and PW2 are not very different from each other as all
involve breakage of hydrogen bonds to CysA6 and CysA11 but significant deviation
among both hexamer interface pathways can be seen in the latter stages of the un-
binding process. The steeper PMF for PW1 in section S1, compared to PW2 is due
to close van der Waals contact of the ligand with the gatekeeper residues (see Chap-
ter 3). Section S2 in PW1 is correlated to the gate-opening mechanism (Fig. 3.4),
while same section corresponds to the gate-leaping mechanism (Fig. 3.5) for PW2, as
described earlier. The lower slope of the PMF is evident in this region for PW2 as
opposed to PW1. This also makes physical sense because it is easier for the ligand to
pass through the narrow channel instead of opening the gate, which in turn results
in relatively higher unbinding forces for PW1. The rotational degrees of freedom
of the ligand (Fig. 3.5 b) allow it to find a lower free energy path in this region by
exiting the hydroxyl group first. In the dimer interface pathway (PW3 in Fig. 3.2),
phenol meets densely packed residues in the monomer core, where steep departure
of the PMF in the very early sections of the RC (S0, S1, and S2) in comparison to
hexamer interface pathways is seen. The unbinding forces for this pathway are the
highest in magnitude (Fig. 4.3) and observance frequency the least (Table 3.1). The
maximum barrier heights with respect to initial state are measured to be 23.63 ±
0.50 kBT (PW1), 19.33 ± 1.60 kBT (PW2), and 26.83 ± 1.10 kBT (PW3), at the
respective reaction coordinate distances of 7.5, 8.5, and 6.0 A˚. In comparison, using
an equilibrium free energy method, Swegat et al. [75] calculated the barrier-height as
∼14.2 kBT at 300K.
Although the ligand has crossed the gate at RC = 10.8 A˚ (Fig. 3.4 d), it interacts
with the flipped imidazole ring of HisF5 for the next 4-5 A˚, related to which a weakly
bound state in this part of RC is visible (S4, and S5 for PW1). The stable intermedi-
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ate state for PW2 corresponds to hydrophobic interactions between phenol, LeuH17,
LeuA13, and IleA10, on the verge of crossing the narrow channel (Fig. 3.5 d). Two dis-
tinctly stable intermediate states are observed for PW3, where the first corresponds
to residual interactions with IleA2, TyrA19, and TyrB26, and the second to interactions
with aromatic ring of PheB25, in β-sheet region of the dimer interface. Interestingly,
several additional m-cresol binding sites are found in the crystal structures of fast-
acting mutant (ProB28→Asp) R6 insulin hexamers, in the vicinity of Tyr
B26, and
IleA2, similar to what we observe in PW3 for native insulin hexamer [113].
The PMFs can also be used to extract the free energy change (∆F) of this dissoci-
ation reaction. The dissociated states of the ligand are nearly identical in free energy
for three pathways, as can be inferred from the individual PMF ending in the same
region within error bars. The free energy difference between initial (RC = 0.0 A˚) and
the end states at 14.5 A˚ for PW1, 15.0 A˚ for PW2, and 16.0 A˚ for PW3, are computed
to be 18.06 ± 0.60 kBT , 17.75 ± 1.06 kBT , and 20.60 ± 2.70 kBT respectively. A
net positive free energy change for this unbinding reaction indicates that the ligand
prefers to be in the bound state at equilibrium.
4.5 Discussion
Free energy calculations were performed using piecewise cv-SMD simulations [122]
which force the unbinding of phenol by pulling it gradually towards a defined point
on the protein surface. Three distinct reaction coordinates for PMF construction, one
for each pathway, were determined based on knowledge of exit routes from RAMD
(see Chapter 3). The PMF for each pathway reveal quantitative information on the
likely mechanism of phenol dissociation from the insulin-phenol complex. Given three
competing dissociation mechanisms, the structural features and the energy barriers
computed from the PMF’s data suggest that the ligands preferentially exchange via
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the gate-leaping mechanism (Fig. 3.5) through a narrow channel along Pathway 2.
Consistent with gate-leaping mechanism, we observed convergence towards PW2 on
lowering the perturbing force in RAMD simulations as well (Table 3.1). It is likely
the choice of only one reaction coordinate that limited Swegat’s previous simula-
tion of phenol dissociation [75] from finding alternate and more frequent dissociation
mechanisms such as gate-leaping.
The events such as gate-opening and gate-leaping for passage across a narrow
channel induce strong non-equilibrium effects on the system [122]. The sensitivity
of the PMF to such effects necessitates carrying them out in the quasi-equilibrium
regime. Therefore, we carried out additional cv-SMD trajectories with much slower
pulling velocities (5×10−6 A˚/fs) to compensate for nonequilibium effects in the PMF
calculations (section S2 for PW1, and PW2, in Table 4.1). A limited number of
such slow trajectories (three in each section in our case) give a reasonably good
resolution of the PMF constructed using the second order cumulant expansion of
Jarzynski’s equality. The second order cumulant expansion is suggested previously
to provide an improved estimate of the PMF in comparison to exponential averaging
using Jarzynski’s equality given fewer slow SMD trajectories [121]. We indeed observe
an improved resolution of the PMF constructed using the cumulant expansion in
multiple independent sections (see Fig. 4.4). We therefore resort to the second order
cumulant expansion of Jarzynski’s equality for the PMFs construction as used in
similar studies [122, 123].
The estimates of free energy change of phenol dissociation reaction show consid-
erable variation among various experiments due to inherent limitations of each tech-
nique used in such measurements [102, 111]. An experimental study using isothermal
titrating calorimetry (ITC) reported ∆F to be ∼39.24 kBT [111], while another one
with circular dichroism (CD)-spectroscopy estimated it to be ∼7.22 kBT [102]. The
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for remaining details.
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modeling of binding curves in CD-spectroscopy [102] is suggested to be oversimplified
because of a serious assumption that free ligand concentration is equal to total ligand
concentration at saturation, which is found not to be the case [111]. Hierarchical
modeling of a complex set of phenol binding curves in ITC experiments [111] however
is limited by the fact that the resultant heat produced is a sum of several processes
(ligand binding, conformational changes, and release of water molecules) that are
difficult to isolate. Different allosteric states of the insulin hexamer in solution and
multiple interdependent binding cavities for phenols further complicate measurements
of free energy change. It should also be noted that binding of each ligand in these
experiments represents the simultaneous sum of all possible bound ligands in solu-
tion as opposed to unique atomistic picture of binding/unbinding of a single phenolic
ligand presented in this work. Free energy computations in this study are used as
a quantitative tool to suggest the most likely (un)binding mechanism out of three
possible escape pathways for phenolic species and should not be over-interpreted as
the true free energy change of this reaction in absence of unambiguous experimental
measurements.
4.6 Conclusions
We have presented the results of free energy calculations for three entry/exit path-
ways for phenolic ligands discovered using RAMD simulations (see Chapter 3). The
energetics of phenol dissociation along each pathway was characterized through the
PMFs computed with the help of second order cumulant expansion of Jarzynski’s
equality and cv-SMD simulations. The energy barriers suggest the gate-leaping to be
a preferred mechanism for phenolic exchange. Additionally, the PMFs show the exis-
tence of weakly bound metastable states along each pathway that were not observed
in the previous simulation study of this complex [75] but are nevertheless supported
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by recent experimental evidence [113].
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Chapter 5: Molecular Simulation Studies of the Insulin Receptor
Ectodomain
5.1 Abstract
The insulin receptor (IR) is a homo-dimeric, disulfide-linked, membrane-spanning
tyrosine kinase. IR displays negative cooperativity in insulin binding to its two pock-
ets, suggesting “see-sawing” between symmetry-inverted conformations. The crystal
structure of the dimeric IR ectodomain, IR∆β [PDB code 2DTG (McKern NM, et al.
(2006) Nature 443:218-221)], provides structural bases for this speculation. Unfor-
tunately, neither binding pocket of the crystallographic IR∆β structure allows steric
accommodation of insulin. During almost 70-ns of all-atom, explicit-water MD simu-
lation (∼0.5 million atoms), IR∆β undergoes significant asymmetric interdomain and
intersubunit conformational fluctuations that do not alter its quaternary structure.
Subtle variations in intersubunit buried surface area coincide with these conforma-
tional fluctuations, resulting in one easily-accessible insulin binding pocket with the
other blocked. We use a combination of Metropolis Monte-Carlo and MD simulations
to dock both T- and R-state insulin into the open binding pocket. Both complexes re-
main stable during 30-ns of MD simulation. In these complexes, “hexamer interface”
residues on insulin directly contact the “site-2” epitope on the first type-III fibronectin
domain (F1) of IR. Our results support the hypothesis that intersubunit flexibility
of IR, governed by alternating modulation of buried intersubunit surface area, is the
physical mechanism underlying a “see-saw” model of negative cooperativity.
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5.2 Introduction
Insulin, a small protein hormone secreted by the pancreatic β cells, is principally
responsible for controlling blood sugar levels in higher organisms. The inefficient
production or improper utilization of insulin leads to diabetes mellitus. Sufferers
of Type 1, or “insulin-dependent” diabetes need exogenous insulin as a life-saving
drug; however, type 2 diabetics are resistant to such treatment. Hence, the treatment
of type 2 diabetes is dependent on developing a molecular level understanding of
pathways by which insulin triggers glucose uptake from blood. Insulin participates
in these pathways by specifically binding to and activating its cognate cell-surface
receptor, the insulin receptor (IR).
IR is a ligand-activated transmembrane glycoprotein of the receptor tyrosine
kinase (RTK) superfamily [5, 48, 124]. The IR family also includes the type-1
insulin-like growth factor receptor (IGF-1R) and the insulin receptor-related receptor
(IRR) [48, 53, 125]. IR chiefly mediates glucose homeostasis in higher organisms,
IGF-1R is required for normal growth and development, and IRR has no known
physiological role [38, 48, 52, 53, 125]. Unlike most other RTK’s, all receptors in
the IR family are constitutively homo-dimeric due to two or more intersubunit disul-
fides [5, 125]. Each subunit in the IR family has an extracellular L1-CR-L2 motif
common to hormone receptors, linked to three fibronectin type-III repeats, F1, F2,
and F3, which connect through the plasma membrane via a single helix to the cyto-
plasmic kinase domain (Fig. 5.1).
Insulin/IR binding involves low- and high-affinity modes and negative cooperativ-
ity between two equivalent binding pockets [126]. Binding of a single insulin molecule
to one pocket is sufficient to activate IR, involving compaction of the ligand-receptor
complex, trans-autophosphorylation in the cytoplasmic kinases, and downstream sig-
naling [5, 8, 126–128]. Conformational changes among apo, low- and high-affinity
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α α
β β
Figure 5.1: Domain structure of IR. Colored domains correspond to resolved structure
of the IR∆β ectodomain. Four horizontal lines between the α-subunits indicate the
α-α disulfides at Cys524, Cys682, Cys683, and Cys685, respectively. (It has yet to be
established whether one, two, or all three of the Cys68x disulfides is intact in IR.) Two
other similar lines denote the α-β Cys647-Cys860 disulfide bonds.
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activated states are thought to alternate between sides of the dimer in a “see-saw”-
like mechanism [5, 47, 129–131].
A detailed picture of the hormone/receptor protein-protein interfaces in low- and
high affinity binding modes is beginning to emerge from investigations with site-
specific mutagenesis and chimeric receptor constructs [132–139]. These interfaces are
currently known to involve the following residues on insulin and IR, respectively [5, 8]:
1. The “classical binding surface” of insulin includes A-chain residues GlyA1, GlnA5,
TyrA19, and AsnA21, and B-chain residues ValB12, TyrB16, PheB24, PheB25, and
TyrB26 [140–143]. The so-called “hexamer forming surface” consists of residues
SerA12, LeuA13, GluA17, HisB10, GluB13, and LeuB17; and
2. The L1 domain residues 12-15, 34, 36, 37, 39, 44, 64, 67, 89-91 and the CT-
peptide residues 705-709, 711, 712, 714, 716, and 717 (Fig. 5.1) [133, 144–
147] are low-affinity binding determinants and likely interact with the classical
insulin binding surface. High-affinity binding is suggested to involve the C-
terminal loops of the first type-III fibronectin domain (F1) and the N-terminal
region of the second type-III fibronectin domain (F2) [48, 53, 148–152]. Specif-
ically, Lys484, Leu552, Asp591 (F1), Ile602, Lys616, Asp620, and Pro621 (F2) are
suggested to be a part of high-affinity epitope on the ectodomain [1].
We illustrate salient structural details of the current understanding of insulin/IR
recognition interfaces in Fig. 5.2. The exact registry of L1 residues and insulin residues
remains unestablished due in part to the fact that there have been so far no detailed
structural models of insulin-bound IR to test. Residues TyrB16 and PheB24 cross-link
to the L1 surface [153, 154], and PheB25 and ValA3 cross-link to CT [153, 155], in
both cases to so far undetermined target residues. Exactly which residues on the
hexamer-forming surface of insulin form a cross-link with suggested residues in the
loops of F1 and F2 to confer high-affinity binding also remains unestablished.
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Figure 5.2: (a) Ribbon representation of the structure of T-insulin showing the A-
chain (red), B-chain (green, residues B1-B8; blue, all others), with disulfides rendered
in wireframe. Accompanying panels highlight the position of classical (green wire-
frame) and hexamer (red wireframe) interface residues on the A and B-chains indi-
vidually. (b) Same as (a) for R-insulin. (c) Ribbon representation of the L1 domain
of IR with important site-1 residues rendered in wireframe. (d) Ribbon represen-
tation of the F1 and partial F2 domains with important site-2 residues rendered as
space-filling. (PDB accession codes for the structures in this figure: T-insulin, 1MSO;
R-insulin, 1ZNJ; IR, 2DTG).
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Figure 5.3: (a) The IR∆β dimer viewed along the +Z direction with subunit 1 in
cartoon and subunit 2 as bonds. (b) F1, F2, and F3 domains of subunit 2 and L1′,
CR′, and L2′ subunits of subunit 1 viewed along the -X direction. The view is oriented
such that the +Y direction would correspond to the membrane surface normal. Color
denotes domain: brown, L1; yellow, CR; green, L2; magenta, F1; cyan, F2; blue, F3.
The intersubunit Cys524-Cys524
′
disulfide is shown in (a) and approximate locations
of site 1′ and site 2 indicated in (b).
The crystal structure of the IR ectodomain IR∆β (PDB code 2DTG), [47] which
we depict in Fig. 5.3, shows that subunits are arranged in the dimer in a “folded-
over” conformation with L2 and F1 domains forming the apex of an inverted “V”, and
L1/F2 interfaces defining insulin binding sites. The L1 domain contributes an epitope
designated “site 1” which has been shown to interact specifically with the “classical”
binding surface of the insulin molecule and confers low-affinity binding [133, 140–147].
F1 and F2 domains from the partner subunit contribute an epitope designated “site 2”
that likely interacts with insulin’s “hexamer-forming” interface to confer high-affinity
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binding [1, 48, 53, 148–152]. It is yet to be established how insulin cross-linking of
site 1 and site 2, each of which can solely confer only low-affinity binding, results in a
productive high-affinity binding mode. The folded-over multidomain IR∆β structure
provides a reasonable basis from which to investigate the details of hormone/receptor
interactions. Unfortunately, the binding pockets in the IR∆β crystal structure are
sterically unable to accommodate insulin [156]. Because IR∆β binds insulin with low
affinity, it must possess significant flexibility at least near the binding pockets, relative
to the crystal structure. The questions motivating this work are the following. (1)
What flexibility mechanisms allow IR∆β to present insulin-accessible binding sites,
and are these mechanisms consistent with “see-sawing”? (2) Does binding of insulin
to IR∆β involve interactions with IR residues outside the classical L1 binding surface?
In this chapter, we report the results of over 135 ns of MD integration of both apo
and insulin-bound IR∆β with the dual aims of presenting a theory of IR flexibility and
predicting details of the hormone/receptor interfaces. In a ∼70-ns apo simulation,
we characterize a spontaneous asymmetric relaxation involving interdomain hinge
angle fluctuations and modulation of intersubunit buried surface area. The most
important aspect of this relaxation is that it renders one of the two binding pockets
accessible to insulin, which we confirm via a custom Metropolis Monte Carlo (MC)
docking procedure. We compare the docked configurations of the so-called T and
R states of insulin. Based on the observed asymmetric relaxation and the insulin-
docked trajectories, we discuss possible structural bases for negative cooperativity,
the suggested see-saw mechanism of IR activation, and high-affinity insulin binding.
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5.3 Simulation description
5.3.1 System preparation and equilibration details
We generated all MD trajectories with NAMDv2.6 [84] and the CHARMM force
field [89, 90]. The classical MD simulation and the CHARMM potential are described
in Sec. 2.4, and Sec. 2.4.4, respectively. We used VMDv1.8.6 for system creation and
visualization [97]. The IR∆β ectodomain considered in this work contains domains
L1, CR, L2, F1, F2, and F3, but lacks the insert domain (residues 656 to 754)
including the CT peptide. Initial coordinates for the apo-IR run were taken from the
3.8-A˚-resolution X-ray crystal structure of the human insulin receptor ectodomain
(PDB code 2DTG) [47]. This structure includes data on one subunit and two attached
Fab fragments. We deleted the Fabs, replicated the subunit to reconstruct the dimer,
labeling the original subunit “1” and the replicate “2”. (It should be noted that
the intact dimer was crystallized but the model-building employed by McKern et al.
enforced 2-fold rotational symmetry.) We use a prime to denote domains and residues
on subunit 1, and unprimed domains and residues refer to subunit 2 (this is because,
a posteriori, we observe that the binding pocket containing L1 of subunit 2 is the one
that fluctuates open spontaneously in a long MD run). The as-deposited IR∆β crystal
structure lacks the α-chain residues 1-3, 656-717, and the β-chain residues 724-734,
754, and 910-916, due to unresolved electron density. One inter-chain α-α disulfide
bond at residue Cys524 is present but three possible symmetric pairs of disulfides at
residues Cys682, Cys683, and Cys685, are missing. Two intrasubunit interchain α-β
disulfide bonds at Cys647-Cys860 are present. We added three (1-3) missing residues
of the α-chain in the modeled structure.
Explicit TIP3P water was added to solvate the protein in a periodic box of di-
mensions 183.79 A˚ × 181.69 A˚ × 138.90A˚. All hydrogen atoms were included. The
system was neutralized with random placement of 143 Na+ and 119 Cl− ions. The
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Figure 5.4: MD simulation systems. Front (a) and side (b) views of the apo-IR∆β
domain. Side views of the T-IR (c) and R-IR (d) simulation domains. IR∆β domain
coloring matches that in Fig. 1 of the main text and Fig. S1 here. The A- and B-chain
of each insulin (T andR) are in red and blue surface representations respectively. Wa-
ter molecules are in wireframe representation, along with neutralizing media, sodium
ions (yellow spheres) and chloride ions (cyan spheres).
system contained 444,480 atoms (Fig. 5.4). Energy-minimization was carried out via
2000 cycles of conjugate-gradient optimization. A 40 ps NPT-MD simulation was
then run to relax the solvent box volume. The temperature was held at 300K us-
ing the Langevin thermostat with damping coefficient of 5 ps−1, and pressure using
the Nose´-Hoover barostat. The equilibration phase was continued in the NVT en-
semble for ∼67 ns. The apo-IR simulation was run with 2-fs time step with rigid
bonds. Non-bonded interactions were cut-off beyond 12 A˚ with smooth switching
taking effect at 10 A˚. Long-range electrostatic interactions were handled using the
particle mesh Ewald (PME) method with a 1 A˚ grid spacing. Configurations were
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saved every 20 ps and energy-like quantities every 2 ps. We also conducted a second
independent MD equilibration of 15 ns in duration initialized with atomic velocities
different from those used in the first simulation.
We carried out further MD simulations of two insulin/IR∆β complexes (one for
T-state insulin and one for R-state insulin) with initial coordinates generated by
the MC docking procedure described below. The solvation boxes measured 171.24
A˚×170.00 A˚×129.96 A˚ and 158.80 A˚×168.28 A˚×130.44 A˚, for the T-IR and R-IR
systems, respectively. (We were able to size the boxes more aggressively after noting
the degree of flexibility displayed by IR∆β in the apo simulation kept the protein
from approaching the boundaries of the box.) The T-IR system was neutralized with
65 Na+ and 39 Cl− ions, and the R-IR one with 60 Na+ and 34 Cl− ions. The
solvated and ionized T-IR and R-IR systems had 359,449 atoms and 330,309 atoms,
respectively (Fig. 5.4). All other MD simulation parameters for both systems were
kept identical to the apo-IR run except that simulations were continued for 30 ns and
configurations were saved every 10 ps.
5.3.2 Monte Carlo docking
Insulin/IR∆β complexes were generated using a custom MD-assisted Monte-Carlo
algorithm (see Code given in Appendix B). The receptor configurations for docking
were sampled from the ∼67 ns long MD simulation and ligand configurations (T;
PDB code 1MSO, and R; PDB code 1ZNJ) from an ensemble of solution confor-
mations generated by two separate ∼1 ns long equilibration trajectories. Our MC
algorithm minimized the van der Waals and electrostatic interaction energies between
all ligand atoms and atoms we defined as forming a binding pocket. The two pock-
ets are defined respectively by the L1-CR-L2 and (F1-F2-F3)′ domains (defining the
observed accessible pocket) and the (L1-CR-L2)′ and (F1-F2-F3) domains (defining
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the observed inaccessible pocket). Specifically, IR∆β residues included in the MC
energy calculation included (i) the L1 residues 12-16, 32, 34, 36-39, 59, 60, 62, 64, 65,
67, 86-91, 94, 96, 97, 118, 120, 121, 144, 146, 147, (ii) the CR residues 270, 271-275,
286-288, (iii) the F1 residues 481-484, 554-557, 593-597, (iv) the F2 residues 619-622,
and 796. The L2 residues 315-320 of the C-chain were additionally included in the
T-state insulin docking. Metropolis MC configurational sampling consisted of trial
moves of global orientation angle displacements of random magnitude upto 2◦ (about
the COM of the ligands) and ligand translational displacements of random magnitude
upto 1 A˚. Initial insulin positions were set by aligning the center of mass of the insulin
with the geometric center of the binding pocket region. Initial orientations of insulin
were randomly generated. A total of 20 000 to 40 000 MC cycles were performed per
docking trial, resulting in 20 docked configurations for each of the T- and R-state
in the accessible pocket, and no successful dockings in the inaccessible pocket nor in
the bare crystal structure. Conformational flexibility was allowed by resampling the
ligand conformations 3-6 times, and the receptor configurations at least once, out of
every 10 trial moves. The docking algorithm was implemented using a Tcl script in
VMD v. 1.8.6 [97].
5.3.3 Definitions of observables: buried surface area (BSA) and binding
pocket radius of gyration (Rg)
The buried surface area (BSA) between any two domains A and B is computed
by subtracting the solvent-accessible surface area (SASA) of the isolated AB complex
from the sum of SASAs of isolated and separate A and B domains:
BSA(AB) = SASA(A) + SASA(B)− SASA(AB) (5.1)
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All SASA calculations were done with VMD using a probe radius of 1.4 A˚. Hereafter,
when referring to the interface between domains A and B, we use the notation “A/B”.
We measure size of the binding pockets using the radius of gyration Rg of the
collection of atoms belonging to residues that directly surround the binding pocket:
(i) the L1 residues 12-16, 32, 34, 36-39, 59, 60, 62, 64, 65, 67, 86-91, 94, 96, 97,
118, 120, 121, 144, 146, 147, (ii) the CR residues 270, 271-275, 286-288, (iii) the F1′
residues 481-484, 554-557, 593-597, (iv) the F2′ residues 619-622, and 796. These
are the same residues used in the MC energy evaluation for the docking calculations.
For any collection of N atoms each having Cartesian position ri and mass mi, Rg is
defined as
R2g =
N∑
i=1
mi (ri − rCM)
2
N∑
i=1
mi
(5.2)
where rCM is the center of mass of the collection.
5.3.4 Collective variable conformational metrics
In order to characterize the overall conformational variability of IR∆β observed
during the MD simulations, we defined a set of collective variables based on the center-
of-mass positions of each domain and the locations of the hinges between them. Each
subunit is conceptualized as a linear chain of “mapping points” that correspond to
positions of domains and the hinges connecting them. Domains L1, L2, F1, F2,
and F3 of each subunit contribute a mapping point. The L1-L2, F1-F2, and F2-F3
intradomain hinge mapping points are defined as the centers of mass, respectively,
of residues 304 to 308; 559, 592, and 621; and 638, 775, 807, and 840. Finally, a
common “apex hinge” mapping point connects L2, L2′, F1, and F1′ and is defined
as the center of mass of the four-domain apex. In this manner, the entire IR∆β
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structure (more than 25,000 atoms distributed over 1,612 residues) is coarse-grained
onto 17 Cartesian positions for conformational analysis.
The set of collective variables considered here based on these mapping points are
(1) the F1-F2 and F1′-F2′ hinge angles; (2) the L1-L2 and L1′-L2′ hinge angles; (3)
the L2/F1′ and L2′/F1 hinge angles, and (4) the L1-L2↔Fn1′-F2′ and L1′-L2′↔F1-F2
interhinge distances. Hereafter, when referring to the hinge angle due to domains A
and B, we use the notation “A-B”. [Note the labelling distinction between interfaces
(“A/B”) and hinge angles (“A-B”)].
5.4 Results
5.4.1 Structural relaxation of apo IR∆β
5.4.2 Intradomain relaxation and flexibility
In Fig. 5.5 (a), we show RMSD evolution of backbone atoms with reference to the
crystal structure [47] for each subunit. These data show that the domains are gen-
erally well-equilibrated after about 30 ns for both subunits. The CR and fibronectin
domains show the largest deviations from the crystal structure. An RMSD of 6 A˚ is
tolerable, however, indicating that the overall fold of all domains is preserved during
equilibration. In Fig. 5.5 (b), we show per-residue RMSF averaged over both sub-
units. These data again show that CR and the fibronectin repeats are relatively more
intrinsically flexible than L1 and L2. Flexibility in CR is highly concentrated in a
single loop immediately C-terminal to L1, as is the case for inter-β-strand loops in
F1. F2 and F3 show pronounced flexibility near free backbone chain ends.
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Figure 5.5: (a) Intra-domain Cα RMSD for each subunit vs simulation time. (b)
RMSF vs residue number averaged over both subunits.
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is a reduced top view showing the apical domains and angles. (b) Traces of hinge
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5.4.3 Interdomain flexibility: collective variables
We developed a coarse-grained representation of the IR∆β structure based on do-
main centers-of-mass and the locations of interdomain hinge residues (see Sec. 5.3.4).
We extracted values for several interdomain hinge angles and distances that collec-
tively illustrate the nature of the conformational flexibility of the dimer. Fig. 5.6 (a)
shows a schematic representation of our coarse-grained structure atop a ribbon repre-
sentation of the IR∆β crystal structure, where each sphere corresponds to a mapping
point. Fig. 5.6 (b) shows traces of the collective variables. In the first 5 ns, the
F1-F2 angles straighten out relative to their initial values by almost 15◦ (Traces ¬
and ­ in Fig. 5.6 (b)). At this instant the (F1-F2)′ hinge (¬) contracts back to
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the crystal structure value while the F1-F2 hinge (­) remains extended. The F1-F2
hinge remains close to the crystal value displayed for about 20 ns, during which time
the extended (F1-F2)′ hinge slowly reacquires this this value. At 30 ns, the (F1-F2)′
hinge closes sharply before recovering after a further 10 ns. After about 50 ns, the
F1-F2 hinge has begun closing. The L1-L2 hinge angles (Traces ® and ¯ in Fig. 5.6)
contract relative to the crystal value. Apart from short-lived asymmetry in the be-
ginning, L1-L2 angles sample substantially the same values for the first 30 ns, after
which the (L1-L2)′ angle (®) closes relative to the L1-L2 angle (¯). L2-F1 hinges (°
and ±) at the apex of the dimer remain close their crystal value for 30 ns, at which
time there is a sharp opening of the L2-F1′ hinge (°).
The distances between the F1-F2 and L1-L2 hinge angles also fluctuate. The
distance between the (F1-F2)′ hinge and the steady L1-L2 hinge increases steadily
(Trace 7 in Fig. 5.6 (b)) for the first 30 ns. The distance between the (F1-F2) hinge
and the steadily closing (L1-L2)′ hinge increases at a relatively more modest pace
(8). On one side of the dimer, hinges fluctuate so as to increase the distance between
them, while on the opposite side, they move much less relative to one another as the
hinges close. It is not until about 40 ns into the simulation that (L1-L2)′-(F1-F2)
side of the dimer experiences an increasing interhinge distance, apparently due to the
accelerating closure of the L1′-L2′ angle (®).
5.4.4 Intersubunit flexibility: buried surface area and binding pocket size
The IR ectodomain has four large (∼1,000 A˚2) patches of intersubunit buried
surface area (BSA): L2/F1′ and L2′/F1 at the apex, and L1/F2′ and L1′/F2, near
the midpoint of the two “legs,” depicted for each side of the dimer schematically in
Fig. 5.7 (a-b). In Fig. 5.7 (c), we show traces of the associated intersubunit BSA for
each of the four interfaces. We observe that all four interfaces remain substantially
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Figure 5.7: (a) Schematic illustration of a side view of IR∆β showing locations of
the L1/F2′ (¬) and L2/F1′ (®) interfaces and the insulin binding pocket defined by
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and vertical lines show the scale of each curve.
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intact throughout the apo-IR simulation. The interfaces involving L1 (traces ¬ and
­ in Fig. 5.7 (c)) are less extensive compared to those involving L2 (traces ® and ¯).
Of particular note is the decrease in the intersubunit BSA associated with L2 and F1′
(®) at the apex of the dimer. This decrease occurs in concert with the opening of the
L2-F1′ hinge angle, suggesting that a late feature in the evolution of an asymmetric
conformation is opening of one L2/F1 intersubunit interface and simultaneous closing
of the other, clearly indicative of “see-sawing.”
Also plotted in Fig. 5.7 (c) are traces of the radius of gyration Rg of each pocket
(° and ±). We observe that the pocket formed by the domains (L1-CR-L2)-(F1-F2)′
begins to open, whereas its counterpart on the other side involving domains (L1-
CR-L2)′-(F1-F2) begins to close, after the first ∼20 ns. The evolution of binding
pocket Rg appears slower than that of the interfacial areas or salt-bridges (below),
but appears to match the rate of change of the hinge angles. (Details regarding
calculation of BSA and Rg appear in Sec. 5.3.3)
5.4.5 Salt bridges
Interdomain interactions often involve salt-bridges. We present several important
interdomain, intra- and intersubunit salt bridge interactions in Fig. 5.8, which shows
both a map of salt-bridge locations as well as interatomic traces from the apo simu-
lation. Several putative bridges across L1/F2 interfaces were predicted based on the
IR∆β crystal structure. [47] The Glu153-Arg804 salt bridge remains intact through-
out the simulation at the L1-F2′ interface (blue trace ¬ in Fig. 5.8 (b)), but it is
broken early at the opposite interface (L1′-F2; red ¬) and remains so throughout
the simulation. Although suggested by the crystal structure, a stable bridge between
Glu154 and Arg804 is not observed for either interface in the dimer (­). Glu124-Arg780
bridges appear intermittant at both interfaces, with a slight preference to be intact
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Figure 5.8: (a) Schematic illustration showing location of selected salt bridge inter-
actions. Across the L1/F2 interfaces: Glu153-Arg804 (¬); Glu154-Arg804 (­); Glu124-
Arg708 (®); Lys102-Asp683 (¯); and Lys149-Glu637 (°). Across the L2/F1 interface:
Glu394-Arg498 (±). At the apex of the dimer: intrasubunit Lys460-Arg464 (²); and
intersubunit Lys460-Arg574 (³). Inset shows close-up of the apical bridges. (b) Traces
of interatomic distances for each salt bridge indicated in (a), measured between side-
chain terminal carbon atoms. Colors signify the two symmetry-related bridges. La-
beled horizontal lines report distances from the IR∆β crystal structure in A˚ and
vertical lines depict a scale of ±10 A˚.
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at the L1/F2′ interface (®). Not predicted by McKern et al. are Lys102-Asp638 and
Lys149-Glu637, both across L1/F2 interfaces, which are predominantly intact across
both interfaces (¯ and °, respectively).
The one obvious salt bridge at the L2/F1 intersubunit interfaces occurs between
the L2 residue Glu394 and the F1 residue Arg498 (traces ± in Fig. 5.8 (b)). We observe
this bridge intermittently in the first 30 ns and then not at all thereafter in the L2/F1′
interface (blue ±), corroborating the observation that the L2-F1′ hinge angle opens
and the L2/F1′ buried interfacial area decreases. This bridge remains intact at the
opposite interface (red ±).
At the apex of the ectodomain, residues Lys460, Asp464, and Asp574 form an ap-
parent asymmetric switching network (traces ² and ³ in Fig. 5.8 (b), respectively).
We observe an intra-subunit Lys460-Asp464 salt bridge that ruptures intermittently
but remains mostly stable (blue ²), while there is no Lys460′ -Asp464′ salt bridge (red
²). Another salt bridge is observed between Lys460′ and Asp574 (blue ³), whereas
no Lys460-Asp574
′
bridge (red ³) is seen, because Lys460 is occupied at the same time
in the Lys460-Asp464 intrasubunit salt bridge. It is possible that each Lys460 can
participate in either an inter- or intrasubunit salt bridging, and that in a globally
asymmetric conformation, these two lysines cannot both participate in the same type
of bridge; when one is intra-, the other is intersubunit.
5.4.6 Model structures of insulin/IR∆β complexes
5.4.7 Monte-Carlo docking
No sterically acceptable docked configurations using either T- or R-state insulin
molecules and the unequilibrated IR∆β crystal structure were generated using our
MC procedure. Likewise, using MD-assisted docking, no acceptable complexes were
generated for the pocket defined by (L1-CR-L2)′-(F1-F2). However, generation of
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docked configurations in the pocket defined by (L1-CR-L2)-(F1-F2)′ was strikingly
easy, so we generated 20 independent docked configurations for each insulin form.
All such dockings had the classical insulin surface in contact with L1. We emphasize
here that all docking calculations were begun with the center of mass of the insulin
molecule on the center of mass of the pocket residues, but with a random orientation,
so the physical interaction energies encoded by the CHARMM potential drove the
orientation and placement of the insulin molecules’ classical surface down onto L1.
We selected from this set of dockings those that displayed the highest degree of
correspondence to known L1 residues involved in insulin binding for each of the T-
and R-insulin cases. From these two configurations we launched an additional 30 ns
of MD equilibration for each.
5.4.8 Post-docking MD equilibration: site-1 and site-2 contacts
The first major result of both MD equilibrations of the insulin/IR∆β complexes
is that both insulin molecules remain stably bound over timescales previously shown
to as relevant for structural relaxation of IR∆β. We show in Fig. 5.9 (a) traces of the
potential energy of interaction between insulin and IR atoms (including electrostatic
and vdW interactions) in time for both post-docking MD equilibrations; no significant
distinction between T and R-state insulin is observed. These data indicate that our
insulin/IR complex is relatively stable on nanosecond timescales. We also show in
Fig. 5.9 (b) traces of the interactions between hexamer interfaces on insulin and
F1 residues on IR∆β, which demonstrates that these contacts are also robust on
nanosecond timescales.
Shown in Fig. 5.10, for both dockings, are side-chains of TyrB16 (insulin) that sit
between Leu37 and Phe39 of L1 domain, where the aromatic rings of tyrosine and
phenylalanine residues interact parallel to each other with occasional direct contact
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Figure 5.9: Non-bonded interaction potential energy traces from MD simulations of
insulin-docked IR∆β. (a) Energy traces for the interaction of all insulin residues
(cyan, T-state insulin; grey, R-state) with residues of the binding pocket given in our
MC docking protocol over the 30-ns long T-IR and R-IR MD trajectories, respectively.
(b) Energy traces for interaction of hexamer surface residues of T- and R-insulin with
F1 residues (AB loop: Asp483, Lys484; EF loop: Leu552, Arg554, Gly555, Leu556, and
Lys557). Boxcar averages (N = 10) are plotted as thick black traces.
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to Leu37. Residue PheB24 lies in the vicinity of L1 domain’s Asp12, Arg14, and Leu36.
However, PheB25 is exposed and does not contact any residue of the L1 surface,
consistent with its requirement to interact with the CT-peptide. [153] The insulin
residues TyrB16 and PheB24, are known to cross-link to the L1 domain, [153, 154] and
our simulations agree with previously suggested residue contacts for TyrB16, [49] but
the contacts for PheB24 on L1 domain are unique here. Only in the R-state dock-
ing, AsnA21 is seen in contact with Asn16 (L1), but the C-terminus of the insulin
B-chain (B21-B30) sterically prevents it from being a stable interaction during the
R-insulin/IR∆β run (data not shown). No other residue of the insulin A-chain comes
into proximity of the L1 domain in either our dockings or MD simulations. Inter-
estingly, we also observe that enough space exists between a docked insulin and the
L1 surface in which the CT-peptide could be accommodated, both for the T- and
R-state insulin.
The steric hindrance posed by the C-terminus of the insulin B-chain (denoted
C in Fig. 5.10) mediates specificity of ligand-binding to the receptor, [157] because
this C-terminal tail must move away from the A-chain N-terminus to expose the
hydrophobic interior of insulin to the L1 binding surface (residues 12-15, 34, 36, 37,
39, 44, 64, 67, 89-91). In our T and R docking simulations, this tail is oriented in a
narrow cleft present between L1 and CR domains (Fig. 5.10 (a) and (b)) and stably
fluctuates in this location throughout the MD trajectories.
Close van der Waals contacts between the hexamer surface residues of both insulins
and residues in the AB and EF loops of F1′ are observed. In particular, in the T-
IR complex, insulin A-chain residues LeuA13 and GluA17 are observed to contact
residues in the EF loop of F1, including most prominently Leu552 but also including
intermittent contact with Arg554, Gly555, Leu556, and Lys557. The insulin in the R-IR
complex has a slightly different orientation than in the T-IR complex, and in this
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case GluA17 is not observed in contact with residues in the EF loop of F1′. In the
both complexes, insulin B-chain residue LeuB17 interacts with the sidechain of Lys484
of the AB loop of F1′.
5.5 Discussion
5.5.1 Dimer asymmetry in IR∆β: Coordinated modulation of interdo-
main flexibility and intersubunit interfaces
The putative “see-saw” mechanism, first articulated by De Meyts [129], explains
the phenomenon of negative cooperativity in binding of insulin [5, 47]. In this mech-
anism, the IR ectodomain rocks back and forth between two equivalent, symmetry-
inverted conformations characterized by one binding pocket capable of binding insulin
and the other not. Rather than being driven solely by insulin binding, our simulation
results suggest that the ectodomain rocks back and forth under thermal conditions
without insulin. A recently proposed “harmonic-oscillator” kinetic model of the re-
ceptor suggests that apo-IR can be driven between asymmetric states with small
amount of thermal energy, and a dynamic equilibrium between the symmetric and
asymmetric states is assumed to explain all available data on complex binding kinetics
of hormone [131]. The observation of spontaneous asymmetry in our MD simulation
is evidence in favor of this view.
More important, however, is the detailed view this simulation provides of the
flexibility mechanisms governing this behavior. We suggest the following mechanism
gives rise to asymmetry in IR∆β. The F1′-F2′ hinge angles, normally near 180◦, can
fluctuate substantially as these two domains move relative to each other. In cases
where such a “closing” fluctuation of this angle moves the hinge point away from the
L1-L2 hinge of the other subunit, this places a stress on the associated intersubunit
L2/F1′ interface, which responds by opening up slightly, manifest also as an increase in
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the L2-F1′ angle. This structural displacement is then “locked in” by a simultaneous
strengthening of the opposite L2′/F1 interface, partially aided by buried salt-bridge
interactions. This is accompanied by closure of the F1-F2 hinge on the other side, but
the strengthened L2′/F1 interface prevents this closure in such a way as to increase the
distance between the F1-F2 hinge and the L1′-L2′ hinge. A large-enough fluctuation
in the now closed F1′-F2′ hinge might drive the conformational transition in the
opposite direction, provided a simultaneous fluctuation of the F1-F2 hinge increases
its distance from the L1′-L2′ hinge. In short, we believe we are observing a flexibility
mechanism in which random thermal fluctuations in interdomain hinge angles are
selected for by modulating intersubunit interfacial interaction strengths at the L2/F1
interfaces.
This picture implies that the L2/F1 interfaces cannot both be at their optimum
strength in a perfectly symmetric conformation. One aspect that seems to drive the
apex of the dimer to a conformation in which one L2/F1 interface is strongly engaged
while the other is relatively open seems to be a tight network of salt-bridge interactions
involving the two Lys460’s. It appears that Lys460 in our simulation either participates
in an intradomain salt bridge with Asp464 or in an interdomain/intersubunit salt
bridge with Asp574. When the intersubunit bridge is engaged, we observe that the
L2/F1 interface is more closed than when the intrasubunit bridge is engaged. We
infer the possibility that the intersubunit bridge helps to lock in the tighter L2/F1
interface, while the complementary intrasubunit bridge frustrates the closing of the
other L2/F1 interface. This implies a crucial role for Lys460, consistent with the
effects of mutations at position 460: the Lys460→Glu mutation accelerates receptor
degradation, and the Lys460→Arg mutation impairs negative cooperativity [158].
Such an interpretation begs the question of how IR∆β was able to be crystallized
in an apparently symmetrical dimeric conformation. It should be noted that the IR∆β
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structure was derived from a co-crystallization involving Fab antibody fragments from
antibodies 83-7 and 83-14 in a 1:1:1 (83-7:83-14:IR∆β subunit) stoichiometry [47]. In
particular, 83-14 binds specifically to F1 near the F1-F2 hinge. This binding could
have greatly reduced the flexibility of the F1-F2 hinges, and stoichiometric binding to
the dimer likely selected for conformations in which these two hinge angles had similar
values. This is consistent with the observation that 83-14 abrogates insulin binding to
intact receptors [159], because, as we argue below, this flexibility mode is required to
generate insulin-accessible binding sites on basal IR. With these constraints released
in our MD simulation, the IR∆β structure experiences F1-F2 hinge angle fluctuations
on both sides, but the side with F1′-F2′ fluctuates open and becomes “locked-open” by
the opposite closure of the L2′-F1 interface, leaving the (L1-CR-L2)-(F1-F2)′ pocket
open enough to accomodate an insulin molecule.
We also would like to comment on the effects of the absence of transmembrane
helices and their association with a plasma membrane. The removal of the trans-
membrane anchors deprives the soluble IR ectodomain of holo-receptor features of
high-affinity insulin binding and negative cooperativity [160]. Though not presented
in the results, we observed very large fluctuations in the F2-F3 hinge angles, presum-
ably because the F3 domains are not membrane-anchored. However, this apparently
large flexibility may also be in part a consequence of the facts that (a) we have not
modeled the insert domains (ID) which were not resolved in the as-published IR∆β
structure [47], and (b) we have not modeled any of the glycans, in particular the
inwardly-oriented glycan at residue 906 [124]. The pair of IDs are disulfide linked by
at least one bond across the the cysteine triplet (Cys682, Cys683, Cys685) [161], and
this constraint may reduce intersubunit flexibility relative to what we observe here.
The glycan at 906 may help keep the F3 domains from approaching one another
too closely. These features remain objects of future study, and the simulations dis-
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cussed here will serve as a valuable basis for interpreting their effects on ectodomain
flexibility.
5.5.2 All-atom models of the insulin/IR∆β complexes
We have presented the first all-atom structural model predictions of the complexes
of insulin and IR∆β. The insulin orientations and placements predicted by the MC
algorithm, down-selected based on experimental evidence, and equilibrated by MD
simulation appear to be physically plausible candidates for insulin/IR∆β structural
models. Our predicted structures differ from those generated by Lou et al. [49] which
used only the L1-CR-L2 domains from IR and a truncated insulin molecule missing
residues 21-30 in the B-chain. The absence of the 10 C-terminal residues of the insulin
B-chain allowed for close contact of several A-chain residues on the L1 surface; we did
not observe as many A-chain contacts. We interpret this difference as being due to
the fact that the C-terminus of the B-chain in our structure has not yet moved away
from the B-chain α helix to expose the A-chain ends making up the insulin molecule’s
hydrophobic core [162]. This conformational change likely involves overcoming free
energy barriers that are sufficiently high that this change is not likely to be observed
in a 30-ns equilibration. Missing from both our docking and that of Lou et al. [49] is
the CT-peptide, and its role in facilitating “opening” of the insulin molecule remains
unestablished.
The fact that the insulin molecule orients properly in the binding pocket in unbi-
ased MC simulation supports the hypothesis that the dual-induced fit model [157] of
insulin binding is correct, because the insulin molecule can recognize the L1 surface
before the B-chain C-terminus moves away to reveal the A-chain contact residues.
We cannot rule out that insulin exposes its hydrophobic core intermittently in the
absence of IR, but our results suggest that it need not do so as a prerequisite to
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recognize IR.
Our complex models predict direct interactions between residues on the hexamer
binding surface of insulin and residues in the type-III fibronectin loops near the bind-
ing pocket, traditionally believed to constitute the site-2 epitope. To date, there have
been only two other major efforts to uniquely assign IR residues to the site-2 epitope:
(1) the alanine-scanning mutagenesis studies of Whittaker et al. [1] and (2) the bioin-
formatics analysis of Renteria et al. [2]. We present the predicted site-2 residues of
these recent works together with our observed site-2 contacts in Table 5.1. Interest-
ingly, only two of the eighteen highly conserved residues identifed by Renteria et al.
seem to be important in insulin binding according the mutagenesis study: Lys616 and
Pro621, both on F2. We observe direct and sustained contact between LeuA13, GluA17,
LeuB17 (insulin) with Lys484 and Leu552 in F1, with slightly more intermittent contact
with residues between Arg554 and Lys557. According to the mutagenesis study, both
Lys484 and Leu552 are among the five most important residues in F1 and F2 in insulin
binding. We observe no direct contacts between insulin and any residues in F2, and
as we mentioned above, a gap which could be occupied by the CT peptide exists
between insulin and F2 in our complexes.
Though indicative, mutagenesis data is not conclusive because it is in principle not
possible to determine precisely by what mechanism an alanine point mutation affects
binding affinity. A mutated residue may interact directly with insulin, or with the CT
peptide, or both, or neither; it may also lend stability to the binding site. This is also
the case for residues determined to be highly conserved in a bioinformatics analysis;
enhanced ligand specificity and/or ligand binding affinity is only one of several selec-
tive pressures on sequence. In light of these concerns, our results lend some support
to the hypothesis that site-2 residues on F1, including Lys484 and Leu552, contribute
to insulin binding affinity via a direct interaction with hexamer-interface residues on
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Table 5.1: IR residues implicated in site-2 insulin binding: A comparison of results
from alanine scanning mutagenesis [1], structural bioinformatics [2], and MD simula-
tion (this work). In Column 1, boldface denotes residues for which a mutation to Ala
resulted in a 2-5 fold reduction in insulin binding affinity; others had less significant
or no effects on binding [1]. In Column 2, all residues listed are designated “highly
conserved” in the IR family [2]. In Column 3, all residues listed were observed to
directly contact insulin in model all-atom complexes. In Columns 2 and 3, boldface
denotes residues demonstrated via alanine scanning to be important for insulin bind-
ing, whereas single dashes denote residues thereby shown not to be important for
insulin binding.
Ref. [1] Ref. [2] This work
S481 Y507 K484
F482 N527- L552
D483 W529- R554-
K484 K557- G555
L486 P558- L556
W559 K557- K557-
N527 S596-
S528 V597-
W529 P598
T530 L599-
L552 D600-
R554 P601-
K557 K614
L558 W615
D591 K616
T593 P617-
N594 P618
S596 P621
V597
L599
D600
P601
I602
K616
P617
S619
D620
P621
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insulin. Our data leaves open the possibility that site-2 residues on F2 may contribute
to insulin binding affinity chiefly by interacting with the CT peptide rather than di-
rectly with insulin. It would be interesting to explore whether insulin binding affinity
becomes insensitive to alanine point mutations on CT when F2 residues Ile610, Lys616,
Asp620 and Pro621 mutated to alanine, thereby perhaps preventing participation of
the CT peptide.
It is significant as well that our complexes involving both forms of insulin show
contacts simultaneously to L1 (site 1) and F1 (site 2), because this suggests that
crosslinking of subunits by insulin is initiated prior to the required conformational
change of insulin. We speculate that the low- to high-affinity transition in the holo-
receptor due to cross-linking of site 1 and site 2 by insulin involves a symmetry reversal
of the ectodomain wherein the insulin-bound side contracts while the insulin-free side
opens. The presence of insulin in the side that closes may serve to lock in this
asymmetric conformation over time scales long enough for displacements transmitted
to the kinase domains to result in activation. The open side could then accomodate
at least one insulin molecule with low affinity, and a second symmetry reversal of the
ectodomain would require the tightly bound insulin on the other side to transition to
a low-affinity form.
It may be possible to simulate this transition in insulin-bound IR∆β by using a
non-equilibrium method (such as targeted molecular dynamics) to drive the symmetry
reversal with insulin bound. However, any results from such a model would be suspect
due to the missing CT peptide. We note in both our docked configurations that a
roughly cylindrical gap is generated by the insulin molecule contacting both L1 and
F1. Interestingly, this gap coincides well with the unidentified electron density in the
original IR∆β crystal structure which was speculated to be due to the CT peptide [47].
We also carried out a second, independent 15-ns long apo-IR equilibration tra-
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Figure 5.11: Side-chain interatomic distance traces for various salt-bridge interactions
from an independent apo-IR∆β MD equilibration. (cf. Fig. 5.8)
jectory as a modest check. Briefly, we observed asymmetry in the sense opposite to
the main simulation in at least three salt bridges (Fig. 5.11), Glu154-Arg804, Glu124-
Arg780, and Lys102-Asp638. At the apex of the dimer, the two Lys460’s interact with
their intrasubunit counterparts, Asp464, rather than either one of them interacting
with their possible intersubunit counterparts, Asp574. Rg of the two binding pockets
also diverges in this simulation (Fig. 5.12), but the pocket that increases in size is on
the (L1-CR-L2)′-(F1-F2) side of the dimer, opposite of what is observed in the main
simulation (see Sec. 5.4.4).
This interpretation also implies that, starting as we did from a perfectly sym-
metric conformation, the probability that one particular side opens and the other
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Figure 5.12: Binding pocket radius of gyration Rg vs. time for the pockets defined
by the (L1-CR-L2)/(F1-F2)′ (red) and (L1-CR-L2)′/(F1-F2) pockets (green) from an
independent apo-IR∆β MD equilibration. The horizontal black line is Rg measured
for the IR∆β crystal structure. (cf. Fig. 5.7)
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closes should be 50%. The shorter second simulation bears out this supposition. It
is notable, however, that the apical salt bridge network in this shorter simulation re-
mains symmetrical with Lys460’s participating equally in their respective intrasubunit
salt-bridges (with Asp464) rather than either one of them linking across the L2/F1
interface to the intersubunit counterpart, Asp574. This emphasizes the point that the
initial hinge-angle fluctations away from the symmetric conformation are apparently
not dependent upon the disposition of the apical salt-bridge network, but that in later
stages of the development of the asymmetric conformation, this network responds in
such a way to accomodate and even stabilize it.
5.5.3 Limitations of all-atom insulin/IR∆β structural models
Though physically plausible, the structural models of the insulin/IR∆β complexes
presented here are inherently biased towards conformation of IR in the IR∆β crystal
structure [47]. Hence, our predictions are limited by the fact that the structural
models have been constructed based upon an unliganded form of IR [51, 131], which
was crystallized not in the presence of insulin, but, of an insulin mimetic peptide
not resolved in the crystallographic data [163]. As mentioned before, our structural
models are also limited in the aspect that we do not incorporate the CT peptide
in our MC docking, chiefly because there was no structural information on the CT
peptide in the original crystal structure [47]. We note that the CT peptide is a
critical structural element for binding of insulin to IR as concluded by earlier site-
specific mutagenesis and chimeric receptor studies [133, 144–147]. Though we can
speculate based on our data that CT can possibly be accommodated between bound
insulin and the F2 domain, our models remain limited in suggesting the required
precise positioning of CT in the putative ligand binding pocket [138] and how that
will affect the conformation of bound hormone.
Moreover, it is important to point out that the structural models presented here
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are based on two different structurally equilibrated forms of insulin, namely T and R
(Fig. 5.2). Although the exact conformation of insulin bound to IR remains elusive,
it is widely believed that on receptor binding, the C-terminus of the insulin B-chain
moves away from the A-chain N-terminus such that insulin presents its hydrophobic
interior to the classical binding surface of the L1 domain [157, 162]. Therefore, insulin
when bound to the receptor may not be strictly in either the T orR state, as modeled
here. We do not observe any significant rearrangement of the C-terminus of insulin
B-chain in our MD simulations (vide supra). Hence, it is likely that our insulin/IR∆β
structural models may not exactly reflect the yet unknown receptor bound state of
the hormone in solution.
Given that the CT peptide is missing from our models, and the possibility that the
conformation of the hormone changes on receptor binding which is not captured in our
MD simulations, it is difficult to conclude at this point whether the structural models
belong to low-affinity or high-affinity insulin/IR complexes despite the observation
that both forms of insulin have simultaneous contacts with the site-1 residues in the
L1 domain and the site-2 residues in the first type-III fibronectin domain. We would
also like to comment on the stoichiometry of insulin binding to IR in our structural
models. We note that using our MC docking protocol, we can dock only a single intact
insulin molecule (T or R) in one out of two similar putative ligand binding pockets of
the structurally equilibrated homo-dimeric IR∆β. Therefore, our models suggest 1:2
(insulin:IR∆β subunit) stoichiometry. The stoichiometry of insulin binding to various
monomeric chimeras of the IR ectodomain in presence of the free CT peptide is known
to be 1:1 (insulin:IR subunit) [137, 139, 147], and to the soluble ectodomain as 2:2
(insulin:IR subunit) [164]. The 2:2 (insulin:IR subunit) stoichiometry is possible in
our structural models because a bound ligand on one side likely loosens intersubunit
interfaces on the unoccupied side and can thereby allow binding of another insulin
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molecule in a similar binding mode to as shown in Fig. 5.10. The stoichiometry of
insulin binding to IR in our structural models is consistent with these experimental
observations despite certain limitations mentioned above. Our future work is aimed
at overcoming these limitations.
5.6 Conclusions
In this chapter, we have reported results from over 135 ns of all-atom explicit-
solvent MD simulation of the insulin receptor ectodomain IR∆β in both its apo and
insulin-bound forms. The originally symmetric IR∆β crystal structure relaxes spon-
taneously to form an asymmetric conformation in which one insulin binding pocket
is accessible and the other is not. This relaxation involves coordinated fluctuations
in interdomain hinges between the first two fibronectin type-III repeats (F1 and F2)
with a “locking in” of the asymmetry due to increased strength of one apical L2/F1
intersubunit interface. We present evidence for an important role for salt-bridge
switching involving Lys460’s at the apex of the dimer. Monte Carlo-based docking
predicts complexes which are consistent with experimental literature and also pre-
dict new insulin/IR contacts, particularly at site 2. Taken together, our results shed
new light on both the flexibility mechanisms of the IR family and protein-protein
interfaces both within IR and in putative insulin/IR complexes.
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Chapter 6: Molecular Simulation Studies of the Type 1 Insulin-like
Growth Factor Receptor Ectodomain
6.1 Abstract
The type 1 insulin-like growth factor receptor (IGF1R) is a membrane-spanning
glycoprotein of the insulin receptor (IR) family and is implicated in a variety of
cancers. The key questions related to molecular mechanisms governing ligand recog-
nition by IGF1R remain unanswered, partly due to the lack of testable structural
models of apo or ligand-bound receptor complexes. Using a homology model of the
IGF1R ectodomain IGF1R∆β, we present the first experimentally consistent all-atom
structural models of IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes. Our explicit-
solvent MD simulation of apo-IGF1R∆β shows that it displays asymmetric flexibility
mechanisms that result in one out of two binding pockets accessible to growth factors
IGF1 and IGF2, as demonstrated via an MD-assisted Monte-Carlo docking proce-
dure. Our MD-generated ensemble of structures of apo and IGF1-bound IGF1R∆β
agree reasonably well with published SAXS data. We observe simultaneous contacts
of each growth factor with site 1 and site 2 of IGF1R, suggesting cross-linking of
receptor subunits. Our models provide direct evidence in favor of suggested electro-
static complementarity between the C-domain (IGF1) and the CR-domain (IGF1R).
Our IGF1/IGF1R∆β model provides structural bases for the observation that a sin-
gle IGF1 molecule binds to IGF1R∆β at low concentrations in SAXS studies. We
also suggest new possible structural bases for differences in affinity of insulin, IGF1,
and IGF2 for their non-cognate receptors.
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6.2 Introduction
The insulin-like growth factor (IGF) family is comprised of the type-1 and type-2 sol-
uble growth factors (IGF1 and IGF2), the type-1 and type-2 transmembrane growth
factor receptors (IGF1R and IGF2R), and six soluble insulin-like growth factor bind-
ing proteins (IGFBPs) [165, 166]. Synergistic interactions among members of the IGF
family are essential for normal cellular growth and development, differentiation, and
the processes related to metabolism [41]. More importantly, the IGF family has been
implicated in tumorigenesis [167], because altered expression of the IGF1R, growth
factors, and/or the IGFBPs leads to cancer development and progression [168–170].
Hence, the IGF family has become a potential target for intensive anti-cancer thera-
peutic efforts [3, 170, 171]. However, the treatment of various cancers is dependent
upon developing a molecular level understanding of mechanisms by which growth
factors, IGF1 and IGF2, activate their cognate cell surface receptors, in particular
IGF1R.
IGF1R is a membrane-spanning glycoprotein of the receptor tyrosine kinase (RTK)
superfamily, which, among others, also includes the closely homologous insulin re-
ceptor (IR) [43, 49]. Both IGF1R and IR are unique among RTKs due to their
covalently-linked homo-dimeric architecture, which also means that these receptors
need domain rearrangements rather than receptor dimerization for activation [41].
Each subunit in the ectodomain of receptors, from the N-terminus to the C-terminus,
is comprised of two leucine-rich domains (L1 and L2), separated by a cysteine-rich
domain (CR), and followed by three type-III fibronectin repeats, F1, F2, and F3
(Fig. 6.1 (a)) [5, 8, 41]. The (L1-CR) and (L2-F1-F2) domains of IGF1R form two
distinct binding epitopes for growth factors, designated traditionally as site 1, and
site 2, respectively (Fig. 6.1 (b)). However, site 1 and site 2 of IR are limited only to
L1 and (F1-F2), respectively [5, 50]. Both IGF1R and IR are also capable of binding
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Figure 6.1: (a) The structure of the dimeric IGF1R∆β homology model viewed along
the +Z direction with subunit 1 in wireframe and subunit 2 in tube representation.
The intersubunit Cys514-Cys514
′
disulfide is also shown. (b) L1, CR, and L2 domains
of subunit 1 and F1′, F2′, and F3′ domains of subunit 2 viewed along the -X direction.
The +Y direction in the presented view would correspond to the membrane surface
normal. Color denotes domain: brown, L1; yellow, CR; green, L2; magenta, F1; cyan,
F2; blue, F3. The approximate locations of site 1 and site 2′ indicated in (b).
three ligands in the system namely IGF1, IGF2, and insulin, albeit with differing
affinities. However, the molecular bases of this discrimination are unclear, as are the
mechanisms underlying ligand binding.
IGF1 and IGF2 are single-chain polypeptide growth factors that are homologous
to each other and to insulin. Each growth factor is comprised of four domains des-
ignated traditionally from the N-terminus to the C-terminus as B, C, A, and D,
respectively [60, 165, 166, 172]. We show NMR structures of IGF1 and IGF2 along-
side insulin in Fig. 6.2 (a); notice that insulin lacks the C and D domains, unlike
IGF1/2. IGF1, IGF2, and insulin each have two independent receptor-binding sur-
faces that are located on opposite sides of each ligand, and are known to independently
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Figure 6.2: (a) Cognate ligands for IR and IGF1R, respectively. (b) and (c) Receptor
binding surfaces of each ligand. Residues of each ligand that likely interact with site
1 and site 2 of their cognate receptors are in red and blue surface representations,
respectively.
interact with site 1 and site 2 of their cognate receptors. Despite structural similari-
ties, these ligands exert their unique biological effects by specifically binding to their
cognate receptors: IGFs and insulin bind with high affinity to IGF1R and IR, respec-
tively [41, 60, 165, 172]. These ligands are also capable of binding to non-cognate
receptors, albeit with a significantly lower affinity [60].
Ligand/receptor binding in the IGFs/IGF1R and insulin/IR system also involves
low- and high affinity binding modes, and/or negative cooperativity between two
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equivalent binding pockets [126, 129, 173, 174]. IGF1R and IR can only bind one
ligand molecule with high affinity and at least one other with lower affinity [131]. A
single ligand molecule in high affinity binding is also known to cross-link individual
subunits of each receptor homo-dimer, potentially binding to the site 1 and site 2
of receptors simultaneously [130, 174]. A “see-saw”-like mechanism for IR has been
proposed to alternate conformational changes between sides of the dimer in the apo,
low-, and high affinity activated states of the receptor [47]. Most likely, conformational
changes in the IGF1R ectodomain are also governed by a similar mechanism [131]. In
spite of these common features, a significant difference between both ligand/receptor
systems is that the growth factors can bind with high affinity to both free as well as the
leg-restricted IGF1R ectodomain [175], while insulin has a considerably lower affinity
for the IR ectodomain, unless the C-termini of the F3 domains (IR) are membrane-
embedded or fused to self-associating proteins [160, 176, 177]. However, molecular
origins of the conformational changes that lead to the differences in ligand binding
characteristics of the IGF1R and IR ectodomain are elusive.
A comprehensive understanding of ligand/receptor interfaces in the IGFs/IGF1R
system is lacking chiefly due to unavailability of any structural data on the holo-
receptor or ligand/receptor complexes. Although ligand/receptor protein-protein in-
terfaces in the insulin/IR system have been extensively studied and are relatively
well-characterized [1, 132–140, 142–152], a detailed understanding of similar inter-
faces in the IGFs/IGF1R system is lacking. Nonetheless, many studies using site-
specific mutagenesis [165, 178–201], and chimeric receptor constructs [177, 202–207],
have mapped following residues of IGF1/2, and IGF1R, that participate in ligand/re-
ceptor interactions, respectively:
1. In Table 6.1, we present the list of at least 28 residues of IGF1, and 19 residues of
IGF2, that compromise IGF1R binding affinity on individual mutations. These
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Figure 6.3: The binding surfaces of IGF1 and IGF2 on the L1 domain of IGF1R,
respectively.
residues collectively form two distinct receptor-binding surfaces on each ligand,
based on which, they can be classified as site-1 and site-2 residues, respectively
(Fig. 6.2 (b) and (c)); and
2. The L1 domain residues 8, 11, 28, 30, 32, 33, 56, 58, 59, 79, and 90 (Fig. 6.3),
and the CT-peptide residues 692-698, 700, and 701 [198, 208], are low affinity
binding determinants for IGF1 and/or IGF2, and likely interact with site-1
residues of growth factors. Also, the CR domain residues R240, F241, E242,
and F251, potentially interact with site-1 residues of only IGF1 [198, 208]. The
residues in the N-terminal loops of L2 and F2, and the C-terminal loops of F1,
have been suggested as high affinity binding determinants, and likely contact
site-2 residues of IGF1 and/or IGF2 [1, 2, 44, 47].
However, previous mutagenesis studies are inconclusive in assigning the following
residues as either site-1 or site-2 participants: R56, M59, Y60, and K65 (IGF1), and
D15 (IGF2). Electrostatic complementarity between the C-domain of IGF1 and the
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Table 6.1: Literature survey of mutagenesis studies of IGF1 and IGF2. Denoted
by single letter code are residues of IGF1 and IGF2 that on individual mutations
compromise IGF1R binding affinity. Mutations depicted in red boldface are
known to have negligible effect on the binding affinity.
IGF1 IGF2
Native→Mutant [Ref.] Native→Mutant [Ref.]
E3→R [185], G [185], Q [178] E6→R [186]
T4→H [190], A [178] E12→A [200]
A8→L [190] V14→T [200]
E9→K [195], Q [195], A [201] D15→A [200]
V11→T [189], I [189], A [192] Q18→A [200]
D12→A [192, 201] F19→A [200]
Q15→S [190], A [192], E [192], Y [178] F26→S [182]
F16→A [192, 201], S [195], L [178] Y27→L [182], E [183]
R21→A [193] F28→L [200]
F23→G [191] S29→(RLPG) [187, 194]
Y24→S [179], L [179, 181] S33→(CGD) [187]
Y31→A [181] V43→M [200],L [182]
R36→A [188] F48→E [184], T [182]
R37→A [188] R49→S [182]
V44→M [165] S50→I [182]
F49→A [196], T [180] L53→A [200]
R50→A [193], S [180] A54→R [182, 197]
S51→I [180] L55→R [182, 197]
D53→A [201] E57→A [200]
L54→A [201]
R55→A [193], Y [180]
R56→A [193], Q [180]
E58→A [201]
M59→F [190]
Y60→L [181], F [189]
A62→L [190]
K65→A [188]
K68→A [188]
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CR domain of IGF1R has been suggested [3, 49], but specific residues of IGF1 and
IGF1R that participate in these interactions are unknown. Also unclear is the role
of the IGF1 D-domain, as contrasting details related to significance of this domain in
ligand binding have been reported: deletion of the IGF1 D-domain negligibly affects
the IGF1R binding affinity [178], yet Ala-mutation of K65 and K68 compromises
the binding affinity by 10-fold [188]. Exactly which residues of L2 and the type
III fibronectin domains (F1-F2) interact with assigned site-2 residues of IGF1 [199],
and IGF2 [200], respectively, remains unestablished. The exact registry of the L1
domain residues of IGF1R with the site-1 residues of IGF1/2 also remains elusive,
due in part to the fact that there have been so far no detailed structural models of
IGFs-bound-IGF1R to test.
An all-atom homology model of the IGF1R ectodomain IGF1R∆β was built using
the crystal structures of the first three domains (L1-CR-L2) of IGF1R [44], and the
IR ectodomain (IR∆β) as structural templates [47], and this model was then shown
to fit the SAXS data with relatively limited domain movement [4]. Shown in Fig. 6.1
is the structure of all-atom IGF1R∆β homo-dimer, in which subunits are arranged
in a “folded-over inverted V” conformation akin to the IR∆β crystal structure [47].
The L2 and F1 domains form the apex of the homo-dimer, and the L1 and F2 do-
mains define the binding pockets for growth factors. The L1 and CR domain form the
aforementioned “site 1” epitope, while L2, F1, and F2, potentially contain a second
epitope designated “site 2” for growth factors IGF1 and/or IGF2. Given that the
IGF1R∆β homology model was able to closely describe the solution state dynamics
of the apo receptor in the SAXS experiments [4], this structure provides a reasonable
basis from which to investigate ligand/receptor interactions. However, modeling the
large number of degrees of freedom associated with inter-domain flexibility is a chal-
lenging task in SAXS experiments. In such situations, molecular simulation can serve
112
as a powerful tool to gain valuable insights at atomistic level into the inter-domain
flexibility mechanisms of IGF1R that allow binding of growth factors.
In this chapter, we report results of over 100 ns of MD integration of both apo
and IGFs-bound IGF1R∆β. We characterize a spontaneous asymmetric relaxation of
apo-IGF1R∆β in an explicit-water MD simulation (30 ns), which renders one binding
pocket of IGF1R∆β accessible to growth hormones IGF1 and IGF2, as demonstrated
using a customMonte Carlo (MC) docking protocol [54]. We observe that both growth
hormones remain stably bound in post-docking (36 ns each) MD trajectories. We pro-
vide evidence in favor of previously suggested [3, 49] electrostatic complementarity
between the C-domain of IGF1 and the CR-domain of the receptor. We also present
detailed hormone/receptor contacts that are consistent with previous mutagenesis
studies. Based on our hormone/receptor complexes, we also suggest several residues
in the L2 and the type III fibronectin domains (F1-F2)′ of IGF1R which contact site-2
residues of IGF1/2, and can serve as prime candidates for future mutagenesis stud-
ies. More importantly, our MD-generated ensemble of structures of apo-IGF1R∆β
and IGF1/IGF1R∆β agree reasonably well with published SAXS data of Whitten et
al. [4].
6.3 Simulation description
6.3.1 Molecular dynamics simulations
A total of five separate MD trajectories were generated: 30 ns of apo-IGF1R∆β, 36
ns each of IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes, and 1 ns each of growth
factors IGF1 and IGF2 (see Table 6.2, and Fig. 6.4, for simulation details). All MD
trajectories were generated using NAMDv2.6 [84] and the CHARMM force field [89,
90]. The classical MD simulation and the CHARMM potential were described in
Sec. 2.4, and Sec. 2.4.4, respectively. VMDv1.8.7 was used for system creation and
protein rendering [97]. Initial coordinates for the apo simulation were taken from
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an all-atom IGF1R∆β homology model that was originally prepared by Whitten et
al. [4]. This structure provided coordinates for the pairs of L1, CR, L2, F1, F2, and
F3 domains, except the insert domain (641-742) including the CT-peptide (residue
numbering scheme adopted from Ullrich et al. [43]). One interchain α-α disulfide
bond at residue Cys514 is also present. Moreover, the interdomain interfaces in the
IGF1R homology model were checked and found to be stereochemically acceptable
as demonstrated by favorable shape and electrostatic complementarity [4]. We use
a prime to denote domains and residues on subunit 2, and unprimed domains and
residues refer to subunit 1. The coordinates for structures of the ligand/receptor
complexes were generated using a custom Metropolis Monte Carlo procedure (vide
infra).
All systems were solvated using explicit (TIP3P) water and all hydrogen atoms
were included. Similar protocols were followed for all simulations: 2000 cycles of
energy-minimization via conjugate-gradient optimization and a constant tempera-
ture (300K) via the Langevin thermostat with damping coefficient of 5 ps−1. The
equilibration phases were carried out in the NVT ensemble using 2-fs time step with
rigid bonds in all simulations, except for the equilibration of IGF1 and IGF2, where
1-fs time step with no rigid bonds was used. Non-bonded interactions were cut-off
beyond 10 A˚ with smooth switching taking effect at 8.5 A˚. Long-range electrostatic
interactions were handled using the particle mesh Ewald (PME) method. Configura-
tions were saved every 10 to 20 ps and energy-like quantities every 2 ps.
6.3.2 Monte Carlo docking
We generated IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes using a custom
MD-assisted Monte-Carlo (MC) algorithm [54]. We implemented the docking al-
gorithm in VMDv.1.8.7 [97] using a Tcl script. Our MC protocol minimized the
non-bonded interaction energy (van der Waals and electrostatics) between all atoms
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Figure 6.4: MD simulation systems. Front and top views of the apo-IGF1R∆β,
IGF1/IGF1R∆β, IGF2/IGF1R∆β. Individual monomers forming IGF1R∆β dimer
are blue and cyan, respectively, and the ligands (IGF1 and IGF2) are in red. Gray
dots represent water molecules.
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Table 6.2: Details of all MD simulation systems.
System No. of traj. Traj. length Initial Box volume System size No. of ions
(N) (ns) coordinates (A˚3) (atoms) (Na+,Cl−)
apo-IGF1R∆β 1 30 Homology 158×170×126 325625 53, 41
modeled
IGF1/IGF1R∆β 1 36 MC docking 155×167×129 320572 51, 40
IGF2/IGF1R∆β 1 36 MC docking 155×167×129 320499 52, 40
IGF1 1 1 PDB ID: 2GF1 53×47×49 11282 1, 2
IGF2 1 1 PDB ID: 1IGL 59×52×54 15543 2, 2
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of each ligand and those receptor atoms which we pre-defined as forming a binding
pocket. The two pockets are defined respectively by the L1-CR-L2 and (F1-F2-F3)′
domains (observed accessible pocket) and the (L1-CR-L2)′ and (F1-F2-F3) domains
(observed inaccessible pocket). Specifically, IGF1R∆β residues included in the MC
energy calculation included (i) the L1 residues 8, 10, 11, 30, 32, 33, 35, 58, 79-85,
90, 112, 114, 138, 140, (ii) the CR residues 241, 242, 255, 259, 260, 263, 274-276,
(iii) the L2 residues 300-306, 309, 310, 312, 315, 316, 318, 319, (iv) the F1 residues
472-474, 518-524, (v) the F2 residues 580-583, and 602-608. We sampled receptor
conformations from the 30 ns apo-IGF1R∆β MD simulation, and conformations of
each ligand from an ensemble of solution conformations generated by two separate
1 ns long equilibration simulations (Table 6.2). The trial moves in Metropolis MC
sampling consisted of (i) global orientation angle displacements of up to 2◦ (about
the COM of the ligands), (ii) ligand translational displacements up to 1 A˚, and (iii)
conformational sampling from MD trajectories. The center of mass of each ligand was
aligned with the geometric center of the binding pocket region to generate initial po-
sitions. We randomly generated the initial ligand orientations, and performed a total
of 20 000 to 30 000 MC cycles per docking trial, which resulted in 15 docked config-
urations for each ligand (IGF1 and IGF2) in the accessible pocket, and no successful
dockings in the inaccessible pocket nor in the IGF1R∆β homology model.
6.3.3 Collective variable conformational metrics
We defined a set of collective variables based on the center-of-mass positions of
each domain and the locations of the hinges between them to characterize the over-
all conformational variability of the IGF1R∆β ectodomain. We conceptualized each
subunit as a linear chain of “mapping points” that correspond to positions of domains
and the hinges connecting them. Domains L1, L2, F1, F2, and F3 of each subunit
contribute a mapping point. The L1-L2, F1-F2, and F2-F3 intradomain hinge map-
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ping points are defined as the centers of mass, respectively, of residues 294 to 298;
543, 579, 607, and 608; and 623, 765, 797, and 830. Finally, a common “apex hinge”
mapping point connects L2, L2′, F1, and F1′ and is defined as the center of mass of the
four-domain apex. In this manner, the entire IGF1R∆β structure (more than 25,000
atoms distributed over 1,590 residues) is coarse-grained onto 17 Cartesian positions
for conformational analysis.
The set of collective variables considered here based on these mapping points are
(1) the F1-F2 and F1′-F2′ hinge angles; (2) the L1-L2 and L1′-L2′ hinge angles; (3)
the L2/F1′ and L2′/F1 hinge angles, and (4) the L1-L2↔Fn1′-F2′ and L1′-L2′↔F1-F2
interhinge distances. Hereafter, when referring to the hinge angle due to domains A
and B, we use the notation “A-B”. (Note the labelling distinction between interfaces
(“A/B”) and hinge angles (“A-B”)).
6.3.4 Definitions of observables: buried surface area (BSA) and binding
pocket radius of gyration (Rg)
We computed the buried surface area (BSA) between any two domains A and B
by subtracting the solvent-accessible surface area (SASA) following equation 5.1. We
performed all SASA calculations under VMDv1.8.7 using a probe radius of 1.4 A˚.
Hereafter, when referring to the interface between domains A and B, we use the nota-
tion “A/B”. Due to the absence of 2-fold rotational symmetry in the IGF1R∆β dimer,
asymmetry exists in four intersubunit BSA: L1/F2′ (∼1667 A˚2), L1′/F2 (∼1115 A˚2),
L2/F1′ (∼1542 A˚2), and L2′/F1 (∼1743 A˚2).
We measure the size of the binding pockets using the radius of gyration Rg (see
equation 5.2) of the collection of atoms belonging to residues that directly surround
the binding pocket: (i) the L1 residues 8, 10, 11, 30, 32, 33, 35, 58, 79-85, 90, 112,
114, 138, 140, (ii) the CR residues 241, 242, 255, 259, 260, 263, 274-276, (iii) the
L2 residues 300-306, 309, 310, 312, 315, 316, 318, 319, (iv) the F1 residues 472-474,
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518-524, (v) the F2 residues 580-583, and 602-608. We used the same residues in the
MC energy evaluation for the docking calculations.
6.3.5 Theoretical X-ray intensity analysis
We computed theoretical X-ray intensity profiles from MD-generated ensemble of
structures of apo and IGF1-bound IGF1R∆β using software packages CRYSOL [209]
and EOM [210]. The structures for this analysis were extracted every nanosecond
from all-atom MD trajectories of apo-IGF1R∆β (30 ns) and IGF1/IGF1R∆β (36 ns).
The carbohydrates at various glycosylation sites were modeled onto these structures
similarly as described by Whitten et al. [4]. We point out that the insert domain
(ID) is missing from these glycosylated structures similar to the IGF1R∆β homology
model. Given an ensemble of structures, the EOM package uses a genetic algorithm
based optimization scheme to compute the theoretical X-ray intensity profiles (shown
by black lines in Fig. 6.17 (a)). The total number of generations were 1000, and 50
cycles of genetic algorithm were used in the calculation. The detailed procedure can
be found elsewhere. The pair-distance distribution functions shown in Fig. 6.17 (b)
were computed using the software package GNOM [211].
6.4 Results
6.4.1 Structural relaxation of apo-IGF1R∆β
6.4.2 Intradomain relaxation and flexibility
In Fig. 6.5 (a), we show the RMSD traces for backbone Cα atoms of each domain
of IGF1R∆β during the 30-ns long apoMD trajectory. In general, these data indicate
that the overall fold of each domain is preserved during MD relaxation given their
modest RMSD values between 2 to 5 A˚. The domains seem well-equilibrated after
∼15 ns for both subunits. The CR domain and fibronectin repeats show relatively
larger deviations than the L1 and L2 domains, which drift very little. We further
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Figure 6.5: (a) Intra-domain Cα RMSD for each domain vs simulation time. (b)
RMSF vs residue number averaged over both subunits.
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show per-residue RMSF averaged over both subunits in Fig. 6.5 (b). The CR and
fibronectin domains seem more intrinsically flexible than L1 and L2 from these data as
well. A single loop in the N-terminus of L1, the C-terminal loops of the CR (junction
of CR and L2), and the inter-β-strand loops of F1 show pronounced flexibility. F2
and F3, however, possess highly flexible backbone chain ends.
6.4.3 Interdomain flexibility: collective variables
We describe large-scale interdomain flexibility of IGF1R∆β via a coarse-grained
representation using collective geometric variables such as interdomain hinge an-
gles and distances defined in terms of Cartesian positions of “mapping points” (see
Sec. 6.3.3). We show the coarse-grained representation on top of the all-atom homol-
ogy model of IGF1R∆β in Fig. 6.6 (a), and the collective variable traces in Fig. 6.6 (b).
In the first 7 ns, the (F1-F2)′ hinge (¬) contracts, while the F1-F2 hinge (­) remains
close to the initial value apart from a sharp decrease in the beginning. The F1-F2
hinge (­) begins to sharply close at 7 ns, and continues so for next 8 ns, whereas the
(F1-F2)′ hinge (¬) recovers such that both hinges are equally closed at 15 ns. In next
10 ns, the F1-F2 hinge (­) remains contracted at the same value, while the (F1-F2)′
hinge (¬) further recovers close to its initial value. After about 25 ns, the (F1-F2)′
hinge (¬) re-contracts and the F1-F2 hinge (­) recovers so that both hinges are again
equally closed at 30 ns. The L1-L2 hinge angles (traces ® and ¯ in Fig. 6.6) fluctuate
about their initial value in the first 10 ns. At this instant, the (L1-L2)′ angle (®)
sharply closes before stabilizing again in the next 15 ns, while the L1-L2 angle (¯)
remains close to its initial value. Hereafter, the (L1-L2)′ angle (®) recovers and the
L1-L2 angle (¯) slightly closes. Except for a small opening of the L2-F1′ hinge angle
(°) in the first 15 ns, none of the L2-F1 or L2-F1′ hinge angles (° and ±) show any
appreciable change from their initial values.
The distances between F1-F2 and L1-L2 hinges do not appreciably change in the
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Figure 6.6: (a) Schematic illustration of the mapping points used to define geometric
collective variables for measuring conformational changes in the IGF1R∆β dimer.
Circled digits identify hinge angles: F1′-F2′ (¬), F1-F2 (­), L1′-L2′ (®), L1-L2
(¯), L2-F1′ (°) and L2′-F1 (±). Digits in squares identify interhinge distances. A
reduced top view of the apical domains and angles between them is shown in the
inset at bottom. (b) Traces of hinge angles and interhinge distances. Horizontal lines
denote values measured in the IGF1R∆β homology model and vertical lines show the
scale of each curve.
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first 7 ns. Thereafter, the distance between the F1-F2 hinge and the steadily closing
(L1-L2)′ hinge increases by ∼15 A˚ (8). However, the distance between the (F1-F2)′
hinge and steady L1-L2 hinge remains close to its initial value (7). The interhinge
distance at (F1-F2)-(L1-L2)′ side of the dimer slightly decreases after about 20 ns,
apparently due to a modest recovery of the (L1-L2)′ hinge angle.
6.4.4 Intersubunit flexibility: buried surface area and binding pocket size
Four large patches of intersubunit buried surface area (BSA) exist in the IGF1R∆β
structure: L1/F2′ and L1′/F2 (∼1,200-1,600 A˚2; symbols ¬ and ­ in Fig. 6.7 (a-
b)), and L2/F1′ and L2′/F1 (∼1,500-1,700 A˚2; symbols ® and ¯ in Fig. 6.7 (a-b)).
The time evolution of BSA at each interface is shown in Fig. 6.7 c. We note that
asymmetry existed in BSA values at four interfaces in the IGF1R∆β homology model
(see Sec. 6.3.4): L1/F2′, and L2′/F1, have larger BSA than their counterparts L1′/F2,
and L2/F1′, respectively. Throughout the trajectory, the L1/F2′ interface maintains
a relatively larger BSA than does the L1′/F2 interface (traces ¬ and ­, respectively,
in Fig. 6.7 c), presumably due to smaller contraction of the F1-F2 hinge angles (traces
¬ and ­ in Fig. 6.6 b). Notable is the steady increase of BSA at the L2′/F1 interface
after the first 5 ns of simulation, which is concomitant with the sharp closing of the
(L1-L2)′ hinge (® in Fig. 6.6 b). The L2/F1′ interface, however, remains substantially
intact due to the rigid L1-L2 hinge (¯ in Fig. 6.6 b).
Depicted in Fig. 6.7 c are also the traces of the radius of gyration (Rg) of each
binding pocket (° and ±). The pocket formed by the domains (L1-CR-L2)/(F1-
F2)′ starts to open and stays open until the end of the trajectory (°), whereas
its counterpart ([(L1-CR-L2)′/(F1-F2)]; ±) remains closed. Because the (L1-CR-
L2)/(F1-F2)′ binding pocket opens in the first 3 ns of the run, it is apparently due
to closing of the (F1-F2)′ hinge (¬ in Fig. 6.6 b), as neither of the L1-L2 or L2-F1
hinges (®, ¯, °, and ± in Fig. 6.6 b) significantly change during this period. (Details
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Figure 6.7: (a) Schematic illustration of a side view of the IGF1R∆β homology model
showing locations of the L1/F2′ (¬) and L2/F1′ (®) interdomain interfaces and the
putative binding pocket for growth factors, IGF1 and IGF2, defined by domains (L1-
CR-L2)-(F1-F2)′ (°). The (L1-CR-L2) and (F1-F2-F3)′ motifs from subunit 1 and
2, are red and blue, respectively. (b) Same as (a) except for L1′/F2 (­), L2′-F1
(¯), and (L1-CR-L2)′-(F1-F2) (±). The (L1-CR-L2)′ and (F1-F2-F3) motifs from
subunit 2 and 1, are blue and red, respectively. (c) Traces of buried surface area and
binding pocket Rg. Horizontal lines denote values measured in the homology model
of IGF1R∆β and vertical lines show the scale of each curve.
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regarding calculation of BSA and Rg appear in Sec. 6.3.4)
6.4.5 Model structures of IGF1/IGF1R∆β and IGF2/IGF1R∆β com-
plexes
6.4.6 Monte-Carlo docking
We generated 15 independent docked models for each of the growth factors, IGF1
and IGF2, onto the IGF1R∆β ectodomain using an MD-assisted MC algorithm (see
Sec. 6.3.2 for details on complex generation). The same algorithm was used to success-
fully generate all-atom structural models of insulin/IR∆β complexes described in the
chapter 5 [54]. Briefly, docking was performed in the open binding pocket defined by
(L1-CR-L2)/(F1-F2)′, where initial orientations of ligands were generated randomly
after shifting the center-of-mass (COM) of the ligand to the COM of the binding
pocket. Two final models, one for each ligand-receptor complex, that displayed high-
est degree of agreement with experimentally known IGF1 and IGF2 interactions (see
Discussion and Table 6.1) with IGF1R∆β ectodomain were chosen for further 36-ns
equilibration via MD simulations. Structural relaxation of the ligand-bound com-
plexes from these MD simulations is described below.
6.4.7 Ligand-receptor contacts: IGF1/IGF1R∆β and IGF2/IGF1R∆β
To elaborate the ligand-receptor contacts, docked views of IGF1 and IGF2 in the
binding pocket defined by (L1-CR-L2)/(F1-F2)′ are shown in Fig. 6.8. The contact
interfaces between each growth factor and the receptor domains L1, CR, L2, F1′,
and F2′, are depicted using small arcs marked by ¬, ­, ®, ¯, and ° in Fig. 6.8.
In Table 6.3, we detail residues of each ligand and the individual domains of the
receptor involved in one-to-one registry at these contact interfaces. The location of
these residues is also shown in Fig. 6.9 to Fig. 6.12.
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Figure 6.8: Representations of the docked configurations of growth factors IGF1
and IGF2. Left and right panels, respectively, are docked views of each ligand in
the relatively open binding pocket formed by domains (L1-CR-L2)-(F1-F2)′. Color
denotes domains of each ligand: red, A-domain; blue, B-domain; cyan, C-domain;
yellow, D-domain. Small arcs marked by circled digits ¬, ­, ®, ¯, and °, denote
contact interfaces between each ligand and the receptor domains L1, CR, L2, F1′, and
F2′, respectively. The red and green arrows indicate viewing directions for residues
of each ligand and the individual domains of the receptor presented in Fig. 6.9−6.12.
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Table 6.3: Residues involved in ligand/receptor contact interfaces. Residues of each ligand are shown in boldface and of the
individual domains of the receptor in parentheses; “∼” indicates residues with partial contact.
IGF1 IGF2
L
1
V11 (F90, R112), D12 (R59), L14 (Y83) G11 (F90, R112), V14 (F82, Y83), D15 (-)
Q15 (L33, F58, R59), F23 (-), Y24 (Y28, H30) Q18 (L32, F58), F26 (L56, Y83)
F25 (F82, Y83), K27 (L54), P28 (L81, Y83, N84)Y27 (Y28, H30), F28 (L81, F82, Y83)
T29 (W79, R108), Y31 (-) S29 (∼K80), S33 (∼Y28, K80)
S35 (W79), I43 (Y83), V44 (N84) V43 (Y83, N84)
C
R
G32 (S260, S261), S33 (∼F241, I255) S33 (S260, S261), R34 (E259)
S34 (G265), S35 (F266, Q275) V35 (I255, L256, F266), S36 (G265)
R36 (R240, E242, Q275, E276), R37 (∼E264) R37 (S263, E264, R283, S286), R38 (E276)
L
2
R56 (D312, ∼S313, ∼T315) R30 (E305), R38 (K300)
M59 (K306, K309, M319), Y60 (∼T315, ∼M319) R40 (M319), D52 (T315)
K65 (E305), K68 (∼K306), T58 (∼K306), P63 (∼K305)
S69 (T310), A70 (D312) A64 (∼K305)
(
F
1
-
F
2
)
′
P2 (W519, M521), E9 (∼L585, L606) A1 (Y496,∼L541, Y547), Y2 (∼Y496, M521)
D12 (∼L585, ∼P607), F16 (S582, L585, P607) R3 (D523, ∼K542), P4 (∼N520, M521)
V17 (P607, N608), D20 (N473, R474) E12 (∼L585), D15 (∼L585)
R21 (∼R474), D53 (-), L54 (L606) T16 (P607), F19 (V580, S582, ∼N608)
R55 (Y496, ∼V522, ∼D523, ∼L526) R24 (R474), L53 (L606)
E58 (H539), K65 (∼R474) E57 (∼H539, ∼G540)
K68 (∼P528, ∼L537, ∼L538) T62 (∼R474)
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Figure 6.9: IGF1 and IGF2 residues in contact with L1 domain residues of IGF1R∆β
(contact interface ¬; cf. Fig. 6.8). Viewing directions for residues of each ligand and
the domains of IGF1R are marked by red and green arrows, respectively.
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Figure 6.10: IGF1 and IGF2 residues in contact with CR domain residues of
IGF1R∆β (contact interface ­; cf. Fig. 6.8).
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Figure 6.11: IGF1 and IGF2 residues in contact with L2 domain residues of IGF1R∆β
(contact interface ®; cf. Fig. 6.8).
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Figure 6.12: IGF1 and IGF2 residues in contact with (F1-F2)′ domain site-2 residues
of IGF1R∆β (contact interfaces ¯ and °; cf. Fig. 6.8). The residues are shown in
blue to distinguish them from site-1 residues.
131
 0
 2
 4
 6
 8
 10
 0  10  20  30 0 10 20 30 40
R
M
SD
 (Å
)
time (ns)
subunit 1 subunit 2
F2CR
 0
 2
 4
 6
 8
 10
 0  10  20  30 0 10 20 30 40
R
M
SD
 (Å
)
time (ns)
subunit 1 subunit 2
F2
CR
a
b
IGF1/IGF1R
IGF2/IGF1R
Figure 6.13: Intra-domain Cα RMSD for each subunit of IGF1R∆β vs simulation
time from each 36-ns long ligand-bound MD trajectory. Color in the RMSD traces
denote different domains of each subunit (cf. Fig. 6.5).
6.4.8 Structural relaxation of IGF1/IGF1R∆β and IGF2/IGF1R∆β
6.4.9 Intradomain relaxation and flexibility
We present the backbone Cα RMSD of each domain from the 36 ns ligand-bound
MD trajectories in Fig. 6.13. We observe similar RMSD trends for each domain as
were observed for apo-IGF1R∆β (see Sec. 6.4.2), except that on the ligand-bound
side of the dimer, the CR-domain depicts increased flexibility and the F2 domain
shows decreased flexibility compared to the apo simulation.
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MD trajectories (cf. Fig. 6.6).
6.4.10 Interdomain flexibility: collective variables
In Fig. 6.14, we present collective variable traces from MD relaxation (36-ns each)
of the IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes, respectively. The receptor
coordinates in docked complexes correspond to about ∼5-ns of the apo-IGF1R∆β
MD trajectory. The ligands are bound on the (L1-L2)-(F1-F2)′ side of the dimer
(collective variables: ¬, ¯, °, 7). Of particular note are fluctuations of the (L1-
L2)′ hinge angles (®) in both complexes, which are suppressed on ligand binding
in comparison to the apo case, while L1-L2 hinge angle remains close to the initial
value except for a slight preference to closing intermittently. Notable are (F1-F2)′
(¬) hinges in both complexes which further contract to accommodate the ligands,
whereas the F1-F2 hinges (­) on the unoccupied side of the dimer close at a relatively
modest pace compared to the apo simulation. On ligand binding, the L2-F1′ hinges
(±) also open (larger opening in the IGF2/IGF1R∆β complex), while L2′-F1 hinge
angles (°) in both complexes do not change significantly. The interhinge distances (7
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Figure 6.15: Traces of buried surface area and binding pocket radius of gyration Rg
from ligand-bound MD trajectories (cf. Fig. 6.7).
and8) on both sides of the dimer in each complex steadily increase due to fluctuations
in the L1-L2 and F1-F2 hinge angles.
6.4.11 Intersubunit flexibility: buried surface area and binding pocket
size
In Fig. 6.15, we show traces for BSA and Rg from the MD trajectories of the
IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes. The interfaces involving L1 do-
mains maintain nearly equal BSA during each ligand-bound run. Of particular note
in each run are the L2/F1′ interfaces (on the ligand-bound side of the dimer), which
significantly open compared to the apo simulation to accommodate ligands. Due
likely to the fact that IGF2 is larger than IGF1, there is a further decrease in BSA
at the L2/F1′ interface to accommodate IGF2. The decrease in BSA at the L2/F1′
interfaces in ligand-bound trajectories occurs in concert with opening of the L2/F1′
hinges (Fig. 6.14). The Rg traces in the ligand-bound trajectories differ in the re-
spect that both pockets of the dimer open in the IGF2/IGF1R∆β run, while only the
pocket on ligand-bound side of the dimer opens in the IGF1/IGF1R∆β simulation.
134
−
65
±3
5
 0  5  10  15  20  25  30  35  40
time (ns)
igf1
igf2
En
er
gy
 (k
ca
l/m
ol)
−
20
±1
5
−
10
±1
5
−
7±
11
−
22
±1
2
 0  5  10  15  20  25  30  35  40
time (ns)
interface¬
interface­
interface®
interface¯°
igf1
igf2
igf1
igf2
igf2
igf1
igf2
igf1
kc
al
/m
ol
a b
Figure 6.16: (a) Non-bonded interaction potential energy in time from each 36-ns long
ligand-bound MD trajectory. Energy traces are for the interaction of all IGF1 and
IGF2 residues with residues of the binding pocket given in our MC docking protocol,
respectively. (b) Traces of interaction energy between residues of each ligand and
individual domains of the receptor shown in Fig. 6.9−6.12. Circled digits ¬, ­, ®,
¯, and ° distinguish energy traces corresponding to various interfaces between each
ligand and the L1, CR, L2, F1′, and F2′ domains (IGF1R), respectively (cf. Fig. 6.8).
Horizontal lines show the average energy values and vertical lines show the scale of
each curve.
6.4.12 Evolution of ligand/receptor contacts on MD equilibration
We checked the stability and robustness of ligand-receptor contacts observed
in our docked models by equilibrating each complex for 36 ns via MD simulation.
From MD equilibration, we notice that each ligand (IGF1 and IGF2) remains stably
bound on timescales relevant to the structural relaxation of IGF1R∆β. Shown in
Fig. 6.16 (a) are the traces of potential energy of interaction (including electrostatic
and vdW interactions) in time between all atoms of each growth factor and bind-
ing pocket atoms of IGF1R∆β (see MC docking in Sec. 6.3.2). These data indicate
that our IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes are stable on nanosecond
timescales. We further looked into time-evolution of the registry of each growth
factor with IGF1R∆β at each interface via two metrics: (a) average buried surface
area (BSA) between each growth factor and the receptor domains L1, CR, L2, F1′,
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Table 6.4: Buried surface area (BSA) values at different contact interfaces between
each ligand and the L1, CR, L2, F1′, and F2′ domains of the receptor from unequi-
librated MC docked models and equilibrated MD trajectories. The arrows indicate
whether BSA of each ligand with each domain of IGF1R increased or decreased on
equilibration. Column “Ref. [3]” denotes values of BSA from a previously proposed
model of the IGF1/IGF1R complex for comparison [3]. Refer to Sec. 6.3.4 for details
of BSA calculations.
BSA (A˚2)
IGF1 IGF2
Domain (IGF1R) MC MD Ref. [3] MC MD
L1 786 966 ↑ 1595 910 1321 ↑
CR 571 279 ↓ 512 811 628 ↓
L2 738 560 ↓ 29 572 973 ↑
F1′ 817 1022 ↑ − 672 587 ↓
F2′ 530 760 ↑ − 420 435 ↑
(L1-CR-L2)−(F1-F2)′ 3442 3587 ↑ − 3385 3944 ↑
and F2′, respectively (Table 6.4); and (b) interaction potential energy in time of
ligand-receptor contacts at each interface (Fig. 6.16 (b)). In the un-equilibrated
ligand-receptor complexes, IGF2 has higher BSA at L1, and CR (interfaces ¬, and
­, in Fig. 6.8), while IGF1 has higher BSA at L2, F1′, and F2′ (interfaces ®, ¯,
and °, in Fig. 6.8), respectively (Table 6.4). On equilibration, we observe that both
IGF1 and IGF2 on average show significant increase in BSA at L1, and decrease at
CR, while IGF2 still maintains a higher BSA than IGF1 with both domains. The
average BSA trends at L2, and F1′, are as follows: IGF1 shows a decrease in BSA at
L2 and increase at F1′ on equilibration, while BSA for IGF2 at L2 and F1′ evolves
exactly opposite to that of IGF1. However, both growth factors show increased BSA
at F2′. Overall, the total average BSA of IGF2 is ∼350 A˚2 higher than IGF1 in
the [(L1-CR-L2)-(F1-F2)′] binding pocket (Table 6.4). The data on interaction po-
tential energy of ligand-receptor contacts at each interface are consistent with BSA
trends, and indicate that IGF2 interacts relatively strongly with L1, and CR (¬ and
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­; Fig. 6.16 (b)), while IGF1 has stronger interactions with (F1-F2)′ (¯ and °;
Fig. 6.16 (b)). However, both growth factors weakly interact with L2 without any
significant distinction (®; Fig. 6.16 (b)).
6.4.13 Theoretical vs. experimental scattering data
The solution structures of the apo and IGF1-bound forms of IGF1R∆β have been
recently probed using SAXS experiments [4]. In these studies, theoretical scattering
profiles were fitted to experimental profiles for apo-IGF1R∆β using rigid body fitting
of an all-atom homology model. No such modeling was presented for IGF1-bound
IGF1R∆β, possibly due to the absence of an atomic model for IGF1/IGF1R∆β.
In this work, we have explored the conformational flexibility of the apo-IGF1R∆β
homology model using unbiased MD simulations and have presented physically plau-
sible all-atom models for IGF1/IGF1R∆β and IGF2/IGF1R∆β. Given an ensemble
of reasonably accurate all-atom models of a macromolecular complex, it is possi-
ble to compute theoretical X-ray scattering profiles that can be directly compared
with no fitting with the available experimental SAXS data [209, 210, 212]. Hence,
we computed scattering profiles (see Sec. 6.3.5) using our MD-generated ensemble
of structures of apo-IGF1R∆β and IGF1/IGF1R∆β, and compared them with ex-
perimental SAXS profiles (Fig. 6.17 (a)). The agreement for apo-IGF1R∆β is re-
markably good throughout, with discrepancy [209, 213] χ=0.78, and the agreement
for IGF1/IGF1R∆β is reasonable, with discrepancy χ=1.17. In Fig. 6.17 (b), we
also present the pair-distance distribution functions [211, 213–215] p(r) calculated
using package GNOM [211], that show a similar level of agreement with SAXS data
for apo-IGF1R∆β and IGF1/IGF1R∆β. The Rg values for our apo-IGF1R∆β and
IGF1/IGF1∆β models are 51.73 A˚ and 52.78 A˚, respectively, compared with 52.50 A˚
and 53.90 A˚ for SAXS experiments [4]. Consistent with these SAXS studies, we also
observe that the p(r) curve for IGF1/IGF1R∆β is slightly shifted to the left in com-
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Figure 6.17: (a) Comparison of experimental and theoretical SAXS intensity
data. The intensity data from SAXS experiments [4] for apo-IGF1R∆β (•) and
IGF1/IGF1R∆β (•) are overlaid with theoretical intensities (black lines) computed
using software packages CRYSOL and EOM based upon our MD-simulated all-atom
models. SAXS intensity data for IGF1/IGF1R∆β in experiments was collected from
solutions with 1:1 (IGF1:IGF1R∆β) stoichiometry. For clarity, the intensity data
for IGF1/IGF1R∆β are offset by a factor of 10−1. (b) Pair-distance distribution
functions p(r) calculated using X-ray scattering data from experiments and our MD
simulations presented in (a).
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parison to apo-IGF1R∆β. Also, our theoretical p(r) curve for IGF1/IGF1R∆β in the
range 60≤r(A˚)≤110 is slightly shifted to the right in comparison to the corresponding
experimental curve. Quantitatively, rigid body fitting of individual domains in SAXS
studies [4] also suggests an overall RMSD of the Cα atoms of IGF1R∆β in solution
to be ∼5.9 A˚ in comparison to the homology model. Our explicit-solvent MD simu-
lations of the apo-IGF1R∆β homology model are consistent with these observations,
and indicate the RMSD of Cα atoms to be ∼6 A˚.
6.5 Discussion
6.5.1 Asymmetry in the apo-IGF1R∆β dimer
A “harmonic-oscillator” kinetic model of IGF1R and IR, articulated recently by
Kiselyov et al. [131], suggests that a small amount of thermal energy can drive apo
ectodomains of IGF1R and IR between symmetry-inverted asymmetric active states
capable of binding ligands. Our MD simulations show that apo-IGF1R∆β can spon-
taneously relax to an asymmetric state that is capable of stably binding growth fac-
tors on simulation time-scales, which is evidence in favor of the harmonic-oscillator
model. Based on our previous MD simulations of IR∆β [54], we also propose that
both IGF1R∆β and homologous IR∆β share common asymmetric mechanisms of
flexibility that are consistent with the harmonic-oscillator model.
More importantly, our simulations provide following details of the flexibility mech-
anisms that lead to asymmetry in apo IGF1R∆β. The F1-F2 hinge angles that are
∼170◦ in the homology model can substantially fluctuate due to movement of these
domains relative to each other. When the F1′-F2′ hinge angle closes in such a way as
to keep the distance from the L1-L2 hinge of other subunit constant, this results in
closing of the L1′-L2′ hinge on the opposite side of the dimer, while the L1-L2 hinge
remains steady. The closing L1′-L2′ hinge leads to strengthening of the L2′/F1 inter-
face, and weakening of the opposite L2/F1′ interface as measured by BSA, apparently
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without any noticeable change in the L2/F1′ or L1/F2′ apical angles. Following this,
closing of the F1-F2 hinge angle which increases its inter-hinge distance from the
L1′-L2′ hinge of other subunit, stabilizes these conformational changes. These struc-
tural displacements result in opening of the [(L1-CR-L2)-(F1-F2)′] binding pocket,
and a slight closing of its counterpart [(L1-CR-L2)′-(F1-F2)] binding pocket. A large
enough random “closing” fluctuation of the now steady L1-L2 hinge can reverse this
conformational transition, given that fluctuations in the F1′-F2′ hinge angles lead to
opening of the now closed L1′-L2′ hinge. Indeed, our ligand-bound trajectories indi-
cate that binding of either IGF1 or IGF2 to the open pocket increases the likelihood
that the L1-L2 hinge on the ligand-bound side of the dimer closes, and the L1′-L2′
hinge on the unoccupied side of the dimer opens (see Sec. 6.4.10).
6.5.2 All-atom IGF1/IGF1R∆β and IGF2/IGF1R∆β complexes
6.5.3 Site-1 contacts with L1 and CR
IGF1 and IGF2 share common binding epitopes on the surface of the L1 domain
of IGF1R (Fig. 6.3) [198, 208]. Consistent with earlier studies, we observe contacts
for all of these residues except for D8 and N11 of L1 in both docked models. Also, at
least 28 out of 70 residues of IGF1, and 19 out of 67 residues of IGF2, on individual
mutations were reported to affect IGF1R binding affinity. We present the list of these
mutations in Table 6.1. It is interesting to note that we observe contacts for the
following residues of each ligand with L1, all of which are known to interact with
IGF1R based on various mutagenesis studies: V11, D12, Q15, F23, Y24, Y31, and
V44 (IGF1), and V14, D15, Q18, F26, Y27, F28, S29, S33, and V43 (IGF2).
Several studies hint at a role for the CR domain (IGF1R) in governing high-affinity
binding and specificity of IGF1 and/or IGF2 for IGF1R [177, 202–204, 204, 205, 208].
Four types of hybrid IGF1R/IR chimeras, all of which bind IGF1 and/or IGF2 with
high affinity, suggest a key function of the CR domain in ligand recognition: (1)
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Andersen et al. [202] replaced the (L1-CR-L2) motif of IR with the corresponding
(L1-CR-L2) motif of IGF1R, (2) Kjeldsen et al., [203] Schumacher et al., [204] and
Zhang et al. [205] substituted the CR-domain of IR by the CR-domain of IGF1R, (3)
Schumacher et al. [204] also replaced L1, and CR, of IR with corresponding domains
of IGF1R, and (4) Hoyne et al. [177] prepared a chimeric IR where residues 260-277
in the CR-domain of IR were replaced by residues 253-266 of IGF1R. Also, alanine
scanning mutagenesis of the whole CR-domain has implicated R240, F241, E242, and
F251 (IGF1R), in IGF1 binding to IGF1R [208]. Our structural models also provide
direct evidence in support of these experimental observations, because both IGFs
contact the CR-domain of IGF1R in our ligand-receptor complexes (Fig. 6.8).
6.5.4 Site-2 contacts with L2, F1′, and F2′
The possibility of the L2 domain contacting bound IGF1/2 has been suggested
earlier [44]. Based on the crystal structure of the isolated (L1-CR-L2) motif of IGF1R,
it was conjectured that the L1 and L2 domains, though far apart in this crystal struc-
ture to simultaneously contact a ligand such as IGF1, can possibly be closer in the
holo-receptor due to a different orientation of L2 (such as a rotation towards L1), al-
lowing IGF1/2 to contact both L1 and L2 domains simultaneously. Our ligand-docked
complexes provide evidence in favor of this view, because we observe simultaneous
contacts of each ligand with the L1 and L2 domains that are stable on MD equi-
libration. Mutagenesis studies on IGF1 (Table 6.1), however, provide evidence for
interaction of the following residues of IGF1 with IGF1R: R56, M59, Y60, K65, and
K68. These studies are inconclusive in suggesting the particular domain of IGF1R
with which these residues interact. Our IGF1/IGF1R∆β model suggests that these
residues of IGF1 likely interact with residues of the L2 domain (Table 6.3).
We also observe contacts of each ligand with the loops of type-III fibronectin
domains (F1-F2)′, the putative site-2 epitope on the receptor. No residues in the
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Figure 6.18: Known site-2 residues of IR [1] and homologous residues of IGF1R in
the first two type-III fibronectin domains F1 and F2.
(F1-F2)′ loops of IGF1R have yet been demonstrated to directly participate in site-2
interactions with either IGF, but a mutagenesis study on IR has suggested residues
in the (F1-F2)′ loops that potentially engage insulin with IR at site 2 [1]. Fig. 6.18
shows these IR residues along with homologous IGF1R residues in the fibronectin
loops. At most four IGF1R residues (R474, L537, L606, P607), corresponding to four
IR residues (K484, L552, D620, P621), in our docked complexes contact either IGF1
or IGF2 at site 2, indicating similarity in binding modes of these ligands to their
cognate receptors. However, two major mutagenesis efforts have been made to map
out the site-2 residues of IGFs: (1) Gauguin et al. [199] assign E9, D12, F16, D53,
L54, and E58, as site-2 residues of IGF1, and (2) Alvino et al. [200] suggest E12, D15,
F19, L53, and L57, as site-2 residues of IGF2. All of these residues are part of the
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site-2 contacts with the (F1-F2)′ loops in our structural models (Table. 6.3), except
for D53 (IGF1), which is also consistent with mutagenesis work, as Ala mutation of
D53 does not change binding affinity of IGF1 to IGF1R. Because we see partial or
no contact of D15 (IGF2) with either F2′ or L1, our data leaves open the possibility
that D15 could be a site-1 residue, as also suggested by Alvino et al. [200]. This is
conceivable based on our IGF1/IGF1R∆β model, because homologous residue D12
of IGF1 stably interacts with a site-1 residue R59 on the L1 domain in this model.
6.5.5 Novel site-2 contacts
We note that the following residues in the (F1-F2)′ loops of IGF1R remain to
be tested in the future and may serve as prime candidates for site-2 contacts with
either IGF: N473, R474, Y496, W519, N520, M521, V522, D523, L526, P528, L537,
L538, H539, G540, L541, K542, Y547, V580, S582, I583, L585, L606, P607, and
N608. However, there is strong indirect evidence from our models in favor of these
IGF1R residues as site-2 participants, because these (F1-F2)′ residues contact exactly
those residues that have been already demonstrated by careful mutagenesis as site-2
contacts on each ligand (vide supra) [199, 200].
6.5.6 Role of the C- and D-domains of IGF1/2
Several studies on ligands indicate that a major contribution to the binding affin-
ity of IGF1 to IGF1R comes from the C-domain of IGF1 (cyan, and marked C, in
Fig. 6.8). Cara et al. [216] prepared a two-chain IGF1/insulin hybrid having the C
domain of IGF1, which has high affinity for IGF1R. Bayne et al. [178] and Gill et
al. [206] replaced residues 28-37 in the C-domain of IGF1 with a 4-residue glycine
linker, which leads to 30 and 100-fold loss in binding affinity of resulting chimeric
IGF1, respectively. De Wolf et al. [217] and Gill et al. [206] prepared a mini IGF1
with C-domain deletion which had no affinity for IGF1R. Jansson et al. [193] and
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Zhang et al. [188] showed that substitution of Ala for positively charged side-chains
(R36 and R37) in the C-domain of IGF1 leads to significant loss in binding affinity of
IGF1 to IGF1R. Denley et al. [218] showed that swapping the C-domain of IGF1 and
IGF2 with each other results in a chimeric IGF1 with 75% reduced binding affinity
for IGF1R, and a chimeric IGF2 with increased affinity for IGF1R. Originally, Bayne
et al. [181] suggested that the Tyr31, a residue in the C-domain of IGF1, is involved in
high affinity binding of IGF1 to IGF1R, but it was not until later that Keyhanfar et
al. [207] assigned the cluster of CR-domain residues F241, F251, and F266, as likely
contacts for Tyr31. Taken together, these studies report three major findings: (1) the
specificity determinants of IGF1 binding likely reside in a loop from residues 253-266
of the CR-domain, (2) the C-domain of IGF1 is critical for its recognition by IGF1R,
and (3) the C-domain of IGF1 directly interacts with the CR-domain of IGF1R. In our
docked complexes, the orientations of both growth factors is such that the C-domain
of each directly contacts the CR-domain of IGF1R (Table 6.3), supporting the consen-
sus of the previous studies. An interesting finding from our IGF1/IGF1R∆β model
is interaction of the C-domain of IGF1 with six residues of IGF1R (255, 260, 261,
264, 265, and 266), all of which reside in the specificity-determining CR loop.
The putative ligand binding CR-loop of IGF1R is predominantly electronegative,
while the C-domain of IGF1 is predominantly positively charged, due to which these
domains were suggested to have electrostatic complementarity [3, 49]. The IGF2 C-
domain is however structurally different from the IGF1 C-domain, having no sequence
similarity, except that it has four arginine residues, two of which at positions R37
and R38, are homologous to R36 and R37 of IGF1. We observe that R36 and R37
(IGF1) interact with the cluster of residues E242, E264, and E276 on IGF1R, while
R37 and R38 (IGF2), interact only with E264 and E276. This indicates a strong
preference for electrostatic interactions between the C-domain of each ligand and the
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Figure 6.19: Comparison of a large CR-domain loop (yellow) of IR and IGF1R. This
region is at least partly helical in both receptors, and in IR, it contains an extra
disulfide bond and a four-residue insertion into the putative insulin binding pocket.
Acidic and basic residues in this loop for each receptor are indicated in red and blue,
respectively. Four residues in the CR domain of IGF1R∆β known to compromise
IGF1 binding affinity on Ala-mutation are also shown in the middle panel. Residues
important to binding of IGF2 in this region are yet unestablished (rightmost panel).
The N- and C- termini of the CR domains of receptors are marked with letter N and
C, respectively.
CR domain of the receptor. In fact, our IGF1-bound MD trajectory directly suggests
electrostatic complementarity between these domains, because we observe a stable
salt-bridge between the C-domain residue R37 of IGF1 and the CR-domain residue
E264 of IGF1R (data not shown). Our findings on IGF1/2 binding to IGF1R may
also bear upon the binding of these ligands to IR, because the CR-loop of IR is chiefly
electropositive, has an extra disulfide bond, and contains four extra residues [49], in
comparison to the CR-loop of IGF1R (Fig. 6.19). That the positively charged C-
domain of IGF1/2 interacts with electronegative CR-loop of IGF1R suggests a lower
affinity of these ligands for IR due to the electropositive CR-loop of IR, which has
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been observed [201]. Conversely, insulin must have significantly lower affinity for
IGF1R due to the absence of the C-domain unlike IGF1/2 (Fig. 6.2), which has also
been suggested [219].
Contrasting reports on the role of D-domain have been reported. Deletion of
the D-domain of IGF1 was reported to have negligible effect on the IGF1R binding
affinity [219], but in contrast to this study, Ala-mutation of the D-domain residues
K65 and K68, results in 10-fold loss in the binding affinity [188]. Similarly, deletion
of the D-domain of IGF2, or, replacement of this domain by the D-domain of IGF1,
changes IGF2 binding affinity [183, 218]. Nonetheless, our models suggest partial
contacts for K65 and K68 (IGF1) with either L2 or F1′, and also partial contacts for
P63 and A64 (IGF2) with L2.
6.5.7 Evidence for subunit cross-linking by IGF1/2
Of particular significance in our ligand-receptor complexes is the fact that we
observe contacts of each ligand with the (L1-CR-L2) motif, and (F1-F2)′ domains, of
IGF1R∆β, which suggests that IGF1/2 can simultaneously recognize site 1 (formed by
L1 and CR), and site 2 (formed by L2, and (F1-F2)′), thereby cross-linking individual
subunits of IGF1R. It has been observed in the insulin/IR system that insulin can
cross-link the IR subunits via simultaneous contacts to site 1 and site 2 [54, 130],
and interestingly, our structural models show that the cross-linking mechanisms are
also common in the IGFs/IGF1R family, which has been suggested previously as
well [174]. However, a key difference between both ligand-receptor systems is that
insulin binds only with low affinity to the IR ectodomain unless the β-subunits of
IR are embedded in the membrane or fused to dimerizing proteins [160, 176, 177],
but IGF1/2 can bind with relatively high affinity to both free as well as the leg-
restricted IGF1R ectodomain [175]. Based on our data, a conceivable explanation
for the higher affinity of IGFs in comparison to insulin for the ectodomains of their
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respective receptors may be that the IGFs have extensive additional contacts with
CR and L2 (IGF1R) due to the presence of the C- and D-domains in each growth
factor, which are both absent in insulin (Fig. 6.2). A clue in favor of this explanation
is provided by the studies of the hybrid IGF1R/IR chimeras with one subunit from
IGF1R, and another subunit from IR, which can bind IGF1 and/or IGF2 with high-
affinity despite the absence of IGFs-specific site-2 contacts [152, 220].
6.5.8 Comparison of all-atom models to SAXS data
A key result of the comparison of theoretical and experimental SAXS profiles here
is that the conformational ensemble generated by MD is a fairly good representa-
tion of the actual ensemble. The agreement for IGF1-bound IGF1R was not perfect,
however. It is possible that due to short time-scale of MD trajectories, certain con-
formational changes on ligand binding to IGF1R∆β may not have been observed
here, but nevertheless may occur in SAXS samples. A conclusive explanation is
unclear at this stage. However, there is currently no SAXS data for IGF2-bound
IGF1R∆β, but given that our MD-generated ensemble of structures of apo- and
IGF1-bound IGF1R∆β agree reasonably well with SAXS data, we believe that the
IGF2/IGF1R∆β model may serve as a guide for future SAXS studies. Our simu-
lations additionally provide a detailed picture of interdomain flexibility mechanisms
governed by fluctuations in interdomain hinge angles and intersubunit interfaces. Our
RMSD/RMSF data (Fig. 6.5) suggest that L1 and L2 domains in the (L1-CR-L2)
motifs are relatively rigid, with pronounced flexibility present only at the junction
of CR and L2 domains, and in the C-terminal loops of F3 domains. However, the
flexibility in these domains has been suggested by rigid body modeling in SAXS stud-
ies [4] consistent with our simulation results. The flexibility at the CR/L2 junction
also suggests that a different relative positioning of L2 with respect to L1 might allow
it to contact the growth factors bound in the putative [(L1-CR-L2)−(F1-F2)′] pocket,
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as has been observed in our ligand/receptor complexes (Table 6.3). Our simulations
also suggest that fluctuations in the interdomain hinge angles can significantly alter
the intersubunit interfaces, particularly on ligand binding, but these interfaces do not
completely dissociate in either apo or ligand-bound runs (Table 6.4). These findings
are in direct agreement with SAXS studies [4], which suggest that conformational
changes on ligand binding to IGF1∆β can be accommodated in the intact IGF1R∆β
dimer without any significant change in global topology of the receptor, though it
may be possible that domains are in relatively sparse contact and likely mobile, as
observed here.
6.5.9 Comparison of all-atom models to an earlier IGF1/IGF1R∆β model
Our predicted structure of the IGF1/IGF1R∆β complex differs from that gener-
ated by Epa et al. [3] in that: (1) the previous docking study used only the (L1-CR-L2)
motif of IGF1R to predict the ligand-receptor complex, though the (L1-CR-L2) motif
by itself does not bind IGF1 [198, 207], (2) no contacts of IGF1 with L2 were observed,
because L2 was not included in the docking protocol, and this domain was placed in
the final predicted complex only through structural alignments, (3) no site-2 contacts
in the type III fibronectin domains were predicted due to absence of these domains,
(4) the predicted complex was not MD equilibrated with explicit solvent to judge the
stability and robustness of the entire complex, and (5) constraints were used in the
docking protocol for the placement of IGF1 on the (L1-CR-L2) motif. However, the
overall orientation of IGF1 in our IGF1/IGF1R∆β complex is qualitatively similar
to that of the previous model (Fig. 6.20), because the IGF1 C-domain in that com-
plex also interacts with the CR-domain, the B-domain (IGF1) has contacts with L1,
and the site-2 residues on IGF1 are free to contact the type III fibronectin domains.
In particular, our IGF1/IGF1R∆β model suggests the following residues of IGF1 as
site-1 contacts with IGF1R, all of which are consistent with the previous model [3]:
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IGF1
L1 (IGF1R)
Figure 6.20: Overlay of our docked IGF1 (blue) and that of Epa et al. [3] (yellow)
on the surface of the L1 domain of IGF1R.
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V11, L14, Q15, F23, Y24, F25, K27, T29, G32, S33, S34, R36, R37, and V44. Though
the type III fibronectin domains were missing from the previous model, based upon
solvent-accessible surface area (SASA), following IGF1 residues were suggested as free
to contact site-2 residues of IGF1R, as has been now demonstrated by our model: E9,
F16, D20, R21, L54, R55, R56, and K65. Missing from both our docking and that of
Epa et al. [3] is the CT-peptide, whose role in facilitating the overall positioning of
ligands in the putative ligand binding pocket is unknown, and remains an object of
future studies.
6.5.10 Limitations of all-atom models of ligand/receptor complexes
We note that the structural models of IGF1/IGF1R∆β and IGF2/IGF1R∆β com-
plexes presented in this work are biased towards the conformation of IGF1R in the
all-atom homology model of Whitten et al. [4]. Although our IGF1/IGF1R∆β model
has been partly validated using experimental SAXS data, our predictions for the
IGF2/IGF1R∆β model are limited due to the absence of SAXS data for the lig-
anded ectodomain. However, we have provided other evidence in favor of the valid-
ity of our IGF2/IGF1R∆β model via residue-specific contacts with IGF1R that are
consistent with several mutagenesis studies. Our models are limited by the lack of
the C-terminal (CT) peptide of the α-subunit in our MC docking protocol, because
the apo-IGF1R∆β homology model was constructed partly based upon the available
crystallographic data on the homologous IR ectodomain [47], which had unresolved
electron density corresponding to the CT-peptide. We note that the CT peptide
is an essential element for binding of IGF1/2 to IGF1R as demonstrated by previ-
ous site-specific mutagenesis and chimeric receptor studies [139, 146, 147, 198, 208].
However, our insulin/IR∆β models (see Chapter 5) have provided structural bases
for the speculation that CT could be accommodated between bound insulin and the
L1 surface [54]. Although a similar situation has been speculated for IGF1 [50], the
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models presented in this work remain limited in suggesting the precise placement of
CT in the putative ligand binding pocket, and its interactions with the bound ligand.
The exact conformations of IGF1/2 bound to IGF1R remain elusive, but it has been
suggested that a conformational change in the N-terminus of IGF1 affects its receptor
binding affinity [221]. We do not observe any significant change in the N-terminus of
IGF1 in our MD simulations. Hence, it is possible that our IGF1/IGF1R∆β model
may not exactly reflect the yet unknown receptor bound state of IGF1.
Although we provide interaction energy traces (Fig. 6.16) between individual do-
mains of IGF1R and each growth factor, due to the absence of the CT peptide, it
is difficult at this point to attribute our models to low affinity or high affinity com-
plexes. This is in spite of the fact that we observe simultaneous contacts of IGF1/2
with site 1 and site 2 of IGF1R which are consistent with previous mutagenesis stud-
ies. We would also like to comment on the stoichiometry of IGF1 binding to soluble
IGF1R∆β specifically, because recent SAXS studies [4] conducted over a range of
stoichiometric ratios of IGF1:IGF1R (1:1 to 10:1) have reported that between 1 to
3 molecules of IGF1 can bind to IGF1R∆β in solution. Consistent with these stud-
ies, our IGF1/IGF1R∆β model provides structural bases for the observation that at
least at low concentrations of IGF1, a single IGF1 molecule can be stably accom-
modated in either of the two identical binding pockets of IGF1R∆β. Based upon
our MD simulation of this model, we envision that a bound ligand on one side of
the IGF1R∆β dimer likely loosens the intersubunit interfaces on the unoccupied side
and can thereby allow binding of at least another identical IGF1 molecule. However,
both our models and SAXS studies remain inconclusive in suggesting how a third
IGF1 molecule can bind to the IGF1R ectodomain. We note that the apo-IGF1R∆β
model used for rigid body modeling in SAXS studies included the scattering mass
of the insert domain (ID) and the carbohydrates, whereas these structural elements
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were not included in our MD simulations. These limitations remain objects of future
studies.
6.6 Conclusions
In this chapter, we have presented results from over 100 ns of explicit-solvent MD
simulations of IGF1R∆β in both its apo and ligand-bound forms using a physically
plausible all-atom homology model of the IGF1R ectodomain IGF1R∆β [4]. We ob-
serve that the IGF1R∆β homology model spontaneously relaxes to an asymmetric
conformation in which only one out of two identical binding pockets is accessible to
growth factors, IGF1 and IGF2. The asymmetry arises due to a sharp closing of the
L1-L2 hinge angles on one side of the IGF1R∆β dimer that leads to strengthening of
L2/F1 interface on the same side, and weakening of the similar interface on the other
side of dimer. Our simulations suggest interdomain flexibility mechanisms at the
junction of the CR and L2 domains, and at the C-terminus of the type-III fibronectin
(F3) domains, that are consistent with recent SAXS observations [4]. Based on our
Monte-Carlo based dockings, we suggest several residues in the type III fibronectin
domains of IGF1R that can be tested as potential site-2 contacts for IGF1 and IGF2
by future mutagenesis studies. Dockings also suggest residue-to-residue contacts of
each hormone with individual domains of the receptor. A stable salt-bridge between
R37 (IGF1) and E264 (IGF1R) provides direct evidence for electrostatic complemen-
tarity between the C-domain of IGF1 and the CR-domain of IGF1R. We also suggest
possible structural bases for the differing affinities of insulin, IGF1, and IGF2, for
their non-cognate receptors.
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Chapter 7: Molecular Simulation Studies of the Insulin Receptor Kinase
Domain
7.1 Abstract
In this chapter, we have studied large-scale inactive-to-active conformational change
in the activation-loop (A-loop) of the insulin receptor kinase domain. The dynamics
of A-loop was accelerated at the atomistic-level via temperature-accelerated molecu-
lar dynamics (TAMD), a technique that requires no target bias to study large-scale
conformational changes in proteins. Starting with the inactive A-loop conformation,
TAMD (50-ns) generated a target A-loop conformation within ∼8 A˚ (RMSD) of the
known active A-loop conformation. A further 20-ns MD-equilibration of this struc-
ture in the presence of ATP and phosphotyrosines stabilizes the A-loop conformation
to an RMSD of ∼4 A˚ with respect to its active state. Due to folding of the A-loop into
a transient three-turn helical conformation, we observe that D1150, F1151, and G1152 of
the highly conserved DFG-motif switch from a “D-out/F-in” to “D-in/F-out” confor-
mation, thereby burying F1151 underneath αC-helix, and simultaneously presenting
D1150 for ATP binding. Such transient helical conformations of the A-loop can po-
tentially be exploited for the design of novel inhibitors that target a specific DFG
conformation, and have been observed in crystal structures of related kinase families.
7.2 Introduction
Receptor tyrosine kinases (RTKs), the allosteric enzymes that catalyze the phos-
phorylation of specific tyrosines on protein substrates, are ligand-activated trans-
membrane glycoproteins with tightly regulated catalytic activity. The biological
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Figure 7.1: The inactive (1IRK.pdb) and active (1IR3.pdb) crystal structures of the
insulin receptor kinase domains. The N- and C-lobe are rendered as dark and trans-
parent white cartoons. The A-loop and αC-helix are red. Three catalytic tyrosines
Y1158, Y1162, and Y1163, and residues of the conserved K1030-E1047 salt-bridge are in
stick representations. In the active structure, the ATP molecule is also shown in stick
representation along-with two magnesium ions rendered as green spheres.
function and ligand-triggered activation of the insulin receptor (IR), a tyrosine ki-
nase, is dependent upon trans-autophosphorylation of three activation loop (A-loop)
tyrosines (1158, 1162, and 1163) located in each cytoplasmic kinase domain of IR
(IRKD) [222, 223]. The inactive [224] and active [225] crystal structures of bi-lobal
IRKD reveal critical differences in two structural motifs: the A-loop is displaced by
∼20 A˚, and the αC-helix in the N-lobe rotates towards the C-lobe by ∼30◦ (Fig-
ure 7.1). The highly conserved “DFG” motif at the N-terminus of the A-loop (D1150,
F1151, and G1152) flips from a “D-out/F-in” to “D-in/F-out” conformation during ac-
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Figure 7.2: DFG-flip is highlighted in the inactive and active crystal structures of
the insulin receptor kinase domains. The A-loop and residues of the DFG-motif are
colored and labeled. The ATP molecule is labeled in the active structure, where it
interacts with D1150 of the DFG-flipped motif. The ATP-related Mg2+ ions are green
transparent spheres.
tivation (Fig. 7.2). The DFG-flip has been suggested to facilitate nucleotide binding
and release during catalysis [226]. However, the exact mechanism of conformational
change in the A-loop which leads to DFG-flip remains elusive, chiefly due to unavail-
ability of structural data on the intermediate conformations of the A-loop. Careful
structural studies have failed to capture these intermediate conformations due likely
to the highly flexible character of the A-loop [227]. It is also unclear exactly how
this conformational change results in solvent exposure of the A-loop tyrosines for
sequential trans-autophosphorylation by its partner kinase.
Molecular simulations can be a powerful tool to study the inactive-to-active con-
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formational transition of the A-loop in atomistic detail, providing valuable insights
into the mechanism of DFG-(back)flip. However, observing large-scale conformational
changes in biomolecules using unbiased molecular dynamics (MD) simulations alone
is particularly challenging because of difficulties in surmounting associated free energy
barriers in reasonable computational time [228]. Given a known final conformation,
methods such as the targeted molecular dynamics (TMD) [66], or the string method
with swarms-of-trajectories [229] have proven useful in studying similar transitions in
other kinases [230, 231]. Abrams and Vanden-Eijnden have demonstrated the useful-
ness of a new technique, temperature-accelerated molecular dynamics (TAMD), that
requires no target bias to study large-scale conformational changes in proteins [232–
234]. TAMD uses an artificially high fictitious temperature to explore the free energy
landscape at the physical temperature of a large set of suitably chosen collective vari-
ables (CVs), which are functions of the Cartesian coordinates of atoms (see Sec. 7.3.2).
In this contribution, we have applied TAMD to the A-loop of inactive IRKD at a ficti-
tious thermal energy β¯−1= 5 kcal/mol, where β¯=1/kBT¯ , kB is Boltzmann’s constant,
and T¯ is the fictitious temperature. We capture the critical DFG-(back)flip, and delin-
eate mechanistic details governing this conformational change. We briefly discuss the
significance of the mechanism behind DFG-(back)flip in designing novel therapeutics
targeting kinases.
7.3 Simulation description
7.3.1 Molecular dynamics simulations: system setup
We generated all MD trajectories using NAMDv2.6 [84] and the CHARMM force
field [89, 90]. VMDv1.8.7 was used for system creation and protein rendering [97].
A total of four separate MD trajectories were generated (Table 7.1 and Fig. 7.3).
The initial coordinates for the inactive IRKD simulation were taken from the crystal
structure of Hubbard et al. [224]. The crystallographic water molecules were retained
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Table 7.1: Details of all MD simulation systems.
System Traj. length Initial Box volume System size No. of ions
(ns) coordinates (A˚3) (atoms) (Na+,Cl−)
Inactive IRKD 5 1IRK[224] 73×76×76 40044 21, 12
System ¬ 20 TAMD 79×80×75 43405 26, 11
System ­ 20 TAMD 79×80×75 43411 26, 11
System ® 20 TAMD 79×80×75 43414 23, 14
but the ethylmecuric phosphate (EMP) molecule was deleted. The crystal structure
provided coordinates for the residues 981-1283, and the missing residues of the N-
terminus at positions 978-980 were added. The initial coordinates for systems ¬, ­,
and ® were generated by our TAMD simulation (vide infra) of equilibrated inactive
IRKD. For systems ¬ and ­, three A-loop catalytic tyrosines Y1158, Y1162, and Y1163
were phosphorylated by applying the phosphotyrosine patch (TP2) in CHARMM.
The coordinates for an ATP molecule along with two associated Mg2+ ions and four
coordinated water molecules in system ¬ were extracted from the known active crystal
structure [225] by aligning its N-lobe with the N-lobe of TAMD-generated active-like
IRKD structure.
We solvated all systems using explicit (TIP3P) water and included all hydrogen
atoms. Charge neutrality was maintained by adding counterions at a salt concen-
tration of 150 mM. Similar protocols were followed for all simulations: 500 cycles of
energy-minimization via conjugate-gradient optimization and a constant temperature
(300K) via the Langevin thermostat with damping coefficient of 5 ps−1. The equili-
bration phases were carried out initially for 40 ps in the NPT ensemble to adjust the
box volume, and thereafter continued in the NVT ensemble using 1-fs time step with
no rigid bonds in all simulations. Periodic boundary conditions were used through-
out. Non-bonded interactions were cut-off beyond 10 A˚ with smooth switching taking
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Figure 7.3: MD simulation systems. Side views of the four simulation domains are
shown: panel a, inactive IRKD structure, and panels b−d, TAMD-generated active-
like IRKD structures of three different systems (¬, ­, ®) discussed in the main
article. The A-loop is red and the protein-backbone is white in all systems. The
counterions are cyan spheres. The tyrosines/phosphotyrosines (Ys/pYs) in panels
b−d are in stick representations. The ATP molecule in system ¬ (panel b) is labeled
and shown in stick representation. The ATP-related Mg2+ ions with four coordinated
crystallographic water molecules are green and black spheres. Water molecules are
rendered gray in wireframe.
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effect at 8.0 A˚. Long-range electrostatic interactions were handled using the particle
mesh Ewald (PME) method.
7.3.2 Temperature accelerated molecular dynamics
The theoretical basis of the temperature-accelerated molecular dynamics was orig-
inally presented by Maragliano and Vanden-Eijnden [233, 234], and has been reviewed
in detail [235]. Also, the TAMD was further developed and applied by Abrams and
Vanden-Eijnden as a unique method to study the large-scale conformational changes
in proteins [232]. Hence, we are going to briefly describe the underlying equations
here. The coupled system of equations describing TAMD are as follows:
mix¨i = −
∂V (x)
∂xi
− κ
m∑
j=1
[θ∗j (x)− θj ]
∂θ∗j (x)
∂xi
− γmix˙i + ηi(t; β)
γ¯m¯j θ˙j = κ[θ
∗
j (x)− θj ] + ξj(t; β¯) (7.1)
where θ∗(x) = (θ∗1(x),θ
∗
2(x),......,θ
∗
m(x)) are collective variables that are functions of
atom Cartesian coordinates, mi and m¯j are the masses of xi and θj , V(x) is the
interatomic MD potential, κ is the “coupling spring-constant”, γ is the Langevin
friction coefficient, η is the white noise satisfying fluctuation-dissipation theorem at
physical temperature β−1, γ¯ and ξ respectively are fictitious friction and thermal
noise at artificial temperature β¯−1.
The aforementioned set of equations describe the motion of x(t) and θ(t) over the
extended potential
Uκ(x, θ) = V (x) +
κ
2
m∑
j=1
[θ∗j (x)− θj ]
2
(7.2)
As shown elsewhere [233], by choosing κ so that θ∗(x(t)) ≈ θ(t) and fictitious
friction coefficient γ¯ so that θ moves slower than x, we can generate a trajectory
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at artificial temperature β¯−1 subject to the free energy computed at the physical
temperature β−1. Hence, we have chosen a TAMD friction γ¯ of 50 ps−1 and a spring
constant κ of 100 kcal/mol·A˚2. Here, we choose the Cartesian coordinates of centers
of mass of spatially contiguous groups of residues as CVs. Particularly, the A-loop
residues 1150-1168 were divided into five subgroups (3 groups of 4 residues each, and
2 groups of 3 residues each) and hence 15 CVs. Therefore, the conformation sampling
of only A-loop was accelerated via TAMD and the remaining atoms in the system
evolved under the CHARMM force field (see Sec. 2.4.4). We did not apply TAMD to
whole structure because alignment of the inactive [224] to active [225] crystal structure
reveals that major contribution to the backbone Cα RMSD comes from the A-loop.
We carried out a ∼40 ns long TAMD simulation starting from an equilibrated (for 5
ns) configuration of the inactive IRKD crystal structure [224]. The final active-like
IRKD structure resulting from TAMD was further equilibrated in three independent
20-ns MD simulations corresponding to three distinct systems (see Sec. 7.3.1).
7.4 Results
7.4.1 TAMD drives the A-loop to its active conformation
In Fig. 7.4, we show representative snapshots and time-evolution of the root-
mean squared deviaton of the A-loop with reference to its known active state [225]
conformation (RMSDa) during three different simulation stages: first 5 ns, initial MD-
equilibration; next ∼40 ns, TAMD simulation; and final ∼20 ns, post-TAMD MD-
equilibration for three systems that differ with respect to tyrosine-phosphorylation
and/or the presence of an ATP molecule. We used explicit solvent and counterions
in all simulations (see Sec. 7.3.1). The inactive conformation of the A-loop displays
an RMSDa of ∼20 A˚. We observe no appreciable change in the RMSDa of the A-loop
during the initial 5 ns MD-equilibration, which indicates that the A-loop is highly sta-
ble and remains close to its inactive conformation (Fig. 7.1 (a)). During the next ∼40
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Figure 7.4: (a) Top-view snapshots of IRKD at t = 5, 24, 43, and 67 ns highlighting
the A-loop, αC-helix, and three tyrosines/phosphotyrosines (Ys/pYs). (b) RMSDa of
the backbone Cα atoms of A-loop during three distinct simulation stages (see text).
The last snapshot in panel a is from the tris-phosphorylated (phosphate groups are
green) and an ATP-bound system (¬).
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ns of TAMD, we observe that the A-loop departs from its inactive conformation and
evolves towards an active-like state as indicated by a significant decrease in its RMSDa
from ∼20 to ∼8 A˚ (Fig. 7.4 (b) and snapshots at t = 24 and 43 ns in Fig. 7.4 (a)).
To judge the stability of active-like A-loop conformation generated by TAMD, we
further equilibrated the IRKD structure in three different settings in independent
∼20-ns MD simulations (see Sec. 7.3.1): system ¬, tris-phosphorylated A-loop and
with ATP; system ­, tris-phosphorylated A-loop but without ATP; and system ®,
unphosphorylated A-loop and without ATP. We observe that the decreasing order of
the stability of the A-loop in these three systems during independent equilibrations
is ¬>­>® (traces ¬, ­, and ® in Fig. 7.4 (b)). This observation posits that the
phosphorylation of three putative A-loop tyrosines essentially stabilizes the active
conformation of this loop, which also explains why the unphosphorylated but active-
like conformations of the A-loop are hard to crystallize [227]. A crystallographically
predicted [225] R1155-pY1163 salt-bridge observed in our simulations (Fig. 7.6) likely
stabilizes the A-loop in system ¬. Also, the fact that the TAMD-generated active-
like IRKD structure is competent to stably bind an ATP molecule lends credence
to the hypothesis that the tris-phosphorylated A-loop permits unrestricted access to
nucleotide and other protein substrates [225]. We briefly note that the ATP molecule
is stabilized by two strong interactions: (1) a coordinated (by β,γ-phosphate groups)
Mg2+ ion interacts with D1150 of the DFG-flipped motif (vide infra), and (2) con-
served K1030 (of the K1030-E1047 salt-bridge) interacts with the α-phosphate group of
ATP (Fig. 7.5). These results support the role of the DFG-motif (via D1150) in nu-
cleotide binding/release [226], and are consistent with the detrimental effect of K1030
mutations on kinase activity [236].
The crystal structures suggest that Y1158 and Y1162 are significantly exposed to
the solvent on phosphorylation, while Y1163 is buried (Fig. 7.1). The A-loop transi-
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Figure 7.5: ATP interactions in the TAMD-generated active-like IRKD structure.
The ATP molecule and interacting residues are rendered and labeled in stick repre-
sentations. The A-loop is rendered in red cartoon and two ATP-related magnesium
ions are green spheres. The backbone of enzyme is in wireframe. D1150 of the DFG-
flipped motif interacts with ATP molecule similar to as seen in the active crystal
structure (Fig. 7.2).
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tion studied here also provides insights into the solvent exposure of these catalytic
tyrosines. We observe that during TAMD, Y1162 is the first residue to leave the active
site and expose itself to the solvent, immediately followed by Y1158 (snapshots at t
= 24 and 43 ns in Fig. 7.4). In response to a major change in the dihedral angles
of Y1162, neighboring Y1163 gets buried, where it participates in the aforementioned
salt-bridge with R1155. These results suggest that Y1162, Y1158, and Y1163 likely are
the first, second, and third tyrosines respectively to get trans-autophosphorylated by
the other kinase domain, which is consistent with an earlier study [237].
7.4.2 R1155 interacts with αC via a salt-bridge
An important characteristic of the active IRKD are two salt-bridges: a kinase-
conserved K1030-E1047 salt-bridge, and an A-loop stabilizing R1155-pY1163 salt-bridge [225].
In Fig. 7.6 (a) (first panel), we show the location of residues participating in these
salt-bridges after initial MD-equilibration, where none of the salt-bridges exists. Dur-
ing the TAMD-driven large-scale conformational change of the A-loop, we observe an
intermittant but stable (for ∼10 ns) R1155-E1047 salt-bridge (Fig. 7.6 (b); and second
panel, Fig. 7.6 (a)). While participating in this salt-bridge, R1155 additionally serves
as a chaperone for the formation of K1030-E1047 salt-bridge by pulling E1047 (and in
turn the αC-helix) towards K1030, which significantly decreases the initial gap (from
∼13 to 7 A˚) between K1030 and E1047 (third panel,Fig. 7.6 (a)). Next, the contin-
ued movement of the A-loop breaks the R1155-E1047 salt-bridge, but simultaneously
allows formation of a stable R1155-pY1163 salt-bridge (last panel, Fig. 7.6 (a); and
Fig. 7.6 (b)).
7.4.3 DFG-(back)flip occurs due to a folding/unfolding transition in the
A-loop
The conformation of the A-loop in the equilibrated inactive IRKD is devoid of
a defined secondary structure (first panel, Fig. 7.7). However, we observe that dur-
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Figure 7.6: (a) Snapshots of IRKD at t = 5, 36, 40, and 55 ns showing selected
salt-bridge interactions. (b) Interatomic distance-traces measured between side-chain
terminal carbon atoms for salt bridges formed by R1155.
ing TAMD, the A-loop immediately begins to adopt a three-turn helical conforma-
tion, which it stably maintains for the first ∼20-ns before unfolding into an extended
active-like conformation (Fig. 7.7). A key implication of the formation of the helical
A-loop is that it concomitantly alters the backbone dihedral angles of D1150, F1151,
and G1152, thereby switching them from a “D-out/F-in” to “D-in/F-out” conforma-
tion (Fig. 7.7). D1150 in the DFG-flipped state can then coordinate with a bound ATP
molecule (Fig. 7.5). The necessary flexibility for the DFG-flip is provided by G1152.
Analysis of the crystal structures of several related protein kinases reveals strong evi-
dence for the occurrence of intermediate helical conformations of the A-loop (Fig. 7.8),
which likely play a key functional role in mediating DFG-flip. We envision that a dy-
namic equilibrium between alternate conformations of the A-loop (which precisely
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Figure 7.7: Snapshots of DFG-flip during TAMD at t = 5, 15, 20, and 35 ns.
control the DFG-flip) possibly exists in solution, and can be exploited for the design
of selective inhibitors targeting IRKD. Particularly, those inhibitors which potentially
stabilize the intermediate helical conformations of the A-loop by blocking DFG-flip
may out-compete ATP for binding in the active site. In summary, our simulations
have provided detailed atomistic insights into the mechanisms governing conforma-
tional change of the A-loop (IRKD) and associated DFG-flip, which may be useful in
the design of potent inhibitors for IRKD.
7.5 Conclusions
We applied TAMD to the A-loop of the inactive structure of IRKD, which gener-
ates a target A-loop conformation very close to the known active A-loop conformation.
A further 20-ns MD-equilibration of this structure in the presence of ATP and phos-
photyrosines stabilizes the A-loop conformation to an RMSD of ∼4 A˚ with respect to
its active state. Significantly, we also capture the DFG-backflip during TAMD, and
observe that this back-flip is facilitated by a transient three-turn helical conformation
of the A-loop, the folding of which draws the placement of the side-chains of D1150 and
F1151. Such transient helical conformations of the A-loop can potentially be exploited
for the design of novel inhibitors that target a specific DFG conformation, and have
been observed in crystal structures of related kinase families.
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Chapter 8: Findings and Future Research Directions
8.1 Findings
Previous computational research in the insulin family has been limited to the
studies of hormone insulin (see Sec. 1.3), and no theoretical or computational inves-
tigations have been reported on the receptors of the insulin family to date. Experi-
mental structures of the ligand-bound receptors are also elusive, due likely to which
the atomic picture of ligand-recognition in the this family is yet to emerge. In this
thesis, we have elucidated the structural bases of ligand-recognition in the IR family
with the help of MD and MC simulations. We report detailed molecular simulation
studies on insulin hexamer, insulin receptor (IR), type-1 insulin like growth factor
receptor (IGF1R), and the insulin receptor kinase domain (IRKD), which provide
new insights into the structure-function relationships in the IR family.
We began by hypothesizing that multiple dissociation mechanisms may exist for
phenolic ligands in R6 insulin hexamer instead of a single route suggested by an earlier
computational study [75]. We tested this hypothesis by applying a novel simulation
technique named random acceleration molecular dynamics (RAMD) to explore bind-
ing/unbinding mechanisms of phenolic ligands in R6 insulin hexamer. We identify and
characterize a variety of phenol dissociation pathways using a judicious combination
of molecular simulation techniques and find that a previously suggested gatekeeper
pathway is likely not the preferred pathway for ligand dissociation. We have also
carried out free-energy calculations to demonstrate that a “gate-leaping” mechanism
is the preferred pathway for phenolic exchange, which differs from a previously sug-
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gested mechanism for phenol dissociation reaction [75].
Next, using the crystal structure of the IR ectodomain (IR∆β), and a homology
model of the IGF1R ectodomain with the help of molecular dynamics simulations,
we have extensively studied the flexibility mechanisms of these proteins that can
allow binding of their cognate ligands. Both receptors are observed to possess asym-
metric mechanisms of flexibility due to interdomain and intersubunit conformational
fluctuations that do not alter their quaternary structures. Subtle variations in inter-
subunit buried surface areas of both receptors are observed to coincide well with these
conformational fluctuations, resulting in one easily-accessible ligand binding pocket
with the other blocked. Further, Monte Carlo (MC) docking simulations are used
to construct all-atom structural models of the ligand/receptor complexes which are
consistent with a variety of known experimental data, and provide detailed structural
bases for ligand-recognition in the IR family.
Finally, we have studied the IRKD using molecular simulations, where we hypoth-
esize that the conformational changes in the activation-loop (A-loop) of the insulin
receptor kinase domain (IRKD) likely facilitate the flip of highly conserved DFG-
motif (D1150, F1151, and G1152). We have tested this hypothesis via a new accel-
erated conformational sampling method for proteins called temperature-accelerated
MD (TAMD) [232–234]. We applied TAMD to the A-loop of the inactive structure of
IRKD, which generates a target A-loop conformation very close to the known active
A-loop conformation. A further 20-ns MD-equilibration of this structure in the pres-
ence of ATP and phosphotyrosines stabilizes the A-loop conformation to an RMSD
of ∼4 A˚ with respect to its active state. Significantly, we also capture the DFG-
(back)flip during TAMD, and observe that this back-flip is facilitated by a transient
three-turn helical conformation of the A-loop, the folding of which draws the place-
ment of the side-chains of D1150 and F1151. Such transient helical conformations of
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the A-loop can potentially be exploited for the design of novel inhibitors that target
a specific DFG conformation, and have been observed in crystal structures of related
kinase families.
In summary, the ligand (un)binding studies in the insulin hexamer have eluci-
dated the mechanisms by which phenolic species stabilize the hexameric shelf-form of
insulin. These mechanisms give detailed insights into the first key step (i.e. phenol
dissociation) in the dissolution kinetics of insulin hexamers that results in biologically
active monomeric form of insulin, which is eventually recognized by the insulin recep-
tor (IR). Moreover, the all-atom structural models of ligand-bound receptors for the
first time provide detailed atomic picture of ligand recognition in the IR family. These
models not only provide structural bases for known ligand/receptor interactions, but
also will inspire future mutagenesis work, and can be very useful in the design of novel
antagonist ligands to target these receptors in various diseases such as diabetes and
cancer.
8.2 Future lines of work
We propose the following suggestions that may motivate some future research
directions.
In chapters 3 and 4, we describe the dissociation mechanisms of phenolic lig-
ands from R6 insulin hexamer, where we have constructed free energy profiles for
phenol dissociation as a function of a one dimensional reaction coordinate, which is
essentially a distance along the pathways. Although it may be inherently difficult to
pre-determine all the reaction coodinates that govern phenol dissociation, some new
approaches have appeared in the literature to construct at least three dimensional free
energy profiles. As an example, Maragliano et al. [238] have mapped the pathways
of CO diffusion in myoglobin, where they provide free energy profiles as a function
of three collective variables which essentially are Cartesian positions (x, y, z) of the
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center of mass of CO molecule. We think that this new approach is more elegant, and
may be tested on insulin-phenol complex to see if free energy profiles look different,
and provide any newer knowledge about phenol dissociation mechanisms.
There are various ways in which studies reported in Chapters 5 and 6 can be ex-
tended. First, we have studied the flexibility mechanisms of IR and IGF1R ectodomains.
These proteins in physiological sense are highly glycosylated, but modeling sugars on
protein molecules remain a daunting task for simulation studies. However, conducting
future studies with the glycans attached to the known surface sites of IR and IGF1R
can provide newer insights into their flexibility. The botteneck in those studies will be
finding a suitable force-field to simulate carbohydrates. In that direction, GLYCAM
force field can be useful (http://glycam.ccrc.uga.edu/). We also suggest model
building membrane helices that are C-terminal to the ectodomains of IR and IGF1R,
and carry out MD equilibrations to understand their flexibility in the membrane en-
vironment. It will be interesting to see if the receptors display different mechanisms
of flexibility that can be correlated to their different behavior reported in membranes
in experimental studies, the phenomenon of negative cooperativity, for example.
The all-atom structural models of ligand/receptor complexes [54, 55] suggest
several new contact residues between ligands and receptors, specifically, the site-2
residues. Future mutagenesis studies can be possibly conducted to test the role of
these residues in site-2 interactions. Also, both structural models have missing CT-
peptide, but in the IR ectodomain, the structure of the CT-peptide has now been
resolved by Smith et al. [239]. Hence, our proposed models need to be refined with
the help of now known CT-structure. Future research can also be focussed on model
building insert domains with the help of known CT structure, but these efforts may
have to be guided by some experimental data. In case the structures of new ana-
logues of insulin or insulin-like growth factors appear in the literature, the docking of
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these ligands is worth a try. New docking methods rooted in lowering the free energy
instead of the interaction energy, as was used by us, may be helpful.
Finally, we have shown that conformational changes in the A-loop of IRKD drive
the DFG-(back)flip. Our TAMD generated pathway can be used to do a string-
method-with-swarms-of-trajectories [231] calculation to compute the free energy pro-
files, which give insights into the likelihood of existence of conformational intermedi-
ates observed in our TAMD runs.
173
Bibliography
[1] Whittaker, L., C. Hao, W. Fu, and J. Whittaker. 2008. High-affinity insulin
binding: insulin interacts with two receptor ligand binding sites. Biochemistry
47:12900–12909.
[2] Renteria, M. E., H. S. Gandhi, P. Vinuesa, E. Helmerhorst, and R. L. Mancera.
2008. A comparative structural bioinformatics analysis of the insulin receptor
family ectodomain based on phylogenetic information. PLoS ONE 3:e3667.
[3] Epa, V. C., and C. W. Ward. 2006. Model for the complex between the insulin-
like growth factor I and its receptor: towards designing antagonists for the
IGF-I receptor. Protein Eng. Des. Sel. 19:377–384.
[4] Whitten, A. E., B. J. Smith, J. G. Menting, M. B. Margetts, N. M. McK-
ern, G. O. Lovrecz, T. E. Adams, K. Richards, J. D. Bentley, J. Trewhella,
C. W. Ward, and M. C. Lawrence. 2009. Solution structure of ectodomains of
the insulin receptor family: the ectodomain of the Type 1 insulin-like growth
factor receptor displays asymmetry of ligand binding accompanied by limited
conformational change. J. Mol. Biol. 394:878–892.
[5] De Meyts, P., and J. Whittaker. 2002. Structural biology of insulin and IGF1
receptors: implications for drug design. Nat. Rev. Drug. Discov. 1:769–783.
[6] van Diepen, M. G. W. T., 1996. Crystallographic studies of modified insulin.
Ph.D. thesis, University of York.
174
[7] Heller, S., P. Kozlovski, and P. Kurtzhals. 2007. Insulin’s 85th anniversary - An
enduring medical miracle. Diabetes Research and Clinical Practice 78:149–158.
[8] De Meyts, P. 2004. Insulin and its receptor: structure, function and evolution.
BioEssays 26:1351–1362.
[9] Bliss, M., 1982. The discovery of insulin. The University of Chicago Press.
[10] Banting, F., and C. Best. 1922. The internal secretion of the pancreas. J. Lab.
Clin. Med. 7:251–266.
[11] Banting, F., C. Best, J. Collip, W. Campbell, and A. Fletcher. 1922. Prancreatic
extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12:141–146.
[12] http://nobelprize.org/nobel_prizes/medicine/articles/lindsten/
index.html.
[13] Poulsen, J. E. 1975. The impact of August Krogh on the insulin treatment of
diabetes and our present status. Acta. Med. Scand. Suppl. 578:7–14.
[14] Hagedorn, H., B. Jensen, N. Krarup, and I. Wodstrup. 1936. Portamine Insuli-
nate. J. Am. Med. Assoc. 106:177–180.
[15] Scott, D., and A. Fisher. 1935. The effect of zinc salts on the action of insulin.
J. Pharmacol. Exp. Ther. 55: 206.
[16] FELIG, P. 1984. Protamine insulin - Hagedorn’s pioneering contribution to
drug delivery in the management of diabetes. J. Am. Med. Assoc. 251:393–396.
[17] Steiner, D. F., and D. E. James. 1992. Cellular and molecular biology of the
beta cell. Diabetologia 35:S41–S48.
175
[18] Brange, J., U. Ribel, J. F. Hansen, G. Dodson, M. T. Hansen, S. Havelund,
S. G. Melberg, F. Norris, K. Norris, L. Snel, A. R. Sorensen, and H. O. Voigt.
1988. Monomeric insulins obtained by protein engineering and their medical
implications. Nature 333:679–682.
[19] Bakaysa, D. L., J. Radziuk, H. A. Havel, M. L. Brader, S. Li, S. W. Dodd,
J. M. Beals, A. H. Pekar, and D. N. Brems. 1996. Physicochemical basis for the
rapid time-action of Lys(B28)Pro(B29)-insulin: Dissociation of a protein-ligand
complex. Prot. Sci. 5:2521–2531.
[20] Birnbaum, D. T., M. A. Kilcomons, M. R. DeFelippis, and J. M. Beals. 1997.
Assembly and dissociation of human insulin and Lys(B28)Pro(B29)-insulin hex-
amers: A comparison study. Pharm. Res. 14:25–36.
[21] Lowman, A. M., M. Morishita, M. Kajita, T. Nagai, and N. A. Peppas. 1999.
Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci.
88:933–937.
[22] Morishita, M., A. M. Lowman, K. Takayama, T. Nagai, and N. A. Peppas.
2002. Elucidation of the mechanism of incorporation of insulin in controlled
release systems based on complexation polymers. J. Control. Release 81:25–32.
[23] Langer, R., and N. A. Peppas. 2003. Advances in biomaterials, drug delivery,
and bionanotechnology. AIChE J. 49:2990–3006.
[24] Foss, A. C., T. Goto, M. Morishita, and N. A. Peppas. 2004. Development of
acrylic-based copolymers for oral insulin delivery. Euro. J. Pharm. Biopharm.
57:163–169.
[25] Stretton, A. O. W. 2002. The first sequence: Fred Sanger and insulin. Genetics
162:527–532.
176
[26] Ferry, G., 1998. Dorothy Hodgkin: A life. Granta Books, London.
[27] Blundell, T. L., G. G. Dodson, D. C. Hodgkin, and D. Mercola. 1972. Insulin:
The structure in the crystal and its reflection in chemistry and biology. Adv.
Protein Chem. 26:279–402.
[28] Bentley, G. A., E. J. Dodson, G. G. Dodson, D. C. Hodgkin, and D. Mercola.
1976. Structure of insulin in 4-zinc insulin. Nature 261:166–168.
[29] Baker, E. N., T. L. Blundell, J. F. Cutfield, S. M. Cutfield, G. G. Dodson,
D. M. C. Hodgkin, R. E. Hubbard, M. W. Issacs, C. D. Reynolds, K. Sakabe,
N. Sakabe, and N. M. Vijayan. 1988. The structure of 2Zn pig insulin crystals
at 1.5 A˚ resolution. Phil. Tran. Roy. Soc. ser. B 319:369–456.
[30] Derewenda, U., Z. Derewenda, E. J. Dodson, G. G. Dodson, C. D. Reynolds,
G. D. Smith, C. Sparks, and D. Sweson. 1989. Phenol stabilizes more helix in
a new symmetrical zinc insulin hexamer. Nature 338:594–596.
[31] Smith, G. D., and G. G. Dodson. 1992. Structure of a rhombohedral R6 in-
sulin/phenol complex. Proteins: Struct. Funct. Genet. 14:401–408.
[32] Smith, G. D., E. Ciszak, and W. Pangborn. 1996. A novel complex of a pheno-
lic derivative with insulin: Structural features related to the T↔R transition.
Protein Sci. 5:1502–1511.
[33] Smith, G. D., and R. H. Blessing. 2003. Lessons from an aged, dried crystal of
T6 human insulin. Acta Crystallogr. D Biol. Crystallogr. D59:1384–1394.
[34] Williamson, K. L., and R. J. P. Williams. 1979. Conformational analysis by
nuclear magnetic resonance: Insulin. Biochemistry 18:5966–5972.
177
[35] Chang, X., A. M. M. Jorgensen, P. Bardrum, and J. J. Led. 1997. Solution
Structures of the R6 human insulin hexamer. Biochemistry 36:9409–9422.
[36] O’Donoghue, S. I., X. Chang, R. Abseher, M. Nilges, and J. J. Led. 2000.
Unraveling the symmetry ambiguity in a hexamer: Calculation of the R6 human
insulin structure. J. Biomol. NMR 16:93–108.
[37] Cuatrecasas, P. 1971. Insulin-receptor interactions in adipose tissue cells: direct
measurement and properties. Proc. Natl. Acad. Sci. USA 68:1264–1268.
[38] Czech, M. 1985. The nature and regulation of the insulin receptor: Structure
and Function. Annu. Rev. Physiol. 47:357–381.
[39] Kasuga, M., F. A. Karlsson, and C. R. Kahn. 1982. Insulin stimulates the phos-
phorylation of the 95,000-Dalton subunit of its own receptor. Science 215:185–
187.
[40] Roth, R. A., and D. J. Cassell. 1983. Insulin Receptor - Evidence that it is a
protein kinase. Science 219:299–301.
[41] Adams, T. E., V. C. Epa, T. P. J. Garrett, and C. W. Ward. 2000. Structure
and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life
Sci. 57:1050–1093.
[42] Ullrich, A., J. R. Bell, E. Y. Chen, R. Herrera, L. M. Petruzzelli, T. J. Dull,
A. Gray, L. Coussens, Y. C. Liao, M. Tsubokawa, A. Mason, P. H. Seeburg,
C. Grunfeld, O. M. Rosen, and J. Ramachandran. 1985. Human insulin receptor
and its relationship to the tyrosine kinase family of oncogenes. Nature 313:756–
761.
[43] Ullrich, A., A. Gray, A. W. Tam, T. Yangfeng, M. Tsubokawa, C. Collins,
W. Henzel, T. Lebon, S. Kathuria, E. Chen, S. Jacobs, U. Francke, J. Ra-
178
machandran, and Y. Fujitayamaguchi. 1986. Insulin-like growth factor-I recep-
tor primary structure - Comparison with insulin-receptor suggests structural
determinants that define functional specificity. EMBO J. 5:2503–2512.
[44] Garrett, T. P. J., N. M. McKern, M. Z. Lou, M. J. Frenkel, J. D. Bentley,
G. Lovrecz, T. C. Elleman, L. J. Cosgrove, and C. W. Ward. 1998. Crystal
structure of the first three domains of the type-1 insulin-like growth factor
receptor. Nature 394:395–399.
[45] Tulloch, P., L. Lawrence, N. McKern, C. Robinson, J. Bentley, L. Cosgrove,
N. Ivancic, G. Lovrecz, K. Siddle, and C. Ward. 1999. Single-molecule imaging
of human insulin receptor ectodomain and its Fab complexes. J. Struc. Biol.
125:11–18.
[46] Luo, R. Z. T., D. R. Beniac, A. Fernandes, C. C.Yip, and F. P. Ottensmeyer.
1999. Quaternary structure of the insulin-insulin receptor complex. Science
285:1077–1080.
[47] McKern, N., M. Lawrence, V. Streltsov, M. Lou, T. Adams, G. Lovrecz, T. Elle-
man, K. Richards, J. Bentley, P. Pilling, P. Hoyne, K. Cartledge, T. Pham,
J. Lewis, S. Sankovich, V. Stoichevska, E. Silva, C. Robinson, M. Frenkel,
L. Sparrow, R. Fernley, V. Epa, and C. Ward. 2006. Structure of the insulin
receptor ectodomain reveals a folded-over conformation. Nature 443:218–221.
[48] Ward, C., M. Lawrence, V. Streltsov, T. Adams, and N. McKern. 2007. The
insulin and EGF receptor structures: new insights into ligand-induced receptor
activation. Trends Biochem. Sci. 32:129–137.
[49] Lou, M., T. Garrett, N. McKern, P. Hoyne, V. Epa, J. Bentley, G. Lovrecz,
L. Cosgrove, M. Frenkel, and C. Ward. 2006. The first three domains of the in-
179
sulin receptor differ structurally from the insulin-like growth factor 1 receptor in
the regions governing ligand specificity. Proc. Natl. Acad. Sci. USA 103:12429–
12434.
[50] Ward, C. W., and M. C. Lawrence. 2009. Ligand-induced activation of the
insulin receptor: a multi-step process involving structural changes in both the
ligand and the receptor. BioEssays 31:422–434.
[51] De Meyts, P. 2008. The insulin receptor: a prototype for dimeric, allosteric
membrane receptors? Trends Biochem. Sci. 33:376–384.
[52] Ward, C., M. Lawrence, V. Streltsov, T. Garrett, N. McKern, M. Lou,
G. Lovrecz, and T. Adams. 2008. Structural insights into ligand-induced acti-
vation of the insulin receptor. Acta Physiol. 192:3–9.
[53] Lawrence, M., N. McKern, and C. Ward. 2007. Insulin receptor structure and
its implications for the IGF-1 receptor. Curr. Opin. Struct. Biol. 17:699–705.
[54] Vashisth, H., and C. F. Abrams. 2010. Docking of insulin to a structurally
equilibrated insulin receptor ectodomain. Proteins: Struct., Funct., Bioinform.
78:1531–1543.
[55] Vashisth, H., and C. F. Abrams. 2010. All-atom structural models for complexes
of insulin-like growth factors IGF1 and IGF2 with their cognate receptor. J.
Mol. Biol., doi: 10.1016/j.jmb.2010.05.025 .
[56] Dodson, G., and D. Steiner. 1998. The role of assembly in insulin’s biosynthesis.
Curr. Op. Struct. Biol. 8:189–194.
[57] Kaarsholm, N. C., H. C. Ko, and M. F. Dunn. 1989. Comparison of solu-
tion structural flexibility and zinc binding domains for insulin, proinsulin, and
miniproinsulin. Biochemistry 28:4427–4435.
180
[58] Roy, M., M. L. Brader, R. W. K. Lee, N. C. Kaarsholm, J. F. Hansen, and M. F.
Dunn. 1989. Spectroscopic signatures of the T to R conformational transition
in the insulin hexamer. J. Mol. Biol. 264:19081–19085.
[59] Berchtold, H., and R. Hilgenfeld. 1999. Binding of phenol to R6 insulin hexam-
ers. Biopolymers 51:165–172.
[60] Humbel, R. E. 1990. Insulin-like growth factor-I and factor-II. Eur. J. Biochem.
190:445–462.
[61] Wodak, S. J., P. Alard, P. Delhaise, and C. Renneboogsquilbin. 1985. Simula-
tion of conformational changes in 2 ZN insulin. J. Mol. Biol. 181:317–322.
[62] Kru¨ger, P., W. Strassβurger, A. Wollmer, W. F. V. Gunsteren, and G. G.
Dodson. 1987. The simulated dynamics of the insulin monomer and their rela-
tionship to the molecules structure. E. Biophys. J. 14:449–459.
[63] Mark, A. E., H. J. C. Berendsen, and W. F. V. Gunsteren. 1991. Conformational
flexibility of aqueous monomeric and dimeric insulin - A molecular dynamics
study. Biochemistry 30:10866–10872.
[64] Falconi, M., M. T. Cambria, A. Cambria, and A. Desideri. 2001. Structure and
stability of the insulin dimer investigated by molecular dynamics simulation. J.
Bimol. Struc. Dynamics 18:761–772.
[65] McCammon, J. A., B. R. Gelin, and M. Karplus. 1977. Dynamics of folded
proteins. Nature 267:585–590.
[66] Schlitter, J., M. Engels, P. Kru¨ger, E. Jacoby, and A. Wollmer. 1993. Targeted
molecular dynamics simulation of conformational change - application to the
T→R transition in insulin. Mol. Simul. 10:291–308.
181
[67] Jacoby, E., Q. X. Hua, A. S. Stern, B. H. Frank, and M. A. Weiss. 1996.
Structure and Dynamics of a protein assembly. 1H-NMR studies of 36kDa R6
insulin hexamer. J. Mol. Biol. 258:136–157.
[68] Budi, A., S. Legge, H. Treutlein, and I. I. Yarovsky. 2004. Effect of external
stresses on protein conformation: a computer modelling study. Euro. Biophys.
J. 33:121–129.
[69] Kim, T., A. Rhee, and C. M. Yip. 2006. Force-induced insulin dimer dissocia-
tion: A molecular dynamics study. J. Am. Chem. Soc. 128:5330–5331.
[70] Legge, F. S., A. Budi, H. Treutlein, and I. Yarovsky. 2006. Protein flexibility:
Multiple molecular dynamics simulations of insulin chain B. Biophys. Chem.
119:146–157.
[71] Todorova, N., F. Marinelli, S. Piana, and I. Yarovsky. 2009. Exploring the
folding free energy landscape of insulin using bias exchange metadynamics. J.
Phys. Chem. B 113:3556–3564.
[72] Zoete, V., and M. Meuwly. 2006. Importance of individual side chains for
the stability of a protein fold: Computational alanine scanning of the insulin
monomer. J. Comp. Chem. 27:1843–1857.
[73] Inaba, T., N. Tsunekawa, T. Hirano, T. Yoshihiro, H. Kashiwagi, and F. Sato.
2007. Density functional calculation of the electronic structure on insulin hex-
amer. Chem. Phys. Lett. 434:331–335.
[74] Zoete, V., M. Meuwly, and M. Karplus. 2004. A comparison of the dynamic
behavior of monomeric and dimeric insulin shows structural rearrangements in
the active monomer. J. Mol. Biol. 342:913–929.
182
[75] Swegat, W., J. Schlitter, P. Kru¨ger, and A. Wollmer. 2003. MD simulation
of protein-ligand interaction: Formation and dissociation of an insulin-phenol
complex. Biophys. J. 84:1493–1506.
[76] Frenkel, D., and B. Smit, 2002. Understanding molecular simulations: From
algorithms to applications. Academic Press, San Diego, second edition.
[77] Leach, A. R., 2001. Molecular modelling: principles and applications. Pearson
Education Limited, England, second edition.
[78] Schlick, T., 2002. Molecular modeling and simulation: an interdisciplinary
guide. Springer, New York, first edition.
[79] Karplus, M., and G. A. Petsko. 1990. Molecular dynamics simulations in biol-
ogy. Nature 347:631–639.
[80] Karplus, M., and J. A. McCammon. 2002. Molecular dynamics simulations of
biomolecules. Nature Struct. Biol. 9:646–652.
[81] Karplus, M., and J. Kuriyan. 2005. Molecular dynamics and protein function.
Proc. Natl. Acad. Sci. USA 102:6679–6685.
[82] van Gunsteren, W. F., and A. E. Mark. 1998. Validation of molecular dynamics
simulation. J. Chem. Phys. 108:6109–6116.
[83] Gunsteren, W. F. V., P. H. Huenberger, A. E. MARK, P. E. Smith, and I. G.
Tironi. 1995. Computer simulation of protein motion. Comp. Phys. Commun.
91:305–319.
[84] Phillips, J., R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa,
C. Chipot, R. Skeel, L. Kale´, and K. Schulten. 2005. Scalable molecular dy-
namics with NAMD. J. Comput. Chem. 26:1781–1802.
183
[85] Metropolis, N., A. W. Rosenbluth, M. N. Rosenbluth, A. N. Teller, and
E. Teller. 1953. Equation of state calculations by fast computing machines.
J. Chem. Phys. 21:1087–1092.
[86] Chandler, D., 1987. Introduction to modern statistical mechanics. Oxford
University Press, first edition.
[87] Swope, W. C., H. C. Andersen, P. H. Berens, and K. R. Wilson. 1982. A
computer simulation method for the calculation of equilibirum constants for
the formation of physical clusters of molecules - application to small water
clusters. J. Chem. Phys. 76:637–649.
[88] Schlick, T., E. Barth, and M. Mandziuk. 1997. Biomolecular dynamics at long
timesteps: Bridging the timescale gap between simulation and experimentation.
Ann. Rev. Biophys. Biomol. Struct. 26:181–222.
[89] MacKerell, Jr., A. D., D. Bashford, M. Bellott, R. L. Dunbrack, Jr., J. D.
Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, D. Joseph-McCarthy,
L. Kuchnir, K. Kuczera, F. K. Lau, C. Mattos, S. Michnick, T. Ngo, D. T.
Nguyen, B. Prodhom, W. E. R. , III, B. Roux, M. Schlenkrich, J. C. Smith,
R. Stote, J. Straub, M. Watanabe, J. Wio´rkiewicz-Kuczera, D. Yin, and
M. Karplus. 1998. All-atom empirical potential for molecular modeling and
dynamics studies of proteins. J. Phys. Chem. B 102:3586–3616.
[90] MacKerell, Jr., A., M. Feig, and C. Brooks, III. 2004. Extending the treatment
of backbone energetics in protein force fields: limitations of gas-phase quantum
mechanics in reproducing protein conformational distributions in molecular dy-
namics simulations. J. Comput. Chem. 25:1400–1415.
184
[91] Andersen, H. C. 1980. Molecular dynamics simulations at constant pressure
and/or temperature. J. Chem. Phys. 72:2384–2393.
[92] Berendsen, H. J. C., J. P. M. Postma, W. F. V. Gunsteren, A. Dinola, and J. R.
Haa. 1984. Molecular dynamics with coupling to an external bath. J. Chem.
Phys. 81:3684–3690.
[93] Nose´, S. 1984. A molecular dynamics method for simulations in the canonical
ensemble. Mol. Phys. 52:255–268.
[94] Hoover, W. G., A. J. C. Ladd, and C. Moran. 1982. High-strain-rate plastic-flow
studied via non-equilibrium molecular dynamics. Phys. Rev. Lett. 48:1818–1820.
[95] Hoover, W. G. 1985. Canonical dynamics - Equilibrium phase-space distribu-
tions. Phys. Rev. A 31:1695–1697.
[96] Sanbonmatsu, K. Y., and C. S. Tung. 2007. High performance computing in
biology: Multimillion atom simulations of nanoscale systems. J. Struct. Biol.
157:470–480.
[97] Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD - Visual Molecular
Dynamics. J. Mol. Graph. 14:33–38.
[98] Lu¨demann, S., V. Lounnas, and R. C. Wade. 2000. How do substrates enter
and products exit the buried active site of cytochrome P450cam? 1. Ran-
dom Expulsion Molecular Dynamics investigation of ligand access channels and
mechanisms. J. Mol. Biol. 303:797–811.
[99] Vashisth, H., and C. F. Abrams. 2008. Ligand escape pathways and (Un)binding
free energy calculations for the hexameric insulin-phenol complex. Biophys. J.
95:4193–4204.
185
[100] Ferrari, D., J. R. Diers, D. F. Bocian, N. C. Kaarsholm, and M. F. Dunn.
2001. Raman signatures of ligand binding and allosteric conformation change
in hexameric insulin. Biopolymers 62:249–260.
[101] Choi, W. E., D. Borchardt, N. C. Kaarsholm, P. S. Brzovic, and M. F. Dunn.
1996. Spectroscopic evidence for preexisting T- and R-state insulin hexamer
conformations. Proteins: Struct. Funct. Genet. 26:377–390.
[102] Jacoby, E., P. Kru¨ger, Y. Karatas, and A. Wollmer. 1993. Distinction of struc-
tural reorganization and ligand binding in the T↔R transition of insulin on the
basis of allosteric models. Biol. Chem. Hoppe-Seyler 374:877–885.
[103] Hassiepen, U., M. Federwisch, T. Mulders, and A. Wollmer. 1999. The lifetime
of insulin hexamers. Biophys. J. 77:1638–1654.
[104] Carlsson, P., S. Burendahl, and L. Nilsson. 2006. Unbinding of retinoic acid from
the retinoic acid receptor by random expulsion molecular dynamics. Biophys.
J. 91:3151–3161.
[105] Kale´, L., R. Skeel, M. Bhandarkar, R. Brunner, A. Gursoy, N. Krawetz,
J. Phillips, A. Shinozaki, K. Varadarajan, and K. Schulten. 1999. NAMD2:
Greater scalability for parallel molecular dynamics. J. Comput. Phys. 151:283–
312.
[106] Whittingham, J. L., S. Chaudhuri, E. J. Dodson, P. C. E. Moody, and G. G.
Dodson. 1995. X-ray crystallographic studies on hexameric insulins in the pres-
ence of helix-stabilizing agents, thiocyanate, methylparaben, and phenol. Bio-
chemistry 34:15553–15563.
[107] Ciszak, E., and G. D. Smith. 1994. Crystallographic evidence for dual co-
186
ordination around Zinc in the T3R3 human insulin hexamer. Biochemistry
33:1512–1517.
[108] Smith, G. D. 1998. The phenolic binding site in T3R
f
3 insulin. J. Mol. Struct.
470:71–80.
[109] Bloom, C. R., R. Heymann, N. C. Kaarsholm, and M. F. Dunn. 1997. Binding of
2,6- and 2,7-Dihydroxynaphthalene to wild-type and E-B13Q insulins: dynamic,
equilibrium, and molecular modeling investigations. Biochemistry 36:12746–
12758.
[110] Bloom, C. R., N. Wu, A. Dunn, N. C. Kaarsholm, and M. F. Dunn. 1998.
Comparison of the allosteric properties of the Co(II)- and Zn(II)-substituted
insulin hexamers. Biochemistry 37:10937–10944.
[111] Birnbaum, D. T., S. W. Dodd, B. E. H. Saxberg, A. D. Varshavsky, and J. M.
Beals. 1996. Hierarchical modeling of phenolic ligand binding to 2Zn-insulin
hexamers. Biochemistry 35:5366–5378.
[112] Jarzynski, C. 1997. Nonequilibrium equality for free energy differences. Phys.
Rev. Lett. 78:2690–2693.
[113] Whittingham, J. L., D. J. Edwards, A. A. Antson, J. M. Clarkson, and G. G.
Dodson. 1998. Interactions of phenol and m-Cresol in the insulin hexamer, and
their effect on the association properties of B28 Pro→Asp insulin analogues.
Biochemistry 37:11516–11523.
[114] Park, S., F. Khalili-Araghi, E. Tajkhorshid, and K. Schulten. 2003. Free en-
ergy calculation from steered molecular dynamics simulations using Jarzynski’s
equality. J. Chem. Phys. 119:3559–3566.
187
[115] Hummer, G., and A. Szabo. 2001. Free energy reconstruction from nonequilib-
rium single-molecule pulling experiments. Proc. Natl. Acad. Sci. USA 98:3658–
3661.
[116] Liphardt, J., S. Dumont, S. B. Smith, I. T. Jr., and C. Bustamante. 2002.
Equilibrium information from nonequilibrium measurements in an experimental
test of Jarzynski’s Equality. Science 296:1832–1835.
[117] Shirts, M., 2004. Calculating precise and accurate free energies in biomolecular
systems. Ph.D. thesis, Stanford University.
[118] Park, S., 2004. Extracting equilibrium from nonequilibrium: Free energy cal-
culation from steered molecular dynamics simulations. Ph.D. thesis, University
of Illinois at Urbana-Champaign.
[119] Kirkwood, J. G. 1935 . Statistical Mechanics of Fluid Mixtures. J. Chem. Phys.
3:300–313.
[120] Trzesniak, D., A. E. Kunz, and W. F. van Gunsteren. 2007. A comparison of
methods to compute the potential of mean force. ChemPhysChem 8:162–169.
[121] Park, S., and K. Schulten. 2004. Calculating potentials of mean force from
steered molecular dynamics simulations. J. Chem. Phys. 120:5946–5961.
[122] Jensen, M. Ø., S. Park, E. Tajkhorshid, and K. Schulten. 2002. Energetics
of glycerol conduction through aquaglyceroporin GlpF. Proc. Natl. Acad. Sci.
USA 99:6731–6736.
[123] Amaro, R., E. Tajkhorshid, and Z. Luthley-Schulten. 2003. Developing an
energy landscape for the novel function of a (β/α)8 barrel: Ammonia conduction
through HisF. Proc. Natl. Acad. Sci. USA 100:7599–7604.
188
[124] Sparrow, L., M. Lawrence, J. Gorman, P. Strike, C. Robinson, N. McKern,
and C. Ward. 2008. N-linked glycans of the human insulin receptor and their
distribution over the crystal structure. Proteins 71:426–439.
[125] Kitamura, T., C. Kahn, and D. Accili. 2003. Insulin receptor knockout mice.
Annu. Rev. Physiol. 65:313–332.
[126] De Meyts, P. 1973. Insulin interactions with its receptors: experimental evi-
dence for negative coooperativity. Biochem. Biophys. Res. Comm. 55:154–161.
[127] Scha¨ffer, L. 1994. A model for insulin binding to the insulin receptor. Eur. J.
Biochem. 221:1127–1132.
[128] Flo¨rke, R., K. Schnaith, W. Passlack, M. Wichert, L. Kuehn, M. Fabry, M. Fed-
erwisch, and H. Reinauer. 2001. Hormone-triggered conformational changes
within the insulin-receptor ectodomain: requirement for transmembrane an-
chors. Biochem. J. 360:189–198.
[129] De Meyts, P. 1994. The structural basis of insulin and insulin-like growth factor-
I receptor binding and negative co-operativity, and its relevance to mitogenic
versus metabolic signalling. Diabetologia 37 (suppl. 2):S135–S148.
[130] Chan, S., S. Nakagawa, and D. Steiner. 2007. Complementation analysis demon-
strates that insulin cross-links both α-subunits in a truncated insulin receptor
dimer. J. Biol. Chem. 282:13754–13758.
[131] Kiselyov, V., S. Versteyhe, L. Gauguin, and P. De Meyts. 2009. Harmonic oscil-
lator model of the insulin and IGF1 receptors’ allosteric binding and activation.
Mol. Syst. Biol. 5:1–12.
[132] Williams, P., D. Mynarcik, G. Yu, and J. Whittaker. 1995. Mapping of an
189
NH2-terminal ligand binding site of the insulin receptor by alanine scanning
mutagenesis. J. Biol. Chem. 270:3012–3016.
[133] Mynarcik, D., P. Williams, L. Schaffer, G. Yu, and J. Whittaker. 1997. Analog
binding properties of insulin receptor mutants. J. Biol. Chem. 272:2077–2081.
[134] Schaefer, E., K. Siddle, and L. Ellis. 1990. Deletion analysis of the human
insulin receptor ectodomain reveals independently folded soluble subdomains
and insulin binding by a monomeric α-subunit. J. Biol. Chem. 265:13248–
13253.
[135] Kristensen, C., A. Andersen, M. Hach, F. Wiberg, L. Scha¨ffer, and T. Kjeldsen.
1995. A single-chain insulin-like growth factor I/insulin hybrid binds with high
affinity to the insulin receptor. Biochem. J. 305:981–986.
[136] Schlein, M., S. Havelund, C. Kristensen, M. Dunn, and N. Kaarsholm. 2000.
Ligand-induced conformational change in the minimized insulin receptor. J.
Mol. Biol. 303:161–169.
[137] Brandt, J., A. Andersen, and C. Kristensen. 2001. Dimeric fragment of the
insulin receptor α-subunit binds insulin with full holoreceptor affinity. J. Biol.
Chem. 276:12378–12384.
[138] Surinya, K., L. Molina, M. Soos, J. Brandt, C. Kristensen, and K. Siddle. 2002.
Role of insulin receptor dimerization domains in ligand binding, cooperativity,
and modulation by anti-receptor antibodies. J. Biol. Chem. 277:16718–16725.
[139] Kristensen, C., A. Andersen, S. Østergaard, P. Hansen, and J. Brandt. 2002.
Functional reconstitution of insulin receptor binding site from non-binding re-
ceptor fragments. J. Biol. Chem. 277:18340–18345.
190
[140] Pullen, R., D. Lindsay, S. Wood, I. Tickle, T. Blundell, A. Wollmer, G. Krail,
D. Brandenburg, H. Zahn, J. Gliemann, and S. Gammeltoft. 1976. Receptor-
binding region of insulin. Nature 259:369–373.
[141] De Meyts, P., E. Obberghen, J. Roth, A. Wollmer, and D. Brandenburg.
1978. Mapping of the residues responsible for the negative cooperativity of
the receptor-binding region of insulin. Nature 273:504–509.
[142] Kristensen, C., T. Kjeldsen, F. Wiberg, L. Scha¨ffer, M. Hach, S. Havelund,
J. Bass, D. Steiner, and A. Andersen. 1997. Alanine scanning mutagenesis of
insulin. J. Biol. Chem. 272:12978–12983.
[143] Chen, H., M. Shi, Z. Guo, Y. Tang, Z. Qiao, Z. Liang, and Y. Feng. 2000.
Four new monomeric insulins obtained by alanine scanning the dimer-forming
surface of the insulin molecule. Protein Eng. 13:779–782.
[144] Kurose, T., M. Pashmforoush, Y. Yoshimasa, R. Carroll, G. Schwartz, G. Burke,
P. Katsoyannis, and D. Steiner. 1994. Cross-linking of a B25 Azidophenylalanine
insulin derivative to the carboxyl-terminal regions of the α-subunit of the insulin
receptor. J. Biol. Chem. 269:29190–29197.
[145] Mynarcik, D., G. Yu, and J. Whittaker. 1996. Alanine-scanning mutagenesis of
a C-terminal ligand binding domain in the insulin receptor α subunit. J. Biol.
Chem. 271:2439–2442.
[146] Kristensen, C., F. Wiberg, and A. Andersen. 1999. Specificity of insulin and
insulin-like growth factor I receptors investigated using chimeric mini-receptors.
J. Biol. Chem. 274:37351–37356.
[147] Molina, L., C. Marino-Buslje, D. Quinn, and K. Siddle. 2000. Structural do-
191
mains of the insulin receptor and IGF receptor required for dimerization and
ligand binding. FEBS Lett. 467:226–230.
[148] Zhang, B., and R. Roth. 1991. A region of the insulin receptor important
for ligand binding (residues 450-601) is recognized by patients’ autoimmune
antibodies and inhibitory monoclonal antibodies. Proc. Natl. Acad. Sci. USA
88:9858–9862.
[149] Fabry, M., E. Schaefer, L. Ellis, E. Kojro, F. Fahrenholz, and D. Brandenburg.
1992. Detection of a new hormone contact site within the insulin receptor
ectodomain by the use of a novel photoreactive insulin. J. Biol. Chem. 267:8950–
8956.
[150] Schumacher, R., M. Soos, J. Schlessinger, D. Brandenburg, K. Siddle, and
A. Ullrich. 1993. Signaling-competent receptor chimeras allow mapping of major
insulin receptor binding domain determinants. J. Biol. Chem. 268:1087–1094.
[151] Hao, C., L. Whittaker, and J. Whittaker. 2006. Characterization of a second
ligand binding site of the insulin receptor. Biochem. Biophys. Res. Commun.
347:334:339.
[152] Benyoucef, S., K. Surinya, D. Hadaschik, and K. Siddle. 2007. Characterization
of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and
Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding
and receptor activation. Biochem. J. 403:603–613.
[153] Xu, B., S. Hu, Y. Chu, K. Huang, S. Nakagawa, P. Katsoyannis, and M. Weiss.
2004. Diabetes-Associated mutations in insulin: consecutive residues in the B
chain contact distinct domains of the insulin receptor. Biochemistry 43:8356–
8372.
192
[154] Huang, K., B. Xu, S. Hu, Y. Chu, Q. Hua, Y. Qu, B. Li, S. Wang, R. Wang,
S. Nakagawa, A. Theede, J. Whittaker, P. De Meyts, P. Katsoyannis, and
M. Weiss. 2004. How insulin binds: the B-chain α-helix contacts the L1 β-
helix of the insulin receptor. J. Mol. Biol. 341:529–550.
[155] Huang, K., S. Chan, Q. Hua, Y. Chu, R. Wang, B. Klaproth, W. Jia, J. Whit-
taker, P. De Meyts, S. Nakagawa, D. Steiner, P. Katsoyannis, and M. Weiss.
2007. The A-chain of insulin contacts the insert domain of the insulin receptor.
J. Biol. Chem. 282:35337–35349.
[156] Lawrence, M. Private communication.
[157] Nakagawa, S., and H. Tager. 1986. Role of the phenylalanine B25 side chain in
directing insulin interaction with its receptor. J. Biol. Chem. 261:7332–7341.
[158] Kadowaki, H., T. Kadowaki, A. Cama, B. Marcus-Samuels, A. Rovira,
C. Bevins, and S. Taylor. 1990. Mutagenesis of Lysine 460 in the human insulin
receptor. J. Biol. Chem. 265:21285–21296.
[159] Soos, M., K. Siddle, M. Baron, J. Heward, J. Luzio, J. Bellatin, and E. Lennox.
1986. Monoclonal antibodies reacting with multiple epitopes on the human
insulin receptor. Biochem. J. 235:199–208.
[160] Whittaker, J., P. Garcia, G. Q. Yu, and D. C. Mynarcik. 1994. Transmembrane
domain interactions are necessary for negative cooperativity of the insulin-
receptor. Mol. Endocrinol. 8:1521–1526.
[161] Sparrow, L., N. McKern, J. Gorman, P. Strike, C. Robinson, J. Bentley, and
C. Ward. 1997. The disulfide bonds in the C-terminal domains of the human
insulin receptor ectodomain. J. Biol. Chem. 272:29460–29467.
193
[162] Nakagawa, S., M. Zhao, Q. Hua, S. Hu, Z. Wan, W. Jia, and M. Weiss. 2005.
Chiral mutagenesis of insulin. Foldability and function are inversely regulated
by a stereospecific switch in the B chain. Biochemistry 44:4984–4999.
[163] Jensen, M., B. Hansen, P. De Meyts, L. Schaeffer, and B. Urso. 2007. Activation
of the insulin receptor by insulin and a synthetic peptide leads to divergent
metabolic and mitogenic signaling and responses. J. Biol. Chem. 282:35179–
35186.
[164] Markussen, J., J. Halstrøm, W. FC, and L. Scha¨ffer. 1991. Immobilized insulin
for high capacity affinity chromatography of insulin receptors. J. Biol. Chem.
266:18814–18818.
[165] Denley, A., C. X. C. Wang, K. A. McNeil, M. J. E. Walenkamp, H. V. Duyven-
voorde, J. M. Wit, J. C. Wallace, R. S. Norton, M. Karperien, and B. E. Forbes.
2005. Structural and functional characteristics of the Val(44)Met insulin-like
growth factor I missense mutation: Correlation with effects on growth and de-
velopment. Mol. Endocrinol. 19:711–721.
[166] Zhang, X., and D. Yee. 2000. Tyrosine kinase signalling in breast cancer insulin-
like growth factors and their receptors in breast cancer. Breast Cancer Res.
2:170–175.
[167] Khandwala, H. M., I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend. 2000. The
effects of insulin-like growth factors on tumorigenesis and neoplastic growth.
Endocr. Rev. 21:215–244.
[168] Leroith, D., and C. T. R. Jr. 2003. The insulin-like growth factor system and
cancer. Cancer Lett. 195:127–137.
194
[169] Belfiore, A. 2007. The role of insulin receptor isoforms and hybrid Insulin/IGF-I
receptors in human cancer. Curr. Pharm. Des. 13:671–686.
[170] Chitnis, M. M., J. S. P. Yuen, A. S. Protheroe, M. Pollak, and V. M. Macaulay.
2008. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer
Res. 14:6364–6370.
[171] Yu, H., and T. Rohan. 2000. Role of the insulin-like growth factor family in
cancer development and progression. J. Natl. Cancer Inst. 92:1472–1489.
[172] Cohick, W. S., and D. R. Clemmons. 1993. The insulin-like growth factors.
Annu. Rev. Physiol. 55:131–153.
[173] Meyts, P. D., A. R. Bianco, and J. Roth. 1976. Site-site interactions among
insulin receptors: characterization of the negative cooperativity. J. Biol. Chem.
251:1877–1888.
[174] Christoffersen, C. T., K. E. Bornfeldt, C. M. Rotella, N. Gonzales, H. Vissing,
R. M. Shymko, J. Tenhoeve, J. Groffen, N. Heisterkamp, and P. D. Meyts.
1994. Negative cooperativity in the insulin-like growth-factor-I receptor and a
chimeric IGF/Insulin receptor. Endocrinology 135:472–475.
[175] Surinya, K. H., B. E. Forbes, F. Occhiodoro, G. W. Booker, G. L. Francis,
K. Siddle, J. C. Wallace, and L. J. Cosgrove. 2008. An investigation of the lig-
and binding properties and negative cooperativity of soluble insulin-like growth
factor receptors. J. Biol. Chem. 283:5355–5363.
[176] Bass, J., T. Kurose, M. Pashmforoush, and D. Steiner. 1996. Fusion of insulin
receptor ectodomains to immunoglobulin constant domains reproduces high-
affinity insulin binding in vitro. J. Biol. Chem. 271:19367–19375.
195
[177] Hoyne, P., L. Cosgrove, N. Mckern, J. Bentley, N. Ivancic, T. Elleman, and
C. Ward. 2000. High affinity insulin binding by soluble insulin receptor extra-
cellular domain fused to a leucine zipper. FEBS Lett. 479:15–18.
[178] Bayne, M. L., J. Applebaum, G. G. Chicchi, N. S. Hayes, B. G. Green, and
M. A. Cascieri. 1988. Structural analogs of human insulin-like growth factor-
I with reduced affinity for serum binding-proteins and the type-2 insulin-like
growth-factor receptor. J. Biol. Chem. 263:6233–6239.
[179] Cascieri, M. A., G. G. Chicchi, J. Applebaum, N. S. Hayes, B. G. Green, and
M. L. Bayne. 1988. Identification of the domains of IGF-I responsible for high-
affinity binding to the type-1 and type-2 IGF receptors (IGF-R1, IGF-R2),
insulin-receptor (IR) and binding-proteins (BP). FASEB J. 2:A1773.
[180] Cascieri, M. A., G. G. Chicchi, J. Applebaum, B. G. Green, N. S. Hayes, and
M. L. Bayne. 1989. Structural analogs of human insulin-like growth-factor
(IGF)-I with altered affinity for type-2 IGF receptors. J. Biol. Chem. 264:2199–
2202.
[181] Bayne, M. L., J. Applebaum, G. G. Chicchi, R. E. Miller, and M. A. Cascieri.
1990. The roles of Tyrosine-24, Tyrosine-31, and Tyrosine-60 in the high-affinity
binding of insulin-like growth factor-I to the type-I insulin-like growth-factor
receptor. J. Biol. Chem. 265:15648–15652.
[182] Sakano, K. I., T. Enjoh, F. Numata, H. Fujiwara, Y. Marumoto, N. Hi-
gashihashi, Y. Sato, J. F. Perdue, and Y. Fujitayamaguchi. 1991. The design,
expression, and characterization of human insulin-like growth factor-II (IGF-II)
mutants specific for either the IGF-II cation-independent Mannose 6-Phosphate
receptor or IGF-1 receptor. J. Biol. Chem. 266:20626–20635.
196
[183] Roth, B. V., D. M. Burgisser, C. Luthi, and R. E. Humbel. 1991. Mutants of
human insulin-like growth factor-II - Expression and characterization of analogs
with a substitution of Tyr27 and/or a deletion of residues 62-67. Biochem.
Biophys. Res. Commun. 181:907–914.
[184] Burgisser, D. M., B. V. Roth, R. Giger, C. Luthi, S. Weigl, J. Zarn, and R. E.
Humbel. 1991. Mutants of human insulin-like growth factor-II with altered
affinities for the type-1 and type-2 insulin-like growth-factor receptor. J. Biol.
Chem. 266:1029–1033.
[185] King, R., J. R. E. Wells, P. Krieg, M. Snoswell, J. Brazier, C. J. Bagley, J. C.
Wallace, F. J. Ballard, M. Ross, and G. L. Francis. 1992. Production and
characterization of recombinant insulin-like growth-factor-I (IGF-I) and potent
analogs of IGF-I, with Gly or Arg substituted for Glu3, following their expres-
sion in Escherichia-Coli as fusion proteins. J. Mol. Endocrinol. 8:29–41.
[186] Francis, G. L., M. Ross, F. J. Ballard, S. J. Milner, C. Senn, K. A. McNeil, J. C.
Wallace, R. King, and J. R. E. Wells. 1992. Novel recombinant fusion protein
analogs of insulin-like growth-factor (IGF)-1 indicate the relative importance of
IGF-binding protein and receptor-binding for enhanced biological potency. J.
Mol. Endocrinol. 8:213–223.
[187] Luthi, C., B. V. Roth, and R. E. Humbel. 1992. Mutants of human insulin-like
growth factor-II (IGF-II) - Expression and characterization of truncated IGF-II
and of two naturally-occurring variants. Eur. J. Biochem. 205:483–490.
[188] Zhang, W. G., T. A. Gustafson, W. J. Rutter, and J. D. Johnson. 1994. Pos-
itively charged side-chains in the insulin-like growth-factor-I C-regions and D-
regions determine receptor-binding specificity. J. Biol. Chem. 269:10609–10613.
197
[189] Hodgson, D. R., F. May, and B. R. Westley. 1995. Mutations at position-11
and position-60 of insulin-like growth factor-1 reveal differences between its
interactions with the type-I insulin-like-growth-factor receptor and the insulin
receptor. Eur. J. Biochem. 233:299–309.
[190] Shooter, G. K., B. Magee, M. A. Soos, G. L. Francis, K. Siddle, and J. C.
Wallace. 1996. Insulin-like growth factor (IGF)-I A- and B-domain analogues
with altered type 1 IGF and insulin receptor binding specificities. J. Mol.
Endocrinol. 17:237–246.
[191] Hodgson, D. R., F. May, and B. R. Westley. 1996. Involvement of phenylalanine
23 in the binding of IGF-1 to the insulin and type I IGF receptor. Regul. Peptides
66:191–196.
[192] Jansson, M., M. Uhlen, and B. Nilsson. 1997. Structural changes in insulin-like
growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF
binding protein 1 and IGF-I receptor. Biochemistry 36:4108–4117.
[193] Jansson, M., G. Andersson, M. Uhlen, B. Nilsson, and J. Kordel. 1998. The
insulin-like growth factor (IGF)binding protein 1 binding epitope on IGF-I
probed by heteronuclear NMR spectroscopy and mutational analysis. J. Biol.
Chem. 273:24701–24707.
[194] Yandell, C. A., G. L. Francis, J. F. Wheldrake, and Z. Upton. 1999. Kangaroo
IGF-II is structurally and functionally similar to the human [Ser(29)]-IGF-II
variant. J. Endocrinol. 161:445–453.
[195] Magee, B. A., G. K. Shooter, J. C. Wallace, and G. L. Francis. 1999. Insulin-like
growth factor I and its binding proteins: A study of the binding interface using
B-domain analogues. Biochemistry 38:15863–15870.
198
[196] Dubaquie, Y., D. L. Mortensen, A. Intintoli, D. A. Hogue, G. Nakamura, P. Ran-
catore, P. Lester, M. D. Sadick, E. Filvaroff, P. J. Fielder, and H. B. Lowman.
2001. Binding protein-3-selective insulin-like growth factor I variants: Engi-
neering, biodistributions, and clearance. Endocrinology 142:165–173.
[197] Forbes, B. E., K. A. McNeil, C. D. Scott, K. H. Surinya, L. J. Cosgrove, and J. C.
Wallace. 2001. Contribution of residues A54 and L55 of the human insulin-like
growth factor-II (IGF-II) A domain to type 2 IGF receptor binding specificity.
Growth Factors 19:163–173.
[198] Sørensen, H., L. Whittaker, J. Hinrichsen, A. Groth, and J. Whittaker. 2004.
Mapping of the insulin-like growth factor II binding site of the type I insulin-like
growth factor receptor by alanine scanning mutagenesis. FEBS Lett. 565:19–22.
[199] Gauguin, L., C. Delaine, C. L. Alvino, K. A. McNeil, J. C. Wallace, B. E.
Forbes, and P. D. Meyts. 2008. Alanine scanning of a putative receptor binding
surface of insulin-like growth factor-I. J. Biol. Chem. 283:20821–20829.
[200] Alvino, C. L., K. A. McNeil, S. C. Ong, C. Delaine, G. W. Booker, J. C.
Wallace, J. Whittaker, and B. E. Forbes. 2009. A novel approach to identify
two distinct receptor binding surfaces of insulin-like growth factor II. J. Biol.
Chem. 284:7656–7664.
[201] Gauguin, L., B. Klaproth, W. Sajid, A. S. Andersen, K. A. McNeil, B. E. Forbes,
and P. D. Meyts. 2008. Structural basis for the lower affinity of the insulin-like
growth factors for the insulin receptor. J. Biol. Chem. 282:2604–2613.
[202] Andersen, A. S., T. Kjeldsen, F. C. Wiberg, P. M. Christensen, J. S. Ramussen,
K. Norris, K. B. Møller, and N. P. H. Møller. 1990. Changing the insulin-
199
receptor to possess insulin-like growth factor-I ligand specificity. Biochemistry
29:7363–7366.
[203] Kjeldsen, T., A. S. Andersen, F. C. Wiberg, J. S. Ramussen, L. Schaffer,
P. Balschmidt, K. B. Møller, and N. P. H. Møller. 1991. The ligand speci-
ficities of the insulin-receptor and the insulin-like growth factor-I receptor re-
side in different regions of a common binding-site. Proc. Natl. Acad. Sci. USA
88:4404–4408.
[204] Schumacher, R., L. Mosthaf, J. Schlessinger, D. Brandenburg, and A. Ullrich.
1991. Insulin and insulin-like growth factor-I binding-specificity is determined
by distinct regions of their cognate receptors. J. Biol. Chem. 266:19288–19295.
[205] Zhang, B., and R. A. Roth. 1991. Binding-properties of chimeric insulin-
receptors containing the cysteine-rich domain of either the insulin-like growth
factor-I receptor or the insulin-receptor related receptor. Biochemistry 30:5113–
5117.
[206] Gill, R., B. Wallach, C. Verma, B. Urso, E. DeWolf, J. Grotzinger, J. Mur-
rayRust, J. Pitts, A. Wollmer, P. DeMeyts, and S. Wood. 1996. Engineering
the C-region of human insulin-like growth factor-1: implications for receptor
binding. Prot. Eng. 9:1011–1019.
[207] Keyhanfar, M., G. W. Booker, J. Whittaker, J. C. Wallace, and B. E. Forbes.
2007. Precise mapping of an IGF-I-binding site on the IGF-1R. Biochem. J.
401:269–277.
[208] Whittaker, J., A. V. Groth, D. C. Mynarcik, L. Pluzek, V. L. Gadsboll, and
L. J. Whittaker. 2001. Alanine scanning mutagenesis of a type 1 insulin-like
growth factor receptor ligand binding site. J. Biol. Chem. 276:43980–43986.
200
[209] Svergun, D. I., C. Barberato, and M. H. J. Koch. 1995. CRYSOL− a program
to evaluate X-ray solution scattering of biological macromolecules from atomic
coordinates. J. Appl. Cryst. 28:768–773.
[210] Bernado´, P., E. Mylonas, M. V. Petoukhov, M. Blackledge, and D. I. Svergun.
2007. Structural characterization of flexible proteins using small-angle X-ray
scattering. J. Am. Chem. Soc. 129:5656–5664.
[211] Svergun, D. I. 1992. Determination of the regularization parameter in indirect-
transform methods using perceptual criteria. J. Appl. Crystallogr. 25:495–503.
[212] Petoukhov, M. V., and D. I. Svergun. 2007. Analysis of X-ray and neutron
scattering from biomacromolecular solutions. Curr. Op. Struc. Biol. 17:562–
571.
[213] Putnam, C. D., M. Hammel, G. L. Hura, and J. A. Tainer. 2007. X-ray solution
scattering (SAXS) combined with crystallography and computation: defining
accurate macromolecular structures, conformations and assemblies in solution.
Quar. Rev. Biophys. 40:191–285.
[214] Svergun, D. I., and M. H. J. Koch. 2003. Small-angle scattering studies of
biological macromolecules in solution. Rep. Prog. Phys. 66:1735–1782.
[215] Koch, M. H. J., P. Vachette, and D. I. Svergun. 2003. Small-angle scatter-
ing: a view on the properties, structures and structural changes of biological
macromolecules in solution. Quar. Rev. Biophys. 36:147–227.
[216] Cara, J. F., R. G. Mirmira, S. H. Nakagawa, and H. S. Tager. 1990. An insulin-
like growth factor-I insulin hybrid exhibiting high potency for interaction with
the type-I insulin-like growth-factor and insulin-receptors of placental plasma-
membranes. J. Biol. Chem. 265:17820–17825.
201
[217] DeWolf, E., R. Gill, S. Geddes, J. Pitts, A. Wollmer, and J. Grotzinger. 1996.
Solution structure of a mini IGF-1. Prot. Sci. 5:2193–2202.
[218] Denley, A., E. R. Bonython, G. W. Booker, L. J. Cosgrove, B. E. Forbes, C. W.
Ward, and J. C. Wallace. 2004. Structural determinants for high-affinity binding
of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus
isoform of the IR. Mol. Endocrinol. 18:2502–2512.
[219] Bayne, M. L., J. Applebaum, D. Underwood, G. G. Chicchi, B. G. Green, N. S.
Hayes, and M. A. Cascieri. 1988. The C-region of human insulin-like growth
factor (IGF) I is required for high-affinity binding to the type-1 IGF receptor.
J. Biol. Chem. 264:11004–11008.
[220] Slaaby, R., L. Schaffer, I. Lautrup-Larsen, A. S. Andersen, A. C. Shaw, I. S.
Mathiasen, and J. Brandt. 2006. Hybrid receptors formed by insulin receptor
(IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high
IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281:25869–
25874.
[221] Sohma, Y., B. L. Pentelute, J. Whittaker, Q. Hua, L. J. Whittaker, M. A.
Weiss, and S. B. H. Kent. 2008. Comparative properties of insulin-like growth
factor 1 (IGF-1) and [Gly7D-Ala]IGF-1 prepared by total chemical synthesis.
Angew. Chem. Int. Ed. 47:1102–1106.
[222] Ellis, L., E. Clauser, D. O. Morgan, M. Edery, R. A. Roth, and W. J. Rutter.
1986. Replacement of insulin receptor tysoine residues 1162 and 1163 com-
promises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell
45:721–732.
[223] Wilden, P. A., C. R. Kahn, K. Siddle, and M. F. White. 1992. Insulin receptor
202
kinase domain autophosphorylation regulates receptor enzymatic function. J.
Biol. Chem. 267:16660–16668.
[224] Hubbard, S. R., L. Wei, L. Elis, and W. A. Hendrickson. 1994. Crystal structure
of the tyrosine kinase domain of the human insulin receptor. Nature 372:746–
754.
[225] Hubbard, S. R. 1997. Crystal structure of the activated insulin receptor tyrosine
kinase in complex with peptide substrate and ATP analog. EMBO J. 16:5572–
5581.
[226] Kannan, N., and A. F. Neuwald. 2005. Did protein kinase regulatory mecha-
nisms evolve through elaboration of a simple structural component? J. Mol.
Biol. 351:956–972.
[227] Till, J. H., A. J. Ablooglu, M. Frankel, S. M. Bishop, R. A. Kohanski, and
S. R. Hubbard. 2001. Crystallographic and solution studies of an activation loop
mutant of the insulin receptor tyrosine kinase - Insights into kinase mechanism.
J. Biol. Chem. 276:10049–10055.
[228] Shan, Y., M. A. Seeliger, M. P. Eastwood, F. Frank, H. Xu, M. Ø. Jensen, R. O.
Dror, J. Kuriyan, and D. E. Shaw. 2009. A conserved protonation-dependent
switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. USA
106:139–144.
[229] Pan, A. C., D. Sezer, and B. Roux. 2008. Finding transition pathways using the
string method with swarms of trajectories. J. Phys. Chem. B 112:3432–3440.
[230] Banavali, N. K., and B. Roux. 2007. Anatomy of a structural pathway for
activation of the catalytic domain of Src kinase Hck. Proteins: Struct., Funct.,
Bioinform. 67:1096–1112.
203
[231] Gan, W., S. Yang, and B. Roux. 2009. Atomistic view of the conformational
activation of Src kinase using the string method with swarms-of-trajectories.
Biophys. J. 97:L8–L10.
[232] Abrams, C. F., and E. Vanden-Eijnden. 2010. Large-scale conformational sam-
pling of proteins using temperature-accelerated molecular dynamics. Proc. Natl.
Acad. Sci. USA 107:4961–4966.
[233] Maragliano, L., and E. Vanden-Eijnden. 2006. A temperature accelerated
method for sampling free energy and determining reaction pathways in rare
events simulations. Chem. Phys. Lett. 426:168–175.
[234] Maragliano, L., and E. Vanden-Eijnden. 2008. Single-sweep methods for free
energy calculations. J. Chem. Phys. 128:184110.
[235] Vanden-Eijnden, E. 2009. Some Recent Techniques for Free Energy Calcula-
tions. J. Comput. Chem. 30:1737–1747.
[236] Ebina, Y., E. Araki, M. Taira, F. Shimada, M. Mori, C. S. Craik, K. Siddle, S. B.
Pierce, R. A. Roth, and W. J. Rutter. 1987. Replacement of lysine residue 1030
in the putative ATP-binding region of the insulin receptor abolishes insulin-
stimulated and antibody-stimulated glucose uptake and receptor kinase activity.
Proc. Natl. Acad. Sci. USA 84:704–708.
[237] Wei, L., S. R. Hubbard, W. A. Hendrickson, and L. Ellis. 1995. Expression,
characterization, and crystallization of the catalytic core of the human insulin
receptor protein tysoine kinase domain. J. Biol. Chem. 270:8122–8130.
[238] Maragliano, L., G. Cottone, G. Ciccotti, and E. Vanden-Eijnden. 2010. Mapping
the network of pathways of CO diffusion in myoglobin. J. Am. Chem. Soc.
132:1010–1017.
204
[239] Smith, B. J., K. Huang, G. Kong, S. J. Chan, S. S. Nakagawa, J. G. Menting,
S. Q. Hu, J. Whittaker, D. F. Steiner, P. G. Katsoyannis, C. W. Ward, M. A.
Weiss, and M. C. Lawrence. 2010. Structural resolution of a tandem hormone-
binding element in the insulin receptor and its implications for design of peptide
agonists. Proc. Natl. Acad. Sci. USA 107:6771–6776.
205
Appendix A: RAMD tcl-code
In the following, we provide the Tcl code used for RAMD simulations described in
Chapter 3. The code takes a few input parameters from the config file of the software
package NAMD. The lines starting with # are comments at appropriate places. An
online copy of this code can also be found in the supplemental material of Ref. [99]
available at the website of Biophysical Journal.
################################################################
# Random Acceleration Molecular Dynamics (RAMD)
# - a ’tclForces’ implementation for NAMDv2.5+
#
# Author: Harish Vashisth
#
# (c) 2008 Board of Trustees of Drexel University
#
# Disclaimer: This code for research purposes only.
# Author takes no responsibility of wrong results with this code
################################################################
# start
# make a list of all the ligand atoms to which force needs to be applied
# atoms indices are taken from input PDB files
set numatoms 5752
set atoms {}
for { set i 5740} { $i <= $numatoms } { incr i } {
lappend atoms $i
}
foreach atom $atoms {
addatom $atom
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}
# make a group of ligand atoms on whose COM force is to be applied
set atomlist {5740 5741 5742 5743 5744 5745 5746 5747 5748 5749 5750 5751 5752}
set groupid [addgroup $atomlist]
print "Ligand’s GROUP ID IS: $groupid "
# make a group of protein atoms
set numatoms1 4720
set atoms1 {}
for { set i 1} { $i <= $numatoms1 } { incr i } {
lappend atoms1 $i
}
set groupid1 [addgroup $atoms1]
print "Protein’s GROUP ID IS: $groupid1 "
# some initializations
# ‘forcefreq’ and ‘rmin’ are read from NAMD config. file as defined below:
# set forcefreq 30
# set rmin 0.012
set force "0.0 0.0 0.0"
# a counter for force and time
set forcecount $forcefreq
set time 0
# old center of mass position
set comold "0.0 0.0 0.0"
set totalwork 0
set totaldist 0
# expulsion parameter which takes values either ‘0’ or ‘1’
set expulsion 0
# distance from initial position at which ligand is considered exited
# it is a system-specific parameter
set R 24.0
set dold "0.0 0.0 0.0"
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set displace 0
####################################################
# Actual force application procedure
# NAMD calls the code written inside proc calcforces
####################################################
proc calcforces { } {
# some global variables defintion
global atoms numatoms
global groupid force
global forcefreq
global forcecount
global comold time totalwork num rmin totaldist
global expulsion R
global dold displace
global atoms1 numatoms1 groupid1
# calculate and print the distance ligand must move in ’N’ steps
# info: a check for correct parameter (‘forcefreq’ and ‘rmin’) reading
set vmin [expr "($rmin)/($forcefreq)"]
if {$time == 0}
{
print " R-minimum (A): $rmin"
print " V-minimum (A/fs): $vmin"
}
# terminate NAMD: successful expulsion or ligand stuck
if {$expulsion == 1} {
set process [pid]
print "Process to be killed is: $process"
exec kill $process
}
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# run further only if the ligand is not ejected
if {$expulsion != 1} {
# info: print force vector details
set f1 [lindex $force 0]
set f2 [lindex $force 1]
set f3 [lindex $force 2]
set fmag [expr "sqrt((($f1)*($f1)+($f2)*($f2)+($f3)*($f3)))"]
print "Force vector added at time $time is: $force"
print "Force constant = $fmag"
# apply force on COM of the ligand
# force applied to the group is automatically distributed all atoms
addforce $groupid $force
# get coordinates and masses of all groups
# atom lists and groups: defined outside this ‘proc’, at the top
loadcoords coords
loadmasses masses
# info: calculate COM position after each force application
set comnew "$coords($groupid)"
print "Ligand-COM is at: $time $comnew"
print "Center of mass new at $time = $comnew"
print "Center of mass old at $time = $comold"
# info: keep track of the ligand’s COM distance
# this is again system-specific
# users can define their own conditions to track the ligand
set protein "$coords($groupid1)"
print "Protein-COM is at: $time $protein"
set d [vecsub $comnew $protein]
set d1 [lindex $d 0]
set d2 [lindex $d 1]
set d3 [lindex $d 2]
set r0 [expr "sqrt((($d1)*($d1)+($d2)*($d2)+($d3)*($d3)))"]
print "Ligand is so far: $time $r0"
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# compute the displacement of the ligand COM and not the distance
set rem0 [expr "$time % $forcefreq"]
if {$rem0 == 0 } {
set dnew "$comnew"
}
if {$rem0 == 0 && $time != 0} {
set disp [vecsub $dnew $dold]
set e [lindex $disp 0]
set f [lindex $disp 1]
set g [lindex $disp 2]
set displace [expr "sqrt((($e)*($e)+($f)*($f)+($g)*($g)))"]
print "Displacement in $time steps is = $displace"
}
# calculate work done, distance moved after first force application
# work done is not needed for expulsion trajectories
# this step is carried out only after time counter is ‘1’
if {$time != 0} {
set dist [vecsub $comnew $comold]
set a [lindex $dist 0]
set b [lindex $dist 1]
set c [lindex $dist 2]
set distance [expr "sqrt((($a)*($a)+($b)*($b)+($c)*($c)))"]
print "Distance moved = $distance"
set work [expr "(($f1)*($a)+($f2)*($b)+($f3)*($c))"]
print "Time step and work done = $time $work"
set totalwork [expr "$totalwork + $work"]
print "Time step, ligand distance, accumlated work=$time $r0 $totalwork"
}
print "TEST PRINT $forcecount = $forcefreq && $displace < $rmin"
# recalculate the random force direction at every ‘forcefreq’ steps
# simultaneously check for minimum velocity threshold too
if { $forcecount == $forcefreq && $displace < $rmin } {
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print "NEW RANDOM FORCE CHOSEN in Kcal/(mol)(A) at $time"
# choice of ‘k’ (kcal/mol.A) is system-specific
# different ‘k’ values should be tried for successful expulsions
# we have used ‘k’ = 20, 10, 15, and 5
set k 20.0
# random choice of Euler angles for x,y,z directions
set pi [expr "2.0*asin(1.0)"]
set p [expr "rand()"]
set phi [expr "(($pi*$p)-($pi)/(2))"]
set t [expr "rand()"]
set theta [expr "((2*$pi*$t)-($pi))"]
set rx [expr "cos($theta)*cos($phi)"]
set ry [expr "sin($theta)*cos($phi)"]
set rz [expr "sin($phi)"]
set r "$rx $ry $rz"
set f [vecscale [expr "$k"] $r ]
# compute the force vector
set force [vecscale [expr 1.0] $f]
# increment force counter
set forcecount 0
}
# print in case the ligand is already in solvent
# we define it as a distance from initial positions and set counter to ‘1’
# it is system-specific and other conditions can be used as well
if {$r0 >= $R && $expulsion == 0 } {
print "EJECTED AT TIME $time $r0"
set expulsion "1"
}
# a distance threshold is defined if the ligand is stuck
# this is also system-specific
if {$r0 <= 11.5} {
print "Moving to center at $time"
set expulsion "1"
}
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# some counter increments
set comold "$comnew"
if {$rem0 == 0 } {
set dold "$dnew"
set forcecount 0
}
incr time
incr forcecount
return
}
}
######################
# END
######################
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Appendix B: MC docking tcl-code
We used the following code for our docking calculations presented in Chapters 5 and
6. The main code is written in tcl, but the energy calculation routine was written in
C. Users have to use SWIG package (http://www.swig.org/) to combine both tcl
code and C code to make it work. In the following, we first provide the C code, and
then the main tcl code.
# Tcl/tk Script written originally by Cameron Abrams.
# The energy evaluation is being carried out in a separate C-code here
# SWIG, a Tcl-C interface building tool is used to generate ‘energy’ package
# (c) June 2008 Harish Vashisth
# Disclaimer: Authors have no responsibility of wrong results with this code
# The code may not be useful for other proteins
# Old way: Load the shared library module to call C functions
# load energy.so energy
# New way: load the energy package implemented in C
# Package available in home directory in a location defined as:
# ‘‘lappend auto_path /home/user/this/pkGdirname/" in ‘.vmdrc’ start-up file
# or, invoke as ‘‘lappend auto_path ." within tcl-script if pkG is in same
# directory as TCL-code
# Following C code was used to build ENERGY package
# \\ symbol denotes line breaks just to accommodate code here
# But code actually is continuous
/*A simple C-function for VDW + Electrostatic energy evaluation*/
double roughenergy(double *r1x, double *r1y, double *r1z, double *r2x, \\
double *r2y, double *r2z, double *e , double *s, int *I1, int *I2,\\
double *Q1, double *Q2, int smmr, int slgr) {
/* initializations*/
int i,j;
double recip_dielectric = 1.0;
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double E = 0.0;
double cut2 = 225.0;
double rij2;
double S,sig2,ep,eLJ,eCOUL,Q;
double *rix, *riy, *riz, *rjx, *rjy, *rjz, *p1, *p2, *q1, *q2;
int *i1, *i2;
/*pointer addresses*/
rix = &r1x[0];
riy = &r1y[0];
riz = &r1z[0];
rjx = &r2x[0];
rjy = &r2y[0];
rjz = &r2z[0];
p1 = &s[0];
p2 = &e[0];
q1 = &Q1[0];
q2 = &Q2[0];
i1 = &I1[0];
i2 = &I2[0];
for (i = 0; i < smmr; i++) {
for (j =0; j < slgr; j++) {
rij2 = (*(rix+i)-*(rjx+j))*(*(rix+i)-*(rjx+j))+(*(riy+i)\\
-*(rjy+j))*(*(riy+i)-*(rjy+j))+(*(riz+i)\\
-*(rjz+j))*(*(riz+i)-*(rjz+j));
if (rij2 < cut2)
{
S = *(p1+*(i1+i)) + *(p1+*(i2+j));
sig2 = S*S;
ep = sqrt((*(p2+*(i1+i))) * (*(p2+*(i2+j))));
Q = (*(q1+i)) * (*(q2+j));
/*All types of energy evaluations*/
eLJ = ep*(pow((sig2/rij2),6)- 2*pow((sig2/rij2),3));
eCOUL = recip_dielectric*(Q/sqrt(rij2));
E = E + eLJ + eCOUL;
}
}
}
return E;
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}
#######################
#The C code ends here
######################
# Main Tcl code which works under VMD begins here
# Now load the package ENERGY
package require energy
# Procedure for choosing random numbers
proc random {min max} {
set sp [expr {$max - $min}]
return [expr {rand() * $sp + $min}]
}
# Load the psf/pdb combination for the SUBSTRATE.
mol new ../../recep/vacuum.psf
mol addfile ../../recep/vacuum.pdb
mol addfile ../../recep/vac_till34.dcd waitfor all autobonds off
set mm_numframes [molinfo top get numframes]
# Load the psf/pdb combination for the LIGAND.
mol new ../../ins_2wrx/psf_2wrx.psf
mol addfile ../../ins_2wrx/aligned_2wrx.pdb
mol addfile ../../ins_2wrx/originalT_aligned.dcd waitfor all autobonds off
set lg_numframes [molinfo top get numframes]
set mmfrm 0
set lgfrm 0
# Choose protein atoms for energy calculations
set mm [atomselect 0 "all" frame $mmfrm]
set mmr [atomselect 0 "DEFINE YOUR VMD SELECTIONS HERE" frame $mmfrm]
# Choose ligand atoms for energy calculations
set lg [atomselect 1 "all" frame $lgfrm]
set lgr [atomselect 1 "all" frame $lgfrm]
set lg_ref [atomselect 1 "all" frame $lgfrm]
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#$mmr num
#$lgr num
# Extraction of CHARMM parameters from par_all27_prot_lipid.inp
set ln0 [exec grep -n NONBONDED par_all22_prot_cmap.inp\\
| awk -F: "\{print \$1\}"]
set ln1 [exec wc -l par_all22_prot_cmap.inp\\
| awk "\{print \$1\}"]
set span [expr $ln1 - $ln0]
puts "$ln0 $ln1 $span"
set PAR1 [list [exec tail -$span par_all22_prot_cmap.inp\\
| awk "\{if (\$2==0.000000) printf(\"%s \",\$1)\}" ]]
set Typ [lindex $PAR1 0]
set PAR1 [list [exec tail -$span par_all22_prot_cmap.inp\\
| awk "\{if (\$2==0.000000) printf(\"%s \",\$3)\}" ]]
set Eps [lindex $PAR1 0]
set PAR1 [list [exec tail -$span par_all22_prot_cmap.inp\\
| awk "\{if (\$2==0.000000) printf(\"%s \",\$4)\}" ]]
set Sig [lindex $PAR1 0]
puts "** PARAMETERS EXTRACTED **"
puts "** epsilon : [llength $Eps]"
puts "** sigma : [llength $Sig]"
# generate index arrays for atom types for each fragment
set TI1 [$mmr get serial]
set i 0
foreach t [$mmr get type] {
set ti [lsearch $Typ $t]
# puts "$t $ti $i"
if { [expr $ti == -1] } {
puts "ERROR! type $t not found in parameter file."
exit
}
lset TI1 $i $ti
incr i
}
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set TI2 [$lgr get serial]
set i 0
foreach t [$lgr get type] {
set ti [lsearch $Typ $t]
# puts "$t $ti $i"
if { [expr $ti == -1] } {
puts "ERROR! type $t ($i) not found in parameter file."
exit
}
lset TI2 $i $ti
incr i
}
#Tcl functions for converting a Tcl double list to a C array
proc ListToArray {l} {
set length [llength $l]
set a [new_array $length]
set i 0
foreach item $l {
array_setitem $a $i $item
incr i 1
}
return $a
}
#Tcl functions for converting a Tcl interger list to a C array
proc intListToArray {l} {
set length [llength $l]
set a [new_arrayint $length]
set i 0
foreach item $l {
arrayint_setitem $a $i $item
incr i 1
}
return $a
}
# Array making for Epsilon and Sigma values
set epsilon [ListToArray $Eps]
set sigma [ListToArray $Sig]
# Macromolecle coordinate lists
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set mx [$mmr get x]
set my [$mmr get y]
set mz [$mmr get z]
# Ligand coordinate lists
set lx [$lgr get x]
set ly [$lgr get y]
set lz [$lgr get z]
# Macromolecule and Ligand arrays from lists
set mmrx [ListToArray $mx]
set mmry [ListToArray $my]
set mmrz [ListToArray $mz]
set lgrx [ListToArray $lx]
set lgry [ListToArray $ly]
set lgrz [ListToArray $lz]
# Charges arrays for both selections
set charge1 [$mmr get charge]
set charge2 [$lgr get charge]
set ch1 [ListToArray $charge1]
set ch2 [ListToArray $charge2]
#set a [llength $charge1]
#set b [llength $charge2]
# Length of all the array
set sizeeps [llength $Eps]
set sizesig [llength $Sig]
set sizemmr [llength $mz]
set sizelgr [llength $lz]
# Index arrays for epsilon and sigma
set index1 [intListToArray $TI1]
set index2 [intListToArray $TI2]
#set a [llength $TI1]
#set b [llength $TI2]
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# Call to the energy function written in C
set E0 [roughenergy $mmrx $mmry $mmrz $lgrx $lgry $lgrz\\
$epsilon $sigma $index1 $index2 $ch1 $ch2 $sizemmr $sizelgr]
set E $E0
# specify number of MC cycles
set nc 10000
# specify trial move magnitudes
set dAngleDeg 2.0
set zmin [expr -$dAngleDeg]
set zmax $dAngleDeg
set cmin 1.0
set cmax [expr {cos($M_PI/180.0*$dAngleDeg)}]
set rmin 0.1
set rmax 1.0
# kT in kcal/mol for 31 deg C
set T 0.604
# Time at the beginning of Monte-Carlo trial moves loop
puts "Docking started at : [clock format [clock seconds] -format {%X %D} ]"
for {set i 0} { $i < $nc } {incr i} {
set MOVE EULER
set chs [expr rand()]
if {[expr ($chs > 0.4 && $chs < 0.6)]} {
set oldmmfrm $mmfrm
# choose a random frame for the macromolecule
set mmfrm [expr int([random 0 [expr $mm_numframes - 1]])]
$mm frame $mmfrm
$mmr frame $mmfrm
set MOVE MM_SAMP
} elseif {[expr ($chs > 0.6)]} {
set oldlgfrm $lgfrm
set lgfrm [expr int([random 0 [expr $lg_numframes -1]])]
$lg frame $lgfrm
$lgr frame $lgfrm
set trans [measure fit $lg $lg_ref]
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$lg move $trans
set MOVE LG_SAMP
} else {
set oldpos [$lg get {x y z}]
# set up Euler rotation + translation trial move transformation matrix
set cnt [measure center $lg]
set z1 [random $zmin $zmax]
set z2 [random $zmin $zmax]
set cx [random $cmin $cmax]
set x [expr acos($cx)]
set x [expr {$x * 57.296}]
if { [expr rand()] < 0.5 } {
set x [expr -$x]
}
# random distance
set r [random $rmin $rmax]
# random direction
set rc [random -1.0 1.0]
set rp [expr acos($rc)]
set a [random -3.14159 3.14159]
set dx [expr {$r*sin($rp)*cos($a)}]
set dy [expr {$r*sin($rp)*sin($a)}]
set dz [expr {$r*cos($rp)}]
# puts "move $i: euler_zxz(deg): $z1 $x $z2; disp: $dx $dy $dz"
set Eulerz1 [trans center $cnt axis z $z1 deg]
set Eulerx [trans center $cnt axis x $x deg]
set Eulerz2 [trans center $cnt axis z $z2 deg]
set R [transmult $Eulerz2 $Eulerx $Eulerz1]
# rotate about the COM
$lg move $R
# translate
$lg moveby [list $dx $dy $dz]
}
# Macromolecle coordinate lists
set mx [$mmr get x]
set my [$mmr get y]
set mz [$mmr get z]
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# Ligand coordinate lists
set lx [$lgr get x]
set ly [$lgr get y]
set lz [$lgr get z]
# Macromolecule and Ligand arrays from lists
set mmrx [ListToArray $mx]
set mmry [ListToArray $my]
set mmrz [ListToArray $mz]
set lgrx [ListToArray $lx]
set lgry [ListToArray $ly]
set lgrz [ListToArray $lz]
set E [roughenergy $mmrx $mmry $mmrz $lgrx $lgry $lgrz\\
$epsilon $sigma $index1 $index2 $ch1 $ch2 $sizemmr $sizelgr]
set X [expr rand()]
set arg [expr {($E0-$E)/$T}]
if {[expr $arg < -20]} {
set B 0.0
} elseif {[expr $arg > 2.8]} {
set B 1.1
} else {
set B [expr {exp(($E0-$E)/$T)}]
}
if {[expr {$X > $B}]} {
if { $MOVE == "MM_SAMP" } {
set mmfrm $oldmmfrm
$mm frame $mmfrm
$mmr frame $mmfrm
} elseif { $MOVE == "LG_SAMP" } {
set lgfrm $oldlgfrm
$lg frame $lgfrm
$lgr frame $lgfrm
} else {
$lg set {x y z} $oldpos
}
puts "$i: REJ $MOVE : dE [expr $E-$E0] $E0"
} else {
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puts "$i: ACC $MOVE : dE [expr $E-$E0] $E"
puts "ACC-$MOVE: mmf $mmfrm lgf $lgfrm energy $E "
set E0 $E
set PDB trialACC[format "%04d" $i]_mmf[format "%05d" $mmfrm]\\
_lgf[format "%05d" $lgfrm].pdb
$lg writepdb $PDB
if { $MOVE == "LG_SAMP" } {
set lg_ref [atomselect 1 "all" frame $lgfrm]
}
}
}
# Time at the end of Monte-Carlo trial moves loop
puts "Docking ended at : [clock format [clock seconds] -format {%X %D} ]"
quit
###############
# END
###############
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